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Abstract 
Skeletal muscle is one of the main regulators of protein metabolism and energy production, also 
involved in important contraction and movement mechanisms. However, alterations of this 
tissue can cause the onset of certain myopathies such as cachexia, a multifactorial syndrome 
characterized by a severe loss of muscle mass (with or without loss of fat mass) which is often 
associated to other chronic illnesses, such as cancer or neurodegenerative diseases (Fearon, 
2011).  
Currently, there are no specific drugs able to reverse this condition and the few attempts made 
with the use of appetite stimulants only caused an increase in weight (due to an accumulation 
of fat), rather than a gain in body mass. However, it has been recently discovered that exercise 
training may positive affect the state of this disease, primarily improving muscle mass and 
strength of cachectic patients, but also stimulating specific proteins involved in mitochondrial 
biogenesis (e.g. PGC1-α) or with cyto-protective effects (e.g. Hsp60). This latter is mainly a 
mitochondrial molecule involved in several cellular processes, and its levels increase in trained 
mice, allowing not only a better protein import and folding, but also promoting mitochondrial 
biogenesis (Barone, 2016). Recently, Hsp60 has also been discovered in the extracellular space, 
associated with small cellular vesicles (microvesicles or nanovesicles) that cells release during 
cell-to-cell communication (Caruso Bavisotto, 2017).  
Based on these previous data, we first focused on the in vitro isolation of micro- nano- vesicles 
harvested from a murine muscle cell line of C2C12, using different techniques of 
ultracentrifugation, tangential flow filtration, size exclusion chromatography and commercial 
kits. The isolation was followed by a morphological and biochemical characterization, in order 
to better study the characteristics of these potential natural carriers for drug delivery, but also 
to identify possible pathways by which nanovesicles could inhibit skeletal muscle wasting. 
We also investigated possible ways to promote the in vitro overexpression of the gene HSPD1 
in C2C12 cells, with the final aim to produced vesicles enriched in Hsp60, which may be able 
to activate PGC-1α isoform 1 in naive C2C12 cells.  
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1. Introduction 
1.1 Muscle Wasting 
Skeletal muscle is one of the most extended tissues of the body, implicated in important 
functions such as movement and contraction (Brown, 2017). Representing around 2/5 of the 
whole body weight, it also plays a pivotal role in more than 3/4 of the total human metabolism 
(Westerblad, 2010) (Koistinen, 2002).  
 Proteins are the main components of this tissue, whose mass is finely regulated by balancing 
mechanisms of protein synthesis and protein degradation (Thompson, 1998) (Anthony, 2016). 
However, if alterations in one of these two processes occur, it can lead to the progression of 
certain myopathies, such as sarcopenia and cachexia (Argilés, 2005) (Bowen, 2015).  
 Sarcopenia is generally referred to a slow and normal loss of muscle during aging, while 
cachexia indicates a multifactorial syndrome, characterized by a severe and involuntary loss of 
muscle mass, with or without loss of fat mass (Fearon, 2011). This latter is a condition that 
cannot be re-established with the normal nutritional support and may be often associated to 
several chronic illnesses, such as cancer and neurodegenerative diseases (Yoshida, 2015).  
 Cachexia has been classified in three main stages: pre-cachexia, cachexia and refractory 
cachexia (Fearon, 2011). Pre-cachexia is intended when clinical and metabolic signs (anorexia 
and metabolic alterations, like damages in glucose tolerance) generate a weight loss less than 
5%; cachexia develops when there is more than 5% in weight loss, a body max index (BMI) 
lower than 2%, or in conditions of sarcopenia with more than 2% of weight loss; the last stage, 
refractory cachexia, develops in presence of an active protein catabolism, with no response to 
any treatment (e.g. anticancer), causing a life expectation of less than 3 months (Zhou, 2018).  
 This syndrome is commonly linked with an acute depletion of skeletal muscle mass and a 
decrease in energy metabolism, triggering a reduction of muscle cells energy capacity (Kyrana, 
2012). Multiple molecular proteolytic pathways are involved in the development of cachexia, 
among which lysosomal (Tardif, 2013), Ca2+-dependent (Costelli, 2001), caspase-dependent 
(Belizário, 2001) and ubiquitin-proteasome-dependent (Khal, 2005), are the four most 
representative. 
 Lysosomal proteolysis is related to the activation of autophagy, a physiological mechanism 
that cells use for the degradation of cellular compromised organelles, such as mitochondria and 
peroxisomes (Penna, 2019). It is one of the main processes used from visceral and skeletal 
muscle tissues, and provokes muscle atrophy through a molecular pathway that involves the 
tumor necrosis factor-α (TNF-α) and the receptor associated factor (TRAF) 6/Fn14 (Paul, 2010) 
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(Penna, 2013). Autophagy related 7 protein (Atg7) is also implicated in muscle cell basal 
autophagy processes, playing a role in the maintenance of an internal cellular homeostasis; 
however, its depletion may provoke muscle atrophy and consequent decrease of muscle strength 
(Bowen, 2015) (Masiero, 2009). 
 In cachexia Ca2+-dependent, specific Ca2+-dependent cysteine proteases (calpains) regulate the 
proteolytic process (Costelli, 2005). These molecules are strongly dependent on Ca2+ levels and 
stimulate muscle protein degradation when cytosolic Ca2+ homeostasis is altered (Wu H. , 
2007). Normally present in the cytosolic space in an inactive form, they switch in their active 
form and move towards the plasma membrane once the intracellular Ca2+ concentration 
increases, cleaving several protein substrates (i.e. cytoskeletal, myofibrillar and membrane 
proteins) that are subsequently degraded by the activity of proteasome (Huang, 1998). 
 However, protein degradation may also depend on other protease groups called caspases (Silva, 
2015). Similarly to calpains, these molecules are present inside the cell in their inactive form 
(pro-caspases), but if a cellular traumatic event occurs, they switch in their activated state, 
forming a molecular complex called apoptosome. Under stress conditions, pro-aptotic signals 
provoke the mitochondrial release of cytochrome-c in the cytosol of the cell; this latter binds 
and triggers the activation of the adaptor protein Apaf-1, which in turn stimulates the initiator 
pro-caspases -9, -3, -6 and -7, promoting the development of the apoptosome complex 
(Chandra, 2003). Caspase-3, is one of the main molecules acting in muscle degradation, being 
involved in the cleavage of actomyosin and myofibrillar proteins, thus supplying substrates that 
are further degraded through the proteasome complex (Du, 2004) (Wang X. , 2010). 
 This latter is a molecular machinery able to degrade altered proteins that were previously 
ubiquitinated thanks to the enzymatic activity of ubiquitin-activating enzyme (E1), conjugation 
enzyme (E2) and ligase enzyme (E3). Ubiquitin is a regulatory protein that covalently binds to 
damaged proteins, serving as a tag for their degradation. In the ubiquitination process, E1 
activates and binds the ubiquitin protein, which is first transferred to E2 enzyme and then to E3 
ligase, an important enzyme that regulates the transferring of ubiquin to the target protein. Once 
ubiquitinated, the damaged protein is then delivered to the proteasome complex for its 
degradation. Two transcription factors FoxO and NF-kB are mainly involved in this process, 
both enhancing proteasome activity through the activation of the two muscle-specific E3 ligases 
MAFbx/atrogin-1 and muscle RING Finger-1 (MuRF1) (Du, 2004). The activation of MuRF-
1 (E3-ubiquitin ligase) may be also stress oxidative dependent, causing an increment of the 
proteasome activity and consequent protein degradation (Li, 2003).  
 Beyond these four mechanisms, other molecules may also stimulate the development of 
cachexia. For instance, interleukin-6 (IL-6) and tumor necrosis factor α (TNF-α) cytokines are 
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among the principal inflammatory molecules associated with cancer muscle wasting (Kayacan, 
2006); indeed, it has been shown that the over expression of IL-6 may activate several 
molecules (e.g. FoxO3, atrogenes, STAT3 and p38) implicated in skeletal muscle atrophy 
(Puppa, 2014). The role of IL-6 during the initial stages of cachexia is of such importance, since 
it promotes the activation of lypolisis mechanisms of the white adipose tissue (WAT) with a 
consequent loss in fat, as well as the parallel white-to-brown trans differentiation of white 
adipocytes into brown adipocytes during latter stages of cachexia (Han J. , 2018).  
 TNF-α mainly originate from activated macrophages (as a consequence of invasive stimuli) 
and it is one of the principal mediators of cancer cachexia (Patel, 2017). Presence of TNF in 
cachectic subjects provokes a series of dysfunctions, such as the down regulation of muscle 
actin and myosin (Tracey, 1988), gastrointestinal motility (Tracey, 1986) and suppression of 
food intake (Dinarello, 1986). In cachectic skeletal muscle it induces the synthesis of IL-1, 
another kind of pro-inflammatory cytokine, promoting the expression of the uncoupling 
proteins UCP2 and UCP3, molecules involved in the regulation of mitochondrial energy 
expenditure and tumor growth (Tijerina, 2004). However, TNF-α role in cachexia seems to be 
a bit controversial: on one hand, its interaction with specific anti-TNF antibodies seems to 
inhibit all those lipid metabolic alterations to which the adipose tissue is subjected, but, on the 
other hand, no correlation has been shown in cachectic patients between the levels of TNF and 
the gravity of weight loss (Costelli, 1993).  
 Other molecular factors control protein degradation, such as inflammatory cytokines (Cheung, 
2010), angiotensin II (Sanders, 2005), insulin like growth factor-1 (Costelli, 2006) and reactive 
oxygen species (Ardies, 2002), also impacting the activity of the mitochondrial biogenesis 
regulator peroxisome proliferator-activated receptor-ɣ coactivator α (PGC-1α) and, 
consequently, the mitochondrial energy production (Joseph, 2006). Mitochondrion is of such 
importance in muscle metabolism processes, since it is the most important organelle involved 
in energy production (Tuena de Gómez-Puyou, 1983), making mitochondria pivotal regulators 
of muscle loss in wasting diseases (Antunes, 2014).  
 Mitochondrion is the energy house of each eukaryotic cell. Thanks to an α-proteobacteria 
endosymbiont that implanted in a host cell, it has its own mtDNA, with a length of ~16.5 kb, 
containing 37 genes encoding for subunits of the electron transport chain (Ventura-Clapier, 
2008). It contributes to most of the total cellular ATP, thus playing an important role in the 
maintaining of cellular homeostasis (Tuena de Gómez-Puyou, 1983). However, if imbalance in 
ATP production/consumption occurs, mitochondria may undergo into a series of dangerous 
disorders, that can be deleterious for the viability of the cell (Spinazzola, 2009).  
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 Mitochondria homeostasis is generally maintained through a regulated mechanism of 
degradation and biogenesis of new organelles, that replace the ones who were damaged or 
degraded (Palikaras, 2014). The biogenesis process can be promoted by many factors, such as: 
cold exposure, caloric restriction, exercise, or oxidative stress; this is a widely complicated 
process where multiple factors (i.e. nuclear respiratory factors NRF1 and NRF2, peroxisome 
proliferator receptors-PPARs and estrogen related receptors-ERRs), interact with the 
peroxisome proliferator-activated receptor-ɣ coactivator α (PGC-1α), the master regulator of 
mitochondria biogenesis (Wenz, 2009). 
 PGC-1α belongs to the family of the peroxisome proliferator-activated receptor gamma (PGC) 
family, a series of transcriptional factors involved in several processes, such as regulation of 
nuclear receptors PPAR,  metabolic and energetic pathways, mitochondrial biogenesis, fatty 
acid oxidation and angiogenesis (Finck, 2006).  
 Firstly discovered in brown adipose tissue (BAT), its activity is controlled both at the 
expression and post-translational levels (Fernandez-Marcos, 2011) (Cantó, 2009). In addition 
to PGC-1α, other two related co-activators were subsequently discovered: PGC-1β (also known 
as PERC) and PGC-1–related co-activator (PRC) (Lin, 2002) (Scarpulla, 2002). PGC-1α and 
PGC-1β are mainly present in tissues with high oxidative activity (i.e. heart, skeletal muscle 
and BAT), where they control cellular metabolism and mitochondrial activity. In contrast to 
them, PRC factor is the least studied and there are poor information regarding its biological 
roles.  
 Transcribed by different genes, these proteins present similar molecular structures, which 
reflect their common physiological roles (Lin, 2005). The expression of PGC-1α is controlled 
by the Pgc-1α gene (PPARGC1A in humans), consisting of an evolutionarily conserved 
alternative promoter, situated 14 kb upstream of the transcription start site (TSS) (Miura, 2008). 
The activity of Pgc-1α gene strongly depends on biological conditions of specific tissues, and 
its expression may generate several mRNAs. In fact, it is composed by many promoter and 
exon regions that, in association with events of alternative splicing, produce distinct transcripts 
and protein structures (Martínez-Redondo, 2015) (Figure 1).  
 Transcripts developing from the distal promoter present a new exon-1b sequence (which differs 
from the classic exon-1a located after the proximal promoter PP) and may be further modified 
through alternative splicing, thus encoding for two different amino terminal sequences shorter 
than the proximal exon-1a (16 amino acid long): Pgc-1α-b and Pgc-1α-c, respectively 12 and 3 
amino acids long (Chinsomboon, 2009). However, exon-1b sequences may be also present in 
other two transcripts, Pgc-1α2 and Pgc-1α3, characteristic isoforms of trained skeletal muscle 
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tissue, which are involved in the expression of the vascular endothelial growth factor (VEGF), 
for the activation of angiogenesis pathways (Martínez-Redondo, 2016).  
 PPARGC1A gene also carry two distinct promoters: (LP) and BP. The first one mainly control 
the expression of a human variant of the liver, while the second one is located 587 kb of distance 
from exon 1a and is mainly characteristic of the brain tissue (Martínez-Redondo, 2015) (Figure 
1). The expression of PGC-1α gene is regulated by different molecular pathways such as Ca2+ 
signalling (Chin, 2004), cyclic AMP and 5′ AMP-activated protein kinase (AMPK) (Irrcher, 
2008),  that promote the activation and translocation of specific transcription factors to PGC-
1α gene regions, for its expression. 
 
Figure 1 - PGC-1α isoform structure and transcriptional origin (Martínez-Redondo, 2015). 
 However, the expression of this gene may also be suppressed through epigenetic modifications 
(i.e. DNA methylation) (Bettscheider, 2012), that may alter its activity, causing the 
development of pathological conditions. 
 During its activity, PGC-1 interacts with specific transcription factors, enhancing the activation 
of protein complexes involved in the transcription of nuclear mitochondrial genes. For instance, 
the binding between the amino-terminal region of PGC-1 with a protein complex constituted 
by the histone acetyltransferase (HAT), as well as CREB-binding protein/p300 or steroid 
receptor coactivator-1 (SRC-1), stimulate the activation of chromatin, which modifies its 
histones, making portions of the genome more accessible to the transcription factors 
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(Puigserver, 1999) (Wallberg, 2003). Moreover, PGC-1α promotes the activation of nuclear 
respiratory factor-1 (NRF-1) and -2 (NRF-2), molecules involved in the regulation of the 
expression of specific mitochondrial transcription factors (i.e. the mitochondrial transcription 
factor A -TFAM-), important for the expression of nuclear mitochondrial genes (Larsson, 1998) 
(Gleyzer, 2005).  
 The activation of PGC-1α is regulated by a considerable number of signaling pathways, and 
exercise is one of these (Handschin, 2008). During training, contractile activity promotes a 
consequent increase of intracellular Ca2+, which in turn activates the calcium-dependent 
phosphatase calcineurin (CaN) and the Ca2+-calmodulin dependent kinase (CaMK), stimulating 
the expression of PGC-1α and the mitochondria biogenesis (Ventura-Clapier, 2008).  
 PGC-1α seems to be a positive mediator of some beneficial effects that physical exercise plays 
in skeletal muscle and its expression is highly concentrated in skeletal muscle fibers (especially 
in those oxidative), where it promotes mitochondrial respiration and fatty acid oxidation 
through the conversion of fast glycolytic fibers to slow and oxidative fibers (Zhang L. , 2017). 
Indeed, it has been demonstrated that both short-term exercise and endurance training may 
stimulate the expression of PGC-1α in skeletal muscle (Pilegaard, 2003), especially in type IIa 
fibers after endurance training  (Russell A. , 2003). Physical exercise also encourages a 
reduction of the chromatin methylation of PGC-1α promoter, thus keeping the gene sequence 
available for its expression (Narkar, 2017). Although the mechanisms underlying the activation 
of muscle PGC-1α during training activity are still poor understood, it is now known that 
calcineurin A, CaMK, p38 MAPK and AMPK pathways may be involved in the muscle gene 
transcription (Egan, 2010) (Schaeffer, 2004). 
 On the basis of these beneficial effects, exercise could be taken in consideration for all those 
cachectic conditions that occur during chronic diseases (Eva, 2016). This syndrome is often 
widely underestimated, since most of the treatments used so far have been ineffective (Tazi, 
2010), with disappointing results of most non-pharmacological (e.g. high-calorie diet) and 
pharmacological strategies (e.g. progesterone therapy based, anabolic steroids, cannabinoids, 
antidepressants etc). Despite new potential drugs are under investigation (i.e. thalidomide, 
selective cox-2 inhibitors, ghrelin mimetics, insulin, oxandrolone and olanzapine), they have 
shown only few auspicious results (Aversa, 2017). 
 Nowadays, progestogen treatment is the only approved drug in Europa, and constitutes the best 
available treatment option for cancer-related cachexia. Progestogen is a steroid hormone, which 
stimulates appetite and weight increase of cachectic patients, through the activity of the 
neuropeptide Y (Madeddu, 2009). Another novel oral drug named Anamorelin, an analogue of 
the circulating hormone ghrelin, has demonstrated positive effects in those mechanisms that 
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influence the development of the syndrome (Currow, 2018). Despite these new evidences, all 
the currently existing treatments against cachexia appear to be aimed at improving anorectic 
conditions, thus lacking specificity versus the syndrome. 
 Therefore, it could be extremely important to identify innovative therapies that can be able to 
mimic the beneficial effects of exercise in these pathological conditions. Physical activity 
stimulates muscle strength and function, increasing a fat free mass that positively affect the 
quality of life. Different cellular responses can be triggered based on the type of training; for 
instance, non-stressful exercise regulates inflammation processes, through the reduction of 
cellular response to inflammatory stimuli and pro-inflammatory cytokines (Gould, 2013). On 
contrary, acute exercise provoke a high expression of cytokines involved in an acute-phase 
inflammatory response (Ostrowski, 1999), even if levels of classic pro-inflammatory cytokines 
(TNF-α and IL-1β) seem not to be directly affected, thus suggesting that cytokine cascade 
induced by physical activity differs from that induced by infections (Gould, 2013).  
 In a recent study, it has been also shown that endurance training of cachectic mice increased 
the expression levels of a mitochondrial chaperonine (heat shock protein 60 -Hsp60-) involved 
in the regulation processes of PGC-1α and mitochondria biogenesis. The study demonstrated a 
correlation between Hsp60 levels with those of PGC-1α, stressing a potential role of physical 
activity in the treatment of cachexia syndrome, as well as in the homeostasis of muscle tissue 
(Barone, 2016). 
1.2 Heat Shock Proteins (Hsps) 
 
Heat shock proteins (Hsps) are a family of ubiquitous molecules present in the cells of all 
organisms (Robert, 2003). Primarily found in the salivary gland of Drosophila, these proteins 
present a highly conserved genome across species, from Prokaryotes to Eukaryotes (Ritossa, 
1962). Originally named, and known, for their expression after exposure to heat stress, this 
family of proteins can also be activated by a range of other environmental and metabolic stress 
conditions, such as: ischemia (Nowak, 1990), heavy metal ions (Wagner, 1999), ethanol 
(Tunici, 1999), nicotine (Hahn, 1991), oxidative stress (Drummond, 1987) and malignant 
transformation (Vargas-Roig, 1997). Hence, they are of such importance for the cells, as they 
protect organisms to non-lethal stress, through mechanisms of thermotolerance and cross-
tolerance. 
  Hsps proteins are implicated in many cellular functions, such as protein folding and 
degradation of damaged-denatured proteins, helping new polypeptides reaching their final 
functional structure, or re-folding, as well as degrading damaged proteins once exposed to stress 
events (Wegele, 2004). In addition, they are also implicated to other cellular functions, such as: 
13 
 
regulation of gene expression, cellular differentiation, DNA replication, signal transduction, 
senescence, programmed cell death and carcinogenesis (Macario, 2005).  
 Under non-stress conditions, Hsps are less expressed, but if cells alterations occur, levels of 
specific heat shock transcription factors (HSF) may strongly increase (Pirkkala, 2001). Once 
activated, these factors (which have a monomer form when inactive) migrate into the nucleus, 
trimerize into the active form and bind to the promoter site of the Hsps gene, promoting the 
synthesis of Hsps mRNAs (Sandqvist, 2009) (Whitley, 1999). These proteins play important 
roles in maintaining cellular homeostasis, controlling apoptotic signaling events (Beere, 2004), 
antigen processing mechanisms (Li Z. , 2002), but they can also be implicated in the pathology 
of several diseases (Yujun, 2007).  
  This class of proteins belong to a multi gene family with a molecular size range from 8 to 150 
kDa, and their name generally refers to their molecular weights, classifying them as: low 
molecular weight Hsp (small Hsps) with a size range of 10-30 kDa, Hsp40, Hsp60 (also called 
chaperonin), Hsp70, Hsp90, Hsp100 and Hsp110 (also known as chaperons) (Hyunseok, 2016). 
Depending on their expression patterns, these proteins may be further divided in other two 
classes: induced and constitutive (heat shock cognate, Hsc) proteins (Somji, 1999). As the name 
suggests, the first group is generally low expressed in physiologically conditions, but it can 
widely rise after stress events, while the second group is constitutive expressed within the cell 
(Garbuz, 2017). Firstly though to be restricted to the only cytoplasm, these proteins are also 
present in cellular organelles, as well as in the plasma membrane (either in the surface or inside 
the cellular membranes) and in the extracellular space (Horváth, 2008).  
 Hsp60 is a mitochondrial protein belonging to the group of chaperonins, multi subunit ATPases 
molecules involved in the folding of new or damaged proteins (Lund, 2003). This group can be 
divided in two families: the prokaryotic GroEL-GroES (and their eukaryotic homologs Hsp60-
Hsp10) (Haldar, 2015), and the CCT family proteins (chaperonins containing t-complex 
polypeptide) (Vallin, 2019). In Eukaryotes, the first family works mainly in the mitochondria, 
while the second one is specific of the cytosol (Garbuz, 2017). In addition to this first 
classification, chaperonins may be further divided in other two classes: class I (found in 
prokaryotes and cell organelles) and class II (in Archea and cytosol of eukaryotes), depending 
respectively on their ability, or not, to interact with other co-chaperonins (Nielsen, 1999).  
 Unlike from their chaperones counterpart, which interact with protein substrates in a 
monomeric or dimeric form, functional chaperonins work as oligomeric rings, in which 
monomeric subunits surround a central cavity where the unfolded protein gets processed 
(Garbuz, 2017) (Hartl, 1992). For instance, Eukariotic Hsp60 is an ATP dependent oligomer 
formed by two stacked heptameric rings, each of them composed by the association of 7 
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monomers and further divided in three domains: apical, intermediate and equatorial; this latter, 
holds the binding site for ATP molecules, while the intermediate domain serve as a linker for 
equatorial and apical domains, also promoting all those conformational protein modifications 
that occur once ATP/ADP and Mg2+ are linked to the equatorial subunit (Karlin, 2000). Thanks 
to this specific conformation, the substrate is literally trapped within the ring and is completely 
isolated from possible other external interactions. However, as a chaperonin, Hsp60 has to 
interact with a co-chaperonin to perform its functions (Hsp10) which is arranged to form a sort 
of cap in the apical and basal areas of the characteristic double ring complex (Vilasi, 2014).  
 Almost 80-85% of Hsp60 from mammalian cells and tissues resides in the matrix space of 
mitochondria, while the rest 15-20% of the protein occupies extra-mitochondrial sites, such as 
the plasma membrane, peroxisomes, the endoplasmic reticulum and the extracellular space 
(Taldone, 2014) (Campanella, 2012) (Merendino, 2010).  
 Its synthesis starts from the nuclear gene HSPD1, that is first transcribed into a specific mRNA, 
which then migrate in the cytosol for its translation. The translated sequence of Hsp60 presents 
an N-terminal signal sequence of 1-26 amino acids, which is responsible for its translocation 
inside the mitochondria and its conversion into its mature 58 kDa conformation (Ishida, 2018).  
 Considering its high mitochondrial distribution, some researchers have speculated a possible 
correlation between Hsp60 expression and mitochondria biogenesis in muscle cells after 
training endurance (Barone, 2016) (Frühbeis, 2015), with a release of chaperonine thought via 
exosomes, since it has been already demonstrated that, under stress conditions, cells are able to 
secrete high levels of HSPs-bearing EVs (i.e. Hsp-90, Hsp-70, Hsp-60) (Taha, 2019) (Kisho, 
2018).   
1.3 Extracellular Vesicles: origin and mechanism of biogenesis 
Extracellular Vesicles (EVs) are small particles composed of a lipid bi-layer containing multiple 
molecules derived from the cytosol, and the cellular membrane, of the donor cell (Akers, 2013). 
First characterized in 1967 in hematopoietic cells (Wolf, 1967), they represent a varied 
population that differs in cellular origin, size, morphology, antigenic composition and 
functional properties (Table 1).  
 Originally thought to be exclusively involved in the secretion of transferrin receptors during 
the maturation of erythrocytes, in the early 1980s, EVs were also found as membranes vesicles 
released during pre-degenerative processes by dying cells (Coleman, 2001). Recent evidences 
have demonstrated that the secretion of these vesicles is a well conserved mechanism, common 
to the majority of the cells (both Prokaryotics or Eukaryotics), and describes vesicles as entities 
released by living cells, through secretory pathways that occur during physiological and 
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degenerative processes (Colombo, 2014). Once in the extracellular space, EVs may act as 
soluble messengers important in cell-to-cell communication among near and distant cells 
(Colombo, 2014). 
Table 1 -Types of Extracellular Vesicles and most common markers 
Type Apoptotic Bodies Microvesiscles 
(Ectosomes, 
Microparticles) 
Nano-vesicles 
(exosomes) 
(small-medium-large) 
Size > 800 nm  >100 nm-1 µm 30-150 nm 
Biogenesis Apoptosis outward budding of 
plasma membrane 
Endocytosis 
Common Markers chemokine (C-X3-C 
motif) ligand 1 
CX3CL1;  
Intercellular adhesion 
molecule 3 (ICAM-3); 
β1 integrins; selectins; 
CD40;  
Matrix metalloproteinase 
(MMP);  
 
Tetraspanins 
(CD63;CD9; CD81);  
Hsps (Hsp70; Hsp90); 
Tumor susceptibility 
gene 101 (TSG101);  
Annexin V-VI; 
Metallopeptidase domain 
10 (ADAM10);  
Alix; 
References (Catchpoole, 1995) (Surman, 2017) (Kowal, 2016) 
   Despite their first classification relied on the basis of their size (e.g. apoptotic bodies 1-5 µm, 
microparticles  from 0.1–1 µm and exosomes, with a diameter of 40–150 nm), their tissue of 
origin (e.g. prostasomes, oncosomes), their function, or their presence outside the cells, one of 
their last classification mainly focuses on their mechanism of biogenesis (Kalra, 2016) (Figure 
2). However, there is still no consensus on specific EV subtypes markers (such as endosome-
origin or plasma membrane-derived) that can be used as unique references for their 
classification into different vesicular sub-groups (i.e. micro- or nano- vesicles); therefore, 
allocate a vesicle to a particular biogenesis pathway is still very difficult, unless it is captured 
during its release in live imaging techniques (Choi, 2017). Hence, in order to classify a 
particular vesicle to a specific subtype, the International Society for studies of Extracellular 
Vesicles (ISEV) has published the last document about the minimal information for the studies 
of Extracellular Vesicles (MISEV 2018). They suggested to sort vesicles based on several 
parameters such as: size [“small EVs” (sEVs) and “medium/large EVs” (m/l- EVs)], density 
(low, middle, high), biochemical composition (CD63C, CD81C, Annexin A5), description of 
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their tissue of origin (prostasomes, oncosomes), their function, their presence outside the cells 
and their biogenesis pathway (Théry, 2018).  
 
Figure 2 - Representation of different extracellular vesicles 
The EVs molecular composition is cell-type specific and is represented by several molecules, 
such nucleic acids (largely constituted by mRNAs and miRNAs), as well as proteins and lipids, 
all reflecting the similar composition of the cell from which they originate (Gutierrez-Vazquez, 
2013). Similarly, their functions are closely related to their cellular origin, being involved in 
several mechanisms such as immune response, inflammation, etc (Zhang, 2014). In addition, 
the composition of their molecular cargo may be also influenced by the choice of specific 
methods of isolation (e.g. ultracentrifugation, SEC, immuno isolation etc.), as well as by the 
sample from which they are harvested (cell culture medium, bio fluids, or tissues) (Lässer, 
2018).  
 The protein content of exosome is mainly divided in four categories: 1) transmembrane or lipid 
bound extracellular proteins (tetraspanins like CD9, CD81, CD63), 2) cytosolic proteins 
normally involved in their biogenesis (RAB proteins, Hsp70, Hsp90), 3) intracellular proteins 
unique of cellular organelles and often absent in exosomes (calnexin, Golgi and ER proteins) 
and 4) extracellular proteins, such as acetylcholinesterase (ACHE). Moreover, membrane and 
cytoskeletal proteins, lysosomal markers enzymes, death receptors (FasL, TRAIL), cytokines, 
HLA class I and II proteins, and some HSPs can be also part of these vesicles (Choi D. , 2015). 
On the basis of this classification, when characterizing these particles, at least one protein of 
each category should be identified (Lotvall, 2014).  
  EVs lipid composition is the least known, mainly due to the few standardized isolation 
methods currently used, that have also caused some confusion in the scientific community in 
the interpretation of results. Moreover, exosomes seem to be more resistant to the use of 
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detergents than apoptotic bodies and microvesicles, thus complicating the interpretation of 
analysis (Osteikoetxea, 2015). However, despite these limitations, it is now known that EVs are 
mainly composed of sphyngolipids, phosphatidyl serine, cholesterol, saturated fatty acids and 
ceramide (Pfrieger, 2018) (Brouwers, 2013). Moreover, it has been shown that extracellular 
vesicles of different diameters are made up of different lipids, with exosomes having a higher 
lipid order than microvesicles or apoptotic bodies (Skotland, 2019).  
 Among all the few EVs lipidomic studies, exosomes seem to be the most analyzed class. 
Similarly to other vesicular components, the bilayer of these nano-vesicles is mainly constituted 
of membrane lipids similar to those of the cell plasma membrane from which they originate 
(Skotland, 2017). In addition, exosomal membranes may also reflect the asymmetric lipid 
organization of cell membrane lipids, with sphingolipids and phosphatidylcholines (PC) 
arranged in the outer leaflet, while the other lipid classes are mostly present in the inner leaflet. 
Overall, exosomes are rich in cholesteryl-esters (CE), triacylglycerols (TAG) and cardiolipins 
(Brouwers, 2013). However, these lipids seem also to be respectively present in the core of lipid 
droplets and in the inner membrane of mitochondria, suggesting that lipid droplets, lipoproteins 
or mitochondria may co-precipitate with exosomes (Yuana, 2014). Exosomes membranes may 
also contain cholesterol, sphingomyelins (SM), as well as ether lipids (mainly found as PC and 
PE), alkenyl-ethers (also called plasmalogens) (Lydic, 2015), glycosphingolipids and 
phosphatidylserine (PS) with levels 2-3 times more concentrated than in cells (Skotland, 2019). 
In contrast, phosphatidylethanolamines (PE), phosphatidylcolines and  phosphatidylinositols 
(PI) are respectively present in similar (PE) and low concentrations than in their parent cells. 
 The biogenesis of extracellular vesicles is a mechanism that differs among various types of 
vesicles. For instance, secretion of apoptotic bodies (>800 nm) occurs during apoptosis, a 
process that cells use to discard undesired cells that can alter the physiological homeostasis 
(Fleisher, 1997). Apoptosis is mainly divided in three steps, which globally describe a process 
of blebbing and retraction of the cell membrane, with the final formation of membrane 
protrusions  that regulate cell fragmentation and its release in the form of apoptotic bodies 
vesicles (Tixeira, 2017) (Coleman, 2001). The formation of membrane protrusions is of 
fundamental importance, since it serves for the detachment of blebs from the plasma membrane 
and the release of apoptotic vesicles (Atkin-Smith, 2015).  
 Apoptotic blebbing is monitored by multiple events (hydrostatic pressure, Actin-myosin 
contraction, microtubules) which promote the translocation of fluids and cell components into 
these new forming membrane blebs (Mills, 1998). Despite the mechanisms of apoptotic bodies 
formation are still not well understood, they seem to play an important role in the intercellular 
communication, since they transport specific biomolecules (such as proteins and microRNAs) 
18 
 
to neighboring cells (Brock, 2019); for instance, apoptotic bodies coming from cancerous 
processes can deliver altered molecules to other recipient cells, stimulating the proliferation of 
new cancer cells and the acceleration of metastatic processes (Bergsmedh, 2001).  
 Microvesicles, also known as shedding vesicles, microparticles, or ectosomes, are particles 
with a diameter range of 0.1–1 µm, originating from the plasma membrane of the cell through 
a process of outward budding (Tricarico, 2017). Specifically, the increase of intracellular Ca2+, 
induced by an external signal, causes changes in the lipid distribution of the bilayer and the 
concomitant membrane blebbing, also due to the activity alteration of the phospholipid 
transportation enzymes flippases, translocases and scramblases (Willms, 2018). This increment 
stimulates the activation of cytosolic proteases (such as calpain and gelsolin), which re-organize 
the cytoskeleton (through the deconstruction of the actin cytoskeletal protein network) and 
cause the protrusion of the plasma membrane with consequent detachment of these vesicles 
(Turturici, 2014) (Cocucci, 2015).  
 Exosomes are the most studied vesicles, mostly defined by their size and their protein content, 
despite the fact that in literature the term “exosome” is improperly used to refer to small EVs 
(Wang, 2017). They are vesicles of 30-150 nm, forming through a well-organized process that 
starts with the invagination of the plasma membrane of the donor cell and the development of 
an endocytic pathway (Baietti, 2011).  
 Cell endocytosis is a molecular mechanism that develops during degradation, recycling, 
signaling, cytokinesis and migration processes (Besterman, 1983). First described in 1971 
(Kerr, 1972), it occurs when plasma membrane introflects towards the center of the cell and 
forms small vesicles named as “endosomes” (Robinson, 1996). The most described endocytic 
process is the clathrin-dependent endocytosis (Richard, 2005), however other pathways exist 
and are classified through their plasma membrane-associated mediators (caveolin, flotillin, etc.) 
(Rejman, 2005) (Glebov, 2006). Endocytosis is mainly regulated through the ubiquitination 
mechanism, a three-step process that addresses ubiquitin molecules to target proteins across the 
activity of ubiquitin -activating, -conjugating and -ligating enzymes (E1,E2 and E3) (Migliano, 
2018); nonetheless, endocytosis may be also develops from ubiquitin-independent pathways 
(Reggiori, 2001).  
 Endosomal maturation is a deeply regulated process, where proteins and lipids [Rab GTPases 
and phosphoinositides (PIP) respectively], work in harmony with the Endoplasmic Reticulum 
(ER) and the trans-Golgi network (TGN), providing enzymes and assisting the exchange of 
membrane components (Huotari, 2011). Endocytosis starts with the invagination of the plasma 
membrane and the formation of an endocytic vesicle, that come off the membrane and fuse with 
previously formed early endosomes (EE), stable structures of the cell that can also form through 
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the fusion of many endocytic vesicles (Jovic, 2010). At this point, the EE stops absorbing 
endocytic vesicles and mature into a sorting endosome, composed of two regions: tubular 
(responsible for the recycling of membrane components) and vacuolar (containing luminal 
cargo for degradation) (Kurten, 2001) (Pagano, 2004). 
 Cytoskeleton plays a pivotal role in this maturation process, since through the polymerization 
of actin it stimulates the movement of both nascent vesicles and early endosome (Oda, 1995); 
simultaneously, myosin VI guides the transfer of nascent vesicles from the actin-rich areas of 
the cell to the early endosome (Nielsen E. , 1999). Moreover, microtubules of the cytoskeleton 
support the interior structure of the endosome, serving as a substrate for the movement of this 
latter, thanks also to the activity of kinesins and dyneins molecules that enable the exchange of 
internalized material between compartments (Oda, 1995).  
 Once endosome matures, it converts into a late endosome (LE), carrying cargo that needs to be 
destroyed by the lysosomal system (Russell, 2006). The degradation of its vacuolar content 
starts with the development of intraluminal vesicles (ILVs), that form from the budding of 
membrane domains in the opposite direction of the tubular region of the early endosomes (EE) 
(Wenzel, 2018); these latter vesicles (ILVs) acquire late endosome (LE) characteristics and 
migrates towards the lysosome (in the perinuclear space) for their degradation. 
 Each step of this maturation is characterized by a distinct luminal pH (6.0–6.5 in EE, 5.0–5.5 
in LEs, 4.5 in lysosomes), responsible for the conversion of the late endosome (LE) into a 
multivesicular body (MVB), as well as for the activation of degrading enzymes (Scott, 2011). 
The transition of the early endosome (EE) into a late endosome (LE) is also regulated by the 
interaction between Rabs proteins and Phosphatidylinositol lipids (Wandinger-Ness, 2014) 
(Fili, 2006).  
 Rab’s proteins belong to a big family of GTPases, which play important roles in membrane 
organization and mainly serve as platforms for the selection of effector proteins (Stenmark, 
2009). Phosphatidylinositols (PIPs) are another group of molecules involved in endosome 
maturation, from clathrin-coated vesicles (PI(4,5)P2 and PIP4P) to the transition of early-late 
endosome (EE-LE) (PI(3)P, PI(5)P and PI(3,5)P2) (Hasegawa, 2017) (Antonescu, 2011).  
 In the early endosome, Rab5 GTPase stimulates the fusion with endocytic and Golgi-derived 
vesicles (Nagano, 2019). This GTPase has three isoforms in mammalian cells, with Rab5a being 
the major species involved in the maturation of early endosomes (EE) to late endosomes (LE). 
During this transition, Rab5 is replaced by Rab7, another GTPase that mediates the fusion 
between the late endosome (LE) and lysosomes (Rink, 2005). Nonetheless, other Rabs proteins, 
such as Rab11 (Wilcke, 2000), Rab4 (D’Souza, 2014), and Rab22 (Kauppi, 2002), are also 
implicated in the recycling pathways of the early endosome.  
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 Rab5 and PI(3)P levels increase at the early development process, dropping in later stages with 
the concomitant raise of Rab7 and PI(3,5)P2 levels, responsible for the formation of 
intraluminal vesicles (ILVs) (Rink, 2005). Rab5 inactivation is also accompanied by the 
reduction of ubiquitinated cargo (sequestered into intraluminal vesicles), the inactivation of 
Rab4 protein and the acidification of the endosomal pH through the activity of the V-ATPase 
vacuolar proton pump. In later stages, endosomes interact with the ER and the interaction 
exponentially expands as the endosome mature, with respectively 50% and 99% of early and 
late endosomes bound to the ER (Friedman, 2013). This contact between endosome-ER allows 
several maturation processes (e.g. cholesterol transportation, biogenesis of intraluminal vesicles 
and the association with the microtubules dynein and kinesin), playing also an important role 
in the storage of Ca2+ levels inside the endosome (provided from the ER storage). Ca2+ is an 
essential ion for the regulation of endosome maturation, since is needed for membrane 
anchoring and fusion (MacDonald, 2005). Endosome membrane seems also to be generated by 
lipid droplets that form transient contact sites with endosomes, furnishing membrane 
components that are used for the maturation of endosome (Liu, 2007). Once Multivesicular 
bodies (MVBs) are formed, the majority of them undergo lysosome degradation, whereas a few 
part escapes from this process to be released in the extracellular space as intercellular 
communicators (exosomes) (Podinovskaia, 2018).  
 The development of the multivesicular body (MVB) is regulated by the activity of the 
Endosomal Sorting Complexes Required for Transport (ESCRT) (Bache, 2003). This latter is 
a molecular machinery composed of a series of 4 protein complexes: ESCRT -0, -I, -II and -III. 
Working together, they package membrane proteins into ILVs which then convert into 
multivesicular bodies (MVBs). The first three groups of ESCRT are mainly involved in the 
binding of ubiquinated proteins on the surface of endosomes (thanks to the presence of specific 
ubiquitin binding domains), while ESCRT-III interacts primarily with intraluminal vesicles 
(ILVs) present within the lumen of endosomes. Once the Multivesicular body (MVB) mature, 
it can follow three fates: fuse with the lysosome causing intraluminal vesicles (ILVs) 
destruction by lysosomal enzymes (Schuh, 2014), be recycled back from the cell, or can be 
secreted in the extracellular space as exosomes (Podinovskaia, 2018) (Klumperman, 2014).  
 Therefore, exosomes are the secretion product of multivesicular bodies (MVBs), which form 
through an endocytosis of the plasma membrane that introflects into the internal part of the cell 
and creates an early endosome vesicle (EE), a membrane bounded compartment within the cell 
(Colombo, 2014). On the basis of the endocytic pathway, the inner budding of the membrane 
of the early endosome replaces the already existing endosomal luminal space with small 
intraluminal vesicles (ILVs), forming the multi-vescicular Body (MVB) or late endosome (LE), 
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filled with proteins, lipids and cytoplasm specifically sorted (Gutierrez-Vazquez, 2013). At this 
point the multi-vesicular body (MVB) merges with the plasma membrane and release its 
intraluminar vesicles in the extracellular space as “exosomes” (Hessvik, 2018).  
 As it happens in endocytic processes, the development of intraluminal vesicles (ILVs) and 
multivesicular bodies (MVBs) is a mechanism that requires the participation of the Endosomal 
Sorting Complex Required for Transport (Colombo M. , 2013). Here, ESCRT-0, a heterodimer 
formed by signal transducing adaptor molecule-STAM and hepatocyte growth factor-regulated 
tyrosine kinase substrate-HRS molecules, recognizes and sequestrates ubiquitinated trans-
membrane proteins into the endosomal membrane and, thanks to the cooperation with 
phosphatidil inositol-3-phospate (PI(3)P), starts their sorting whitin the multivesicular body 
(MVB) by recruiting ESCRT-I through the activity of tumor susceptibility gene 101-TSG101 
protein (Kojima, 2014). ESCRT-I, instead, is composed of several proteins: vacuolar sorting 
proteins (VPS), multivesicular body (MVB), ubiquitin associated (UBAP) and the tumor 
susceptibility gene 101 (TSG101); together with ESCRT-II, it is responsible for the deflection 
of the membrane of multivesicular bodies, which stretches into buds with specific cargo and 
forms a sort of vesicle neck; the last complex, ESCRT-III, mainly composed of charged 
multivesicular body proteins-CHMP, is implicated in the detachment of the formed vesicle and 
the development of intraluminal vesicles (ILVs). Once formed, ESCRT-III binds Vps4 ATPase 
for its disassembly (Hanson, 2012).  
 The development of exosomes is controlled by several components such as syndecans (Baietti, 
2011), heparan sulphate (Roucourt, 2015) and syntenin (Friand, 2015). This latter interacts with 
the auxiliary protein of the ESCRT complex ALIX (also known as PDCD6IP) and assists the 
invagination of endosomal membranes. ALIX and syntenin are two of the 20 most frequently 
proteins identified in exosomes, generating a distinctive class of vesicles (flotillin-1-negative) 
(Baietti, 2011). The presence of all these molecules is very important for the biogenesis of 
exosomes; for instance, the over expression of syntenin increases the levels of exosomal 
syndecans, ALIX and other exosomal markers (i.e. CD63 and HSP70), also providing heparan 
sulphate molecules that are important for many of the signalling events occurring at the cell 
surfaces during the biogenesis of intraluminal vesicles (ILVs) and exosomes (Fares, 2017). It 
also collaborates with the small GTPase ADP-Ribosylation Factor 6 (ARF6), located on cell 
membranes and endosomes, and is involved in various cellular mechanisms (membrane 
transport, vesicular traffic and membrane remodeling), by controlling the actin cytoskeleton 
and the metabolism of phosphoinositides (Ghossoub, 2014). ARF6 is extremely important for 
the development of exosomes, especially at the stage of intraluminal vesicles (ILVs), and its 
inhactivation causes a considerable decrease in exosomal proteins (Hessvik, 2018). 
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 Various populations of ILVs, with different lipids and cargo, can co-habit and form within 
MVBs, and can be distinguished based on their size and their mechanism of formation. 
However, their mechanisms of formation and sorting still remain partially understood, with the 
complex ESCRT process the best described so far; nonetheless, some other ESCRT-
independent pathways have also been identified and might coexist with ESCRT-dependent 
machinery, thus confirming the presence of different multi-vesicular bodies (MVBs) sub-
populations (Babst, 2011).  
 Despite the mechanism of exosomes secretion is still not well understood, its release might 
occurs through the remodeling of the cytoskeleton, further controlled by the increase of internal 
Ca2+ and phospholipase D (PLD2) (Laulagnier, 2004). Once in the extracellular space, these 
vesicles can be either internalized by receiving cells, or they can act as transmembrane signals 
by binding receptors on the plasma membrane of the cells (Mulcahy, 2014) (Feng, 2010). 
Indeed, endocytosis is also the mechanism used from EVs during their internalization in 
receiving cells; however, it has been recently proposed that their uptake could also occur 
through a mechanism of “passive endocytosis”, which appears during the natural recycling of 
the plasma membrane of the cells and could passively drag exosomes attached to the surface of 
a cell. 
1.4 Methods of isolation and characterization of extracellular vesicles 
 
Currently, characterization of EVs is a combination of several methods that include: 
microscopy (TEM, SEM, CrioTEM), Western Blot, -omics analysis (proteomic, lipidomic, 
metabolomic), dynamic light scattering techniques (Nanoparticle Tracking Analysis-NTA and 
Zetasizer), Tunable Resistive Pulse Sensing (TRPS), as well as immunohistochemical and flow 
cytometry analysis of specific EVs markers, used to describe their morphology, biochemical 
composition and receptors localized on their membranes (Momen-Heravi, 2012) (Table 2). 
However, one of the main issue when purifying these particles is that, currently, there is no 
consensus for a unique standard isolation protocol (Szatanek, 2015).  
 Ideally, the method used for their isolation should be simple, fast and inexpensive. Overall, 
three main methodologies are currently used for their isolation: 1) differential centrifugation 
coupled to ultracentrifugation with, or without, a sucrose gradient/cushion (Iwai, 2016), 2) 
adsorption to magnetic/non-magnetic micro-beads (Koliha, 2016) and 3) size exclusion 
chromatography (Nordin, 2015). Each method has its own advantages and disadvantages, and 
the choice of one rather than another can result in different EV subpopulations with different 
properties (Davis, 2019). Therefore, at the moment there is no single standardized method for 
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the isolation of EVs, which could be also able to minimize co-isolating protein aggregates and 
other membranous particles from a sample of EVs.  
Table 2 - Most common EV isolation and characterization methods 
Isolation References Characterization References 
Ultracentrifugation 
Density gradient 
(Théry, 2006) 
(Zhang Z. , 2014) 
Electron Microscopy: 
TEM; 
SEM; 
cryo-EM; 
 (Escola, 1998) 
 (Sokolova, 
2011) 
(Poliakov, 2009) 
 
 
Size Exclusion Chromatography  
(SEC) 
 
 
(Böing, 2014) 
Dinamic Light Scattering 
(DLS); 
Nanoparticle Tracking 
Analysis (NTA); 
Tunable Resistive Pulse 
Sensing (TRPS) 
(Kesimer, 2015) 
(Gercel-Taylor, 
2012) 
(Maas, 2014) 
Immunological separation: 
Magnetic beads; 
ELISA exoTEST 
 
(Pedersen, 2017) 
(Logozzi, 2009) 
Biochemical analysis 
(Western Blot) 
(Théry, 2018) 
Polymer-based precipitation (Brown P. , 2017) Flow cytometry (Pospichalova, 
2015) 
Flow-field fractionation (Sitar, 2015) -omics analysis: 
Proteomic; 
Lipidomic; 
(Schey, 2015) 
(Haraszti, 2016) 
Commercial Kits 
ExoQuick 
Total Exosomes Isolation (TEI) 
Exo-Spin (ExoS) 
 
(Ding, 2018) 
 
 
 
 
Filtration 
Stirred Cell 
Tangential Flow Filtration 
 
(Busatto, 2018) 
 
  
PEG based (Lv, 2018)   
  As already mentioned, currently the gold standard method for vesicles preparation is 
differential centrifugation/ultracentrifugation coupled with sucrose/iodixanol density gradient 
(Gupta S. , 2018), and EVs obtained from this technology have been classified into: (1) large 
EVs, pelleted at low speed, (2) medium-sized EVs, pelleted at intermediate speed and (3) small 
EVs (sEVs), pelleted at high speed. This latter were further divided into four sub-categories: 
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(1) sEVs rich in tetraspanines CD63, CD9 and CD81 and endosomal markers (better known as 
exosomes); (2) sEVs without CD63 and CD81, but rich in CD9; (3) sEVs without 
CD63/CD9/CD81; (4) sEVs rich in extracellular matrix or serum factors. The last two-listed 
sEV are not associated with exosomes (Kowal, 2016).  
 In order to compare different isolation methods, several researchers have isolated EVs using 4 
of the most common methods (ultracentrifugation, density gradient, exo-kit and total exosome 
isolation) for the evaluation of yield, size, morphology, protein and RNA content of vesicles 
(Van Deun, 2014). They demonstrated that density gradient ultracentrifugation gave the purest 
exosome preparations as respect to the other three techniques which have also co-isolated 
contaminating factors. Skottvoll et al. evaluated the performance of different isolation methods 
based on differential ultracentrifugation and a commercial isolation kit (total exosome isolation 
reagent), demonstrating that the two isolation methods had similar performance with only some 
differences based on the origin of the cell (Skottvoll, 2019).  
 In another study, size-exclusion chromatography (SEC) was suggested as capable of 
eliminating most of the abundant proteins contained in body fluids, also maintaining the 
vesicular structure and conformation of EVs, thus making this procedure ideal for biomarker 
discovery, as well as for therapeutic applications (Gamez-Valero, 2016). These data were also 
confirmed by another research group, which showed that ultrafiltration followed by size 
exclusion chromatography (UF-SEC) provides well-concentrated EVs for proteomic and 
functional analysis (Benedikter, 2017). Thanks to its efficient capability to separate EVs from 
contaminant proteins (especially from large initial volumes), UF-SEC seemed to give a higher 
yield of pure vesicles if compared to those isolated by simple ultracentrifugation (Nordin, 
2015). 
 Despite the wide range of isolation methods currently available, the scientific community is 
still arguing about the choice of the best protocol to use, since each of them may be suitable for 
the analysis of one type of sample, rather than another (Szatanek, 2015). Hence, in absence of 
a precise standardization, the choice of the isolation method should follow the characteristics 
of the sample that have to be analyzed.  
1.5 Extracellular vesicles in health 
Extracellular vesicles are components of cell-to-cell communication, leading physiological and 
pathological processes in all living organisms, from Prokaryotes to Eukaryotes (Yuana, 2013) 
(Turturici, 2014) (Soekmadji, 2019) (Figure 3). 
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Figure 3 - Extracellular vesicles in health and diseases 
 For instance, Bacteria release small EVs particles from both Gram-negative (known as outer 
membrane vesicles -OMVs-) and Gram-positive bacteria, during microbiome communication 
processes (Kulp, 2010) (Lee, 2009). Under physiological conditions, these vesicles are 
primarily involved in the maintenance of bacterial homeostasis of parent and other bacteria cells 
(Kang, 2013), transporting nutrients, antimicrobial resistance factors (Lee J. , 2013) and 
suppressing toxic, or altered, proteins from the cellular environment (Vorkapic, 2016). For 
instance, commensal Bacteria release a specific type of vesicles implicated in the protection of 
the host organism against potential inflammatory bowel diseases (Li M. , 2017). Moreover, they 
can also promote the growth of peculiar species in specific intestinal environments, in order to 
facilitate bacterial communication. Thanks to these unique features, bacteria EVs could be 
thought as promising tools for the developments of therapeutic products, such as vaccines 
(Gnopo, 2017) (Stevenson, 2018).  
 Similarly to Prokaryotes, Eukaryote EVs also play an important role in several physiological 
processes such as: coagulation (Berckmans, 2001), pregnancy (Salomon, 2014), metabolism 
(Tramontano, 2010), immunity (Groot Kormelink, 2018) and apoptosis  (Bergsmedh, 2001).  
 Coagulation is a natural physiological mechanism that occurs during the repair of a wound, in 
which blood consistency changes from liquid into a sort of gel, thus allowing the closure of the 
wound and the end of bleeding (process called hemostasis) (Bloom, 1990). Briefly, if a wound 
occurs, the integral protein membrane tissue factor (TF) rushes to the damaged site and binds 
with coagulation factors VII and X, promoting the production of thrombine and the conversion 
of the soluble fibrinogen into the insoluble fibrin, with the formation of a thrombus (Rock, 
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1997). Coagulation factors need a phospholipid membrane to which they can bind, normally 
represented by phosphatidyl serine and negative charged phospholipids (Lentz, 2003). Hence, 
platelet-derived EVs, together with the presence of ion Ca2+, assist the binding of coagulation 
factors (e.g. tannins complex and the prothrombin complex) through the exhibition of a 
phospholipid surface, mainly made of phosphatidylserine (Chargaff, 1946) (Tripisciano, 2017) 
(Müller, 2003). 
 EVs are also well known in several immunomodulatory processes; indeed, all cells of the 
immune system are able to collect EVs-signals from non-immune cells (e.g. microbes, tumor 
cells, etc.), that are then converted and packed into vesicles, allowing the communication 
among immune system cells (Fernández-Messina, 2015). Therefore, immune cells can, 
themselves, secrete EVs carrying signals to other cells (Groot Kormelink, 2018) which can 
participate in various immune regulatory functions (such as immunosuppression and immune 
activation). For instance, neutrophil-EVs control anti-inflammatory and pro-thrombotic events 
(Dalli, 2008), while natural killer cells (NK) secrete EVs with specific NK cell markers (FasL 
and perforin) (Wu, 2019); in addition, monocytes- and macrophages- EVs are implicated in 
several processes that include antigen presentation, myeloid cell proliferation and 
differentiation (Garzetti, 2014), while mast cell and dendritic cell derived EVs enhance the 
proliferation of T- and B- cells, acting also as a reservoir for different immune modulatory 
proteins involved in antigen presentation (Kim D. , 2018).  
 In lungs, bronchial epithelial cells-EVs are involved in the regulation of communication among 
respiratory cells (Kesimer, 2015). Similarly, alveolar macrophage-EVs supervise cellular 
homeostasis, and the inflammatory signaling, by transferring suppressor cytokines to lung 
epithelial cells, while epithelial-EVs regulate the innate immunity in the airway, equilibrating 
lung interactions between epithelial and mesenchymal cells (Schneider, 2017) (Kesimer, 2009). 
 In stress conditions (e.g. ionizing radiations, osmotic alterations, hypoxia, temperature 
variations, presence of toxins and infections) (Diaz-Hidalgo, 2016), EVs act as messengers of 
stress response with close and distant cells (Bewicke-Copley, 2017). Stress events affect not 
only the amount of secreted EVs, but also their molecular composition, resulting in altered 
vesicles that can be used as a fount of biomarkers in several diseases (Boukouris, 2015). Indeed, 
they might act as reservoirs of dangerous molecules (e.g. unfolded proteins, mutated DNA or 
pathogens), that could modify cell physiology and thus need to be eliminated through normal 
clearance (Sproviero, 2018) (Cai, 2013). For instance, it seems that the release of endothelial-
EVs carrying high levels of caspase-3, an enzyme implicated in programmed death cell, may 
contribute in the cellular homeostasis, avoiding its aberrant increase inside the cells (Abid 
Hussein, 2005). In another example, it has been proposed that, when normal activity of the 
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endoplasmic reticulum fails, due to stress events, cell release stressed EVs that trap 
damaged/unfolded proteins inside their lumen, in order to preserve the endoplasmic reticulum 
homeostasis and cell vitality (Diaz-Hidalgo, 2016). Another interpretation of “stressed”-EVs 
describes these vesicles as sort of alarm bells that warn cells, and the immune system, of 
possible dangers caused by stressed events (Marcilla, 2014) (Mitsuhashi, 2016). For instance, 
cells of the immune system may be activated through the interaction with EVs carrying major 
histocompatibility complex (MHC-complexes), thus taking part to the antigen presentation 
process to inform cells about stress factors (Kleijmeer, 2001). Moreover, it was also proven that 
during oxidative stress cells secrete EVs rich in specific RNAs, able to act as messengers in the 
preservation of receiving cells from oxidative damages (Eldh, 2010).  
 EVs also regulate the communication among cells of the nervous system. It is now known that 
neurons secrete EVs able to interact with both neurons and glia cells, and are probably involved  
in processes of neuronal electrical activity (Frühbeis, 2013). Neuronal communication through 
EVs is regulated and combined to the neuronal electrical activity and the neurotransmitter 
signaling, suggesting that brain activity triggers EVs signaling (Borroto-Escuela, 2015). 
Neural-EVs not only regulate the homeostasis of the central nervous system, helping the 
plasticity of neural signaling processes, but they also enhance neuronal maintenance 
and regeneration through the passage of information between the brain and the periphery 
(Lopez-Verrilli, 2013) (Pegtel, 2014).  
 Under physiological condition, neuronal-EVs are mainly involved in the regulation of 
homeostasis and in those mechanisms of plasticity of the nervous system (Chivet, 2012). For 
instance, oligodendrocytes accumulate high levels of EVs close to the axon, that are then 
subsequently secreted under the neurotransmitter glutamate signal, this latter released by 
neurons cells as a consequence of their electrical activity (Frühbeis, 2019) (Frühbeis, 2013). 
Once in the extracellular space, they are normally internalized by endocytosis from the majority 
of neuronal cells and absorbed by macropinocytosis in the case of microglial cells (Fitzner, 
2011). Oligodendroglial-EVs play important roles in maintaining neuronal homeostasis and 
regulating neuroprotection during stress conditions (e.g. oxidative stress or nutrient 
deprivation) (Pegtel, 2014). Similarly, astrocytes secrete different types of EVs, mainly 
composed of small and large EVs, that seem to be implicated in neuroprotection and in the 
modulation of inflammatory events of the central nervous system (CNS) (Pascua-Maestro, 
2018). Even microglia cells release EVs, which regulate synaptic transmission during excitatory 
mechanisms, neuro-inflammation processes (Yang Y. , 2018), in the clearance of dangerous or 
unwanted cellular molecules (Antonucci, 2012), as well as the delivery of endocannabinoids, 
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molecules responsible for the alteration of the neurotransmission in inhibitory neurons 
(Lemaire, 2019). 
 High concentrations of EVs have also been found during senescence pathways. Generally, 
upon senescence cells undergo a series of modifications that end with their inability to continue 
proliferative processes, as well as irreversible morphological alterations that convert cells into 
flat and hypertrophic units (Ohtani, 2013). EVs originating from this type of cells carry different 
molecules with a modified profile (e.g. genomic DNA fragments), which can take part to many 
mechanisms like DNA damage activation, tumor progression (in the involved area) and immune 
cell activation (Xu, 2013). 
EVs have also been described in reproductive processes. For instance, EVs isolated from 
reproductive tracts of both female and man transport messages involved in female reproduction, 
sperm activity and modulation of female immune response (Almiñana, 2020). Male EVs are 
implicated in several pathways that include sperm maturation (Nixon, 2019), protection from 
female immune response, sperm motility and acrosome reaction (Sullivan, 2016). Female EVs 
are of such importance during reproduction and pregnancy processes, monitoring the 
maturation of the follicle, as well as in the communication with the embryo (Machtinger, 2016).  
 Recent studies have demonstrated that, during fertilization, oolemma EVs are directly involved 
in the interaction between sperm and oolemma (IZUMO1-JUNO), since they carry Juno 
receptor on their membranes, a molecule responsible for the block of polyspermy. (Bianchi, 
2014). In pregnancy, EVs translocate in the uterine tissue for its remodeling, preparing the 
reproductive tract for the implantation of the embryo (Yang, 2019); their presence persists for 
the whole period of maternal pregnancy, with higher levels of EVs rich in CD9 and CD63 
tetraspanins during early stages of pregnancy, serving as important messengers for the 
communication between the placenta and the mother (Mellisho, 2017). Among all the placenta 
derived EVs, those coming from the synctiotrophonblast (STB), the epithelium lining the 
placenta that provides nutrients circulation between the embryo and the mother, are the most 
representative (Mincheva-Nilsson, 2014). In normal pregnancy, cells of the synctiotrophonblast 
secrete extracellular vesicles (called STBEVs) implicated in the down regulation of the 
innate immune system, also promoting the release of pro-inflammatory cytokines from 
peripheral blood (Gupta, 2004).  
1.6 Extracellular vesicles in diseases 
The role of EVs in the development of various pathological conditions has aroused a lot of  
interest in the recent years, demonstrating their active involvement in several diseases (Ciregia, 
2017) (Gao, 2017).  
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 For instance, EVs of Gram-negative and Gram-positive bacteria are involved in 
many pathophysiological functions, such as bacteria-bacteria (Soler, 2008) and bacteria-host 
interactions (Bitto, 2017). Bacteria-bacteria interactions are important for antibiotic 
resistance, bacterial survival and the death of other competitors bacteria (Mashburn-Warren, 
2008), while bacteria-host interactions regulate the transmission of virulence factors, as well as 
processes of bacteria adhesion, invasion and elusion of the host immune system (Bielaszewska, 
2017). During bacterial infections, host neutrophil cells produce vesicles able to aggregate 
around bacteria, causing a reduction in its growth (Timár, 2013). Immune cells can be further 
activated through the presence of vesicles derived from infected cell, which deliver microbial 
and viral molecules to antigen presenting cells (Veerman, 2019) (O'Neill, 2008). Moreover, 
immune-EVs may be implicated in chronic inflammations (such as allergy) and auto-immune 
diseases (i.e. rheumatoid arthritis), enclosing multiple auto-antigens that can be presented and 
delivered across EVs, thus causing the beginning of auto immune responses  (Wu G. , 2015) 
(Knijff-Dutmer, 2002). 
 In pathogenic infection diseases, EVs act as extracellular signals that help the survival of 
pathogens among inhospitable cellular environments (rendered hostile through the activation 
of the immune system of the host), through the manipulation of the host responses and the 
communication with other pathogens (or host cells) during differentiation, transmission, 
growth and virulence coordination processes  (Marcilla, 2014) (Ofir-Birin, 2017) (Rodrigues, 
2018). For instance, in cerebral malaria, the presence of Plasmodium falciparum parasite is 
responsible for an increase of circulating EVs in infected patients, which travel the endothelium 
of brain infected vessels altering their activity and characteristics (Pierre-Yves, 2014) 
(Sampaio, 2018).  
 Enveloped viruses may be considered as another kind of pathogenic EVs, since they are a 
specific type of nanovesicles, arising from host cells, that use cellular components not only for 
the duplication of their viral genome, but also for the transport of cellular molecules inside their 
lumen (Sun, 2006). One example are HIV virions, small vesicles similar to several circulating 
EVs, which originate from endosomic vesicles (or cholesterol rich domains) of the host 
membrane through an endocytic pathway, carrying host proteins on their surfaces (Briggs, 
2003). They are able to encode proteins present in the plasma membrane of the host cell that 
allow viruses to co-operate and fuse with the host cell target, infecting this latter with their viral 
units that will be subsequently released in the extracellular space, eluding the immune system 
of the host (Vazirabadi, 2003) (Altan-Bonnet, 2016). Of interest, viruses may infect host cells 
by delivering their genome molecules directly inside extracellular vesicles, without the 
necessity to use the entire virion  (Kouwaki, 2017).  
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 EVs have also been isolated from different fungal species, especially in many human 
pathogens, where they work as messengers for the communication between both host-fungal 
and fungal-fungal cells during the modulation of the pathogenesis (Joffe, 2016). These type of 
vesicles are similar to those of the host cells but, unlike mammalian cells, fungal EVs must 
cross the cell wall in order to be released in the extracellular space; therefore, some of them 
may get trapped in this compartment, contributing to the remodeling of the cell wall and serving 
as surface components (de Toledo, 2019) (Rodrigues M. , 2013). 
 Mammalian EVs are involved in the regulation of different diseases mechanisms, such as: 
coagulation, immunity, metabolomic alterations, cancer, etc. 
 In pathogenic coagulation, EVs vesicles regulate the activation and migration of platelets at a 
site of the local damage, causing an increase of the levels of different coagulation factors 
responsible for the formation of plaques that clog the vessels and cause the formation of 
defective thrombi (Bick, 1992) (Zwicker, 2008). For instance, in cancer-related coagulation 
processes, circulating tumor EVs are highly concentrated and serve as a reservoir system for 
the transport of the tissue factor molecule (Thomas, 2009).  
 Another important role of EVs has been also shown in several metabolic processes (Göran 
Ronquist, 2019) (Kobayashi, 2018), affecting serum metabolome modifications in different 
areas of the organism (Royo, 2017). For example, it has been demonstrated that high levels of 
EVs rich in arginase are involved in the conversion of arginine into ornithine, causing 
consequent anomalies in processes of vascularization, neuronal toxicity and cancer (Caldwell, 
2018). Arginine is an important amino acid, necessary for its conversion into nitric oxide (NO) 
during normal processes of vasodilation blood vessels. However, if metabolic alterations 
occurs, circulating EVs cause a reduction of nitric oxide (NO) in favor of an increase of reactive 
oxygen species within the endothelial cells, thus resulting in endothelial dysfunctions and 
consequent development of pathological conditions (Bode-Böger, 1998). One of the most 
representative donors of arginase-EVs are hepatocytes and their levels may strongly increase 
after liver damage (Royo, 2017) (Eguchi, 2019). 
 However, these alterations are not limited to the activity of the only liver, but also stem cells, 
platelets, red blood cells and endothelial cells can release enzymes within EVs that may 
increase the risk of pathological conditions (e.g. high blood pressure, elevated glucose and 
triglyceride levels) and dangerous diseases (e.g. type 2 diabetes, dyslipidemia, obesity) (Iraci, 
2017) (Lakhter, 2015) (Santamaria-Martos, 2019) (Freeman, 2018).  
 In the adipose tissue, high levels of EVs may be responsible for different pathological 
conditions (i.e. insulin resistance and secretion of pro-inflammatory adipokines) and chronic 
inflammations (Eguchi, 2016). In a diet rich of calories and fats white adipose tissue expand 
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while oxygen levels decrease, causing a hypoxic environment within the tissue; at the same 
time, cell macrophages migrate in the tissue secreting pro-inflammatory cytokines and, as a 
result, adipocytes release compromise EVs that might have effects on other cells and tissues 
(Maëva, 2017).  
 Metabolic alterations may also be caused by the activity of the intestinal microbiota. This latter 
releases outer membrane vesicles (OMVs) that, in normal conditions, maintain gut barrier 
integrity; however, if alterations in the microbiota occurs, epithelium become more vulnerable 
and OMVs may migrate from the intestinal barriers to the bloodstream of the host, facilitating 
the development of inflammatory processes (Jun, 2013) (Ahmadi Badi, 2017).  
 In pregnancy, circulating EVs can be used as a promising tool for the monitoring of pregnancy 
disorders caused by placenta dysfunctions such as pre-eclampsia, a severe and dangerous 
human syndrome that provokes hypertension and proteinuria in the second half of 
pregnancy, degenerating in maternal mortality. (Han, 2019). Before the development of the 
syndrome, the placenta undergo a series of modifications, which are also reflected in the 
number and phenotype of EVs released in maternal circulation (Gill, 2019).  
 In cancer progression, EVs are implicated in several features of the pathology, especially in 
the activation of aberrant proliferative and suppressor pathways (Minciacchi, 2015) (Tominaga, 
2015). Tumor EVs carry specific molecules that may be taken up by other cells and alter the 
expression of pro- and anti- proliferation genes (Lunavat, 2015). For instance, they are able to 
transport specific altered nucleic acids (miRNA and DNA) to recipient cells, provoking 
morphological changes that may also stimulate the development of new malignant foci (Huber, 
2018) (Vagner, 2018).  
 Tumor micro-environment is a complex dynamic system, made up of several cells (e.g. 
cancerous cells, fibroblasts, endothelial cells, adipocytes and immune cells) who coexist in the 
same environment under the regulation of soluble growth factors and other molecules of the 
extracellular matrix (Hirata, 2017). EVs take part in the modulation of the tumor micro 
environment, carrying altered molecules that can modify the physiology of the surroundings, 
increasing tumor growth (Choi, 2014). 
 Interactions among EVs, cancer cells and the surrounding micro-environment may occurs in 
several ways: by directly binding the cellular surface of the cell (via the interaction between 
ligand-membrane receptors), through the release of their luminal content near the target cells, 
or by simply merging with the plasma membrane of the cells (partially or totally endocytosed) 
and delivering their cargo within the lumen of the recipient cell (Mulcahy, 2014).  
 Through these  interactions, cancer-EVs may transfer their metastatic phenotype to different 
cells, influencing their fate. For instance, cancer EVs carry glycolytic enzymes and metabolites 
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that may provoke a series of endothelial cell alterations, modifying the metabolic activity of 
cells and enhancing the development of a pro-metastatic micro-environment (Lawson, 2017) 
(Puhka, 2017). Cancer EVs may also affect the proliferative capacity of donor cells in an 
autocrine manner, through the interaction with their own plasma membrane (Raimondo, 2015).  
 Cancer-EVs also regulate tumor angiogenesis processes (an essential pathway for tumor 
growth), controlling the formation of new blood vessels and delivering growth factors and cargo 
to the cells (Perut, 2019). Tumor micro-environment is highly hypoxic, due to the excessive 
consumption of glucose by tumor cells (Koukourakis, 2006); under these conditions, levels of 
alterated EVs increase (as compared to EVs released from normoxic cells) and  carry mRNA 
and microRNA transcripts involved in pro-angiogenesis processess (van der Vos, 2016) 
(Patton, 2020). Therefore, as a consequence of excessive hypoxia, cancer-EVs stimulate the 
production of new vessels that will positively affect tumor growth (Ko, 2019). However, tumor 
angiogenesis may also occur indirectly, through the interaction of EVs with other cells (i.e. 
fibroblasts), causing the secretion of several pro-angiogenic factors that guide endothelial cells 
migration and vessels formation (Ko, 2019).  
 Cancer-EVs are also implicated in the development of cancer-related thrombi (Gheldof, 2017), 
where they carry coagulant proteins (i.e. tissue factor -TF-) that interact with other clotting 
factors within the blood and cause the development of a thrombus (Hisada, 2019) (P. Y. Che, 
2017). 
 However, among all these activities, one of the main roles of cancer-EVs occurs during 
mechanisms of tumor invasion and metastasis (Endzeliņš, 2018). During these processes, cells 
have to colonize new different cellular sites through a series of events (e.g. disruption of the 
cellular matrix and interaction with endothelial cells) that end with the passage of cells into the 
circulation (bloodstream or lymph) and the colonization of a new distinct site (Gkretsi, 2018). 
The rupture of the extracellular matrix may be also promoted by the activity of metastatic EVs 
that, thanks to the presence of surface integrins and metalloproteinases, interact with the 
extracellular matrix and guide the migration of other EVs through this latter (Nawaz, 
2018). Metastasization may be also stimulated through the communication between EVs and 
stromal cells, by the regulation of inflammation processes that increase tumor malignancy and 
growth (Gener Lahav, 2019). For instance, tumor derived-EVs are able to acquire features 
similar to those of cancer fibroblasts (the principal cell type within the microenvironment of 
solid tumors), which can then regulate the activation of these stromal cells for the release of 
stromal-EVs into the microenvironment, thus contributing in the development of tumor 
fibroblasts (Vu, 2019). EVs play an important role in the communication between cancer cells 
and the surrounding stroma, being rich in extracellular matrix components  (e.g. heparan sulfate 
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and proteoglycans) that are essential for the interaction with the extracellular matrix and cells 
(Cerezo-Magaña, 2019).   
 Therefore, EVs act as intercellular communicators between tumor cells and distant organs 
during metastatic colonization; for instance, some kind of metastatic cells preferably colonize 
precise organs (lung, liver, brain) releasing EVs that, through the blood, migrate to these new 
sites and prepare them to the metastatic colonization (Valencia, 2014). This is also possible 
because during tumor growth, the newly formed blood vessels have a weak structural 
organization, letting cancer cells enter into the circulation for the colonization of distant areas 
of the body (Nishida, 2006). During these steps, EVs promote cellular proliferation by 
transferring specific cargoes that may enhance the expression (or mutation) of oncogenes, as 
well as activate intracellular signaling pathways, or inhibit negative feedback mechanisms 
(Maacha, 2019) (Ji, 2020).  
 Metastatization may be also caused by the treatment of tumors with specific chemotherapy 
drugs that may affect the activity of cancer EVs. For instance, after these treatments, EVs 
released by cancer cells may deliver resistance proteins and nucleic acids that stimulate the 
development of a multi-drug resistance phenotype (MDR) in tumor cells (Lopes-Rodrigues, 
2017) (Kaye, 1988). According to this hypothesis, it has been shown that cells treated with 
different type of therapies (e.g. ionizing radiation and chemo-therapeutics), secrete vesicles that 
may interact with distant cells and provoke stress response or proliferative processes (Kim M. 
, 2016) (O'Neill C. , 2019). The onset of chemoresistance may be explained by the fact that 
tumor cells absorb the drug in their cytoplasm and pack it within EVs that are then expelled in 
the extracellular space (Sousa, 2015). Another reason could be that EVs block cancer toxin 
drugs through the exposition of specific antigens that are targeted by specific antibodies 
(Markov, 2019).  
 Cancer EVs play also an important role during immune evasion, impacting the activity of 
immune system cells (e.g. NK- and T- cells) and inhibiting their natural functions of killing 
tumor cells (Ricklefs, 2018) (Abramowicz, 2019). It seems that they regulate the interaction 
between tumor cells and immune system (Menay, 2017), promoting many pro- and anti-tumoral 
effects, such as the immunosuppression of dendritic and T-cells, or the decrease of cytotoxicity 
of NK-cells (Al-Samadi, 2017). Unlike to all these pro-tumor processes, cancer-EVs can also 
exert anti-tumor effects, acting as antigen vesicles that promote anti-tumor immune responses 
and activate dendritic, NKs- and macrophages cells (Zhang B. , 2014). For instance, once 
dendritic cells have absorbed tumor cells and tumor antigens, they release EVs loaded with 
those antigens that may positively increase immune responses (Zeng, 2018).  
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 Several studies have been performed to modulate cancer EVs secretion in vivo, which mainly 
focused on the activity of small GTPases, molecules involved in the secretion of EVs. For 
instance, it was demonstrated that the inhibition of RAB27A, or RAB35, reduced the secretion 
of EVs (especially exosomes) in several tumors (Li W. , 2014) (Yang L. , 2019). 
 The role of circulating EVs has been also investigated in some cardiovascular diseases. Under 
physiological conditions endothelial cells, platelets and leukocytes release EVs in the bloody 
stream (Hutcheson, 2018) (Brahmer, 2019), but their plasma levels increase in subjects 
with cardiovascular diseases, or with some cardiovascular risk factors, such as: hypertension 
(Kosanovic, 2019), smoking (Serban, 2016), hypercholesterolemia (Nielsen M. , 2015) and 
diabetes (Jia, 2016). For instance, it has been shown that circulating levels of leukocyte derived 
EVs associate with atherosclerotic plaques and can be responsible for some endothelial 
disorders in patients with coronary diseases (Schiro, 2015). Similarly, plasma levels of platelet 
EVs seem to intensify in patients with cardiovascular risks, being involved in deleterious effects 
(e.g. thrombosis) (Bank, 2015). Atherosclerotic EVs accumulate in atherosclerotic lesions 
expressing specific ligands at their surface (i.e. CD40), which are responsible for plaque 
progression and thrombi formation (Chistiakov, 2015). Circulating EVs arising from 
myocardial infarction affect the vascular structure, by altering the release of endothelial nitric 
oxide (NO) and increasing the expression of tissue factor (TF) and endothelial 
apoptotic processes (Amabile, 2005) (Boulanger, 2001).  
 These vesicles can cause both inflammatory and anti-inflammatory effects, stimulating the 
increase of pro-inflammatory cytokines (e.g. IL-6 and IL-8) from endothelial cells and 
leukocytes, thus promoting the adhesion of monocytes to the endothelium and its migration 
through the plaques (Beez, 2019). Endothelial and platelet derived EVs may also encourage 
endothelial permeability through the delivery of specific apoptotic enzymes within their lumen 
(i.e. caspase-3), increasing apoptotic processes and enhancing leukocyte adhesion to the 
endothelial cells (Boulanger, 2017). Similarly, plasma vesicles could also support the 
adhesion of inflammatory cells to the endothelium, enhancing not only the expression of 
adhesion molecules (i.e. ICAM-1) and receptors on the surface of monocytes, but also 
delivering pro-atherogenic chemokines from platelet EVs to the endothelial cells (Boulanger, 
2017).   
 In smooth muscle, EVs may cause arterial micro-calcification (Nik, 2017) and the formation 
of atherosclerotic plaques (Goettsch, 2016), while cardiomyocytes and other cardiac cells of 
the heart produce EVs that may be responsible for some hypoxia injuries through the 
transmission of hypoxic signals to normoxic cardiomyocytes (Yarana, 2018). Cardiomyocytes-
EVs can also deliver molecules with glycolytic activity to endothelial cells, exerting 
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controversial effects that can either stimulate angiogenesis or pro-inflammatory responses in 
myocardial infaction (Garcia, 2016) (Ribeiro-Rodrigues, 2017).  
 Another interesting role of pathogenic EVs has been shown on respiratory cells; here, EVs 
originating during stress events (e.g. cigarette smoke) carry a different cargo that alter cellular 
homeostasis and may damage lung epithelial and endothelial cells, provoking potential chronic 
obstructive pulmonary diseases (Benedikter, 2017) (Benedikter, 2019).  
 EVs may be also implicated in some blood diseases (Tissot J. , 2013). For instance, platelets 
(Aatonen, 2014), erythrocytes (Nguyen, 2016), leukocytes (Pugholm, 2016), endothelial cells 
(Cantaluppi, 2015), as well as tissues or organs (i.e. tumor cells), may release altered EVs that 
can provoke some blood related pathologies (Nomura, 2017). 
 Platelet-EVs (PEVs), the main type of blood circulating EVs, play several roles in the 
activation of the immune system through the interaction with leukocytes cells (Weiss, 2018), 
in atherosclerotic lesions formation (Suades, 2015), in coagulation processes (Suades, 2012) 
(Zhao, 2016), as well as in inflammation events (Badimon, 2016). Their activity is of such 
importance and, a reduction of their levels, may be responsible for impaired pro-coagulant and 
coagulation functions. Beyond platelet-EVs, other circulating blood EVs are involved in pro-
coagulant activities, carrying specific molecules on their membranes (e.g. phosphatidylserine 
and the tissue factor) extremely important during coagulation mechanisms (Del Conde, 2005) 
(Lentz, 2003). EVs-coagulant function may depends on the presence of these molecules, as 
microvesicles negative for both of molecules could exert poor pro-coagulant activity, 
while those expressing one, or both type of molecules are moderate and highly pro-coagulants 
respectively.   
 Of interest is the role of EVs in the development of some neurodegenerative diseases 
(Thompson A. , 2016). All cells of the nervous system are able to release nanovesicles, however 
its structural complexity makes in vivo studies very difficult, with the majority of them coming 
from the supernatant of cultured cells (Frühbeis, 2013). During inflammation and brain damage 
events, EVs cross the blood-brain barrier and regulate communication, in both directions, 
between the central nervous system and the periphery (Dickens, 2017). These type of vesicles 
carry altered and aggregated proteins (e.g. beta-amyloid or prion proteins) that are associated 
with some neurodegenerative diseases (Karnati, 2019). For instance, proteins involved in the 
progression of Alzheimer's disease, such as the normal and oligomeric form of tau protein 
(Guix, 2018) and the amyloid precursor protein (Laulagnier, 2018), have been found to be 
transported through EVs. Similarly, in Parkinson’s disease, neuron-EVs carry altered molecules 
of SOD1 (Silverman, 2016) and alpha-synuclein (Chistiakov, 2017), suggesting their pivotal 
role in neuronal pathogenic processes.  
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1.7 Synthetic nanoparticles: current delivery systems 
Nanoparticles have been widely proposed in several fields, especially in pharmaceutical and 
biomedical Industry (Bhatia, 2016). Among all the proposed kind of nanoparticles (e.g. 
inorganic, polymeric nanoparticles, carbon nanotubes and nanogels), lipid-based nanovesicles 
(L-NVs) have been the most promising, mainly for their therapeutic and diagnostic potential 
applications (Elizondo, 2011) (Bulbake, 2017).  
 They are small bilayered-spherical vesicles, constituted of various lipids of different nature 
(i.e. fats, waxes, sterols, vitamins, monoglycerides, diglycerides), with hydrophobic or 
amphipathic properties (Kraft, 2014). Their classification is mainly done on the basis of 
different parameters, comprising structural characteristics, methods of preparation  and lipid 
composition (Akbarzadeh, 2013) (Dua, 2012). This new kind of colloidal carriers have aroused 
a lot of interest in the last few years, as they present greater solubility and lifespan in solution, 
allowing an efficient targeting of organs and tissues through the release of the drug in the 
specific area (Wu J. , 2018) (Cuenca, 2006).  
 Their classification is mainly based on morphological and dimensional characteristics and 
divide them into: small unilamellar vesicles/nanovesicles (SUVs, size < 200 nm and single 
bilayer) (Hope, 1986), large unilamellar vesicles (LUVs, single bilayered vesicles of 200-1000 
nm) (Mimms, 1981), giant unilamellar vesicles (GUVs, single bilayered vesicles >1000 nm) 
(Bagatolli, 2000), multilamellar vesicles (MLVs, several concentric bilayers) (Lichtenberg, 
1984) and multivesicular vesicles (MVVs, several small vesicles entrapped into larger ones)  
(Kim S. , 1983). Their surface can also be easily functionalized with different ligands, thus 
providing also multifunctional systems.  
 Among all kind of nanoparticles, SUVs are the most used in drug delivery system; in fact, 
thanks to their unique size, they are able to escape from the rapid renal-clearance, facilitating 
their longer circulation in the body and increasing their possibility to reach the target cells 
(Blanco, 2015). 
 Another type of solid lipid nanoparticles are Micro- and Nano- emulsions, thermodynamically 
stable dispersion of oil and water  (Trotta, 1996) (Dipak, 2005). Micro- and Nano- emulsions 
are significantly different from the conventional emulsions, since they have specific physical 
properties (transparency, low viscosity, diameter <100–200 nm) and a low energy barrier that 
allow their spontaneously formation (Mc Clements, 2012).  
 Micro-emulsions are made from at least three components: a polar phase (usually water), a 
non-polar phase (usually oil) and a surfactant, with this latter forming an interfacial film that 
divides the polar and the non-polar domains (Gasco, 2009). Within this film, all reagents form 
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different microstructures, passing from droplets of oil dispersed in a continuous water phase 
(O/W-microemulsion), to water droplets dispersed in a continuous oil phase (W/O-
microemulsion) (Malik, 2012). 
 Homogeneous micro-emulsion can be prepared over a wide range of surfactant concentrations 
of oil-to-water ratios (10–80%), resulting in fluid solution of low viscosity  (Solans, 1997). 
Originally, these nanocarriers were produced with lipid materials such as fatty acids, 
triglycerides, waxes and oils, with the addition of a surfactant, commonly in combination with 
a co-surfactant or co-solvent, in order to increase the curvature of the interfacial film on the 
oil/water interface. These two initial faces (oil and water) are then melted above 40 ºC, since 
some lipid matrix are solid at body and room temperature and need to be melted (Cavalli, 2007). 
 The selection of the lipid material to use takes into account some parameters, such as: the lipid 
structure (it should be similar to the physiological conditions), the state of lipids (solid or 
liquid), regulatory aspects related to the pharmaceutical Industry and drug properties (the lipid 
should be able to solubilize the drug into the lipid droplet). 
 Once synthesized, the new formulation is then followed by steps of purification/separation, 
mainly based on techniques of Size Exclusion Chromatography, Tangential Flow Filtration and 
Ultrafiltration, that have been studied and developed for both purification and physic-chemical 
characterization of the products (Dalwadi, 2007) (Sivamohan, 1999) (Heydenreich, 2003). 
 In Italy, there are only few Companies expert in this type of nanocarriers, and Nanovector s.r.l. 
is one of them. It is a small Company, based in Turin, specialized in the research and 
development of nanostructured lipid systems for drug delivery, in both cosmetic and nutritional 
field. Nanovector has been operating in the field for over 15 years, taking part at many European 
projects and developing several families of patents. 
 Their technology focuses on the formulation of characteristic microemulsions and solid lipid 
nanoparticles (SLN), which are produced at room temperature, or using their original patented 
method of warm microemulsions (WµE), which can be furthered functionalized through the 
incorporation of different kind of drugs. One of their main target focuses on the investigation 
of new eye drug delivery systems, such as Solin™ product, an eye nanocarrier that can be 
administrated in form of eye drops and has been efficiently functionalized with different 
physico-chemical strategies, improving its performance and targeting.  
1.8 Latest trends on EVs: tool for delivery system and molecular biomarkers 
 
Interest on EVs is growing very fast over the years. Thanks to their characteristics (specifically 
their non-immunogenic nature due to their similar composition to the cell from which they 
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originate) they were recently taken into consideration for their use as drug delivery vehicles 
(Batrakova, 2015).  
 Actually, liposomes are the most used drug delivery system, but their biocompatibility and 
safety are still unknown. Unlike these synthetic systems, natural EVs have long circulating half-
life, are biocompatible, stable and have minimal, or no inherent, toxicity issues. Moreover, 
thanks to their small size, they are able to cross the blood-brain barrier (BBB), thus providing 
a useful carrier for the delivery of small drugs across this area. Indeed, 98% of drugs potentially 
effective cannot cross the BBB and their conceptual efficacy shown in labs has not a counterpart 
in clinical trials (Haney, 2015). In addition, thanks to their capability to carry different 
molecules (protein and miRNA among others), EVs can also eliminate all those problems 
related to the instability of drugs based on nucleic acid (Liang, 2018). Of importance, the 
possibility to isolate them from several biological fluids in non-invasive way, have suggested 
their use for diagnostic applications, since circulating EVs can be correlated to some specific 
diseases (Aryani, 2016). Therefore, if compared with their synthetic counterparts, they seem to 
be a better choice, exceeding those synthetic nanoparticles limitations (Busatto, 2019) and 
constituting one of the most promising drug delivery systems, especially in the gene therapy of 
different disorders (e.g. genetic deficiencies or anti tumor progression) (O'Loughlin, 2012). 
Similarly to natural nano-vesicles, EVs-based semi-synthetic nano-vesicles (NVs) represent 
another type of vesicle delivery system, that includes all those natural EVs with some 
modifications for specific purposes. 
 EVs-based therapies mainly focus on two approaches that differ from the way EVs are used: 
in their native or modified form. In the first case, EVs are harvested from the sample of interest 
(e.g. cell type, tissue, or fluid) and directly used for specific analysis (Tian, 2014). In the second 
case, they undergo specific modifications (e.g. insertion of biological molecules, at the surface 
of their membrane or inside their lumen), in order to have functional EVs with different 
capabilities, as respect to their original form (Tian T. , 2018). 
 The techniques used to package biological molecules into EVs are extremely important and 
mainly develop through two different ways: one method targets EVs that have already been 
produced, while the other type targets the cells that secrete these specific EVs (Luan, 2017). In 
the first case, EVs are normally loaded through a passive incubation with the molecules, or 
drugs, that have to be associated with EVs (Sun D. , 2010). For instance, some researchers have 
encapsulated doxorubicin (a drug currently used for breast and solid cancer) into exosomes to 
increase local dosage of the molecule and reduce its adverse effects on other organs (Gomari, 
2018). However, the functionalization of EVs may also require an active intervention, such as 
electroporation, that temporarily disrupt membrane integrity (Kim M. , 2019).  
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 In the second case, loading of EVs occurs indirectly, through the modification of their parent 
cells, for instance through the transfection of this latter, thus improving levels of released EVs 
(Lou, 2015). Once loaded with a specific cargo, EVs are administered to the patient through 
several methods, including oral and intranasal routes, as well as injection, or under the skin. 
 Native EVs have been used in many therapeutic approaches, as they are natural reservoirs of 
biological molecules, important in treating diseases (Batrakova, 2015). For instance, EVs have 
aroused a lot of interest for the treatment of several chronic and neurodegenerative diseases 
(Ha, 2016). Indeed, it has been demonstrated that intravenously injected Rabies Virus 
Glycoprotein (RVG) targeted exosomes delivered GAPDH siRNA specifically in the brain, 
resulting in a specific gene knockdown (Alvarez-Erviti, 2011). A similar result was also 
confirmed by others, showing that exogenous siRNA transfected into cells can be packaged by 
exosomes and delivered into recipient cells to regulate gene silencing, indicating that exosomes 
can serve as siRNA delivery vesicles in gene therapy for cancer and other diseases (Liu Y. , 
2015). In another study, large size plasmid DNA was encapsulated into exosomes and 
successfully transferred to MSCs (Lin Y. , 2018). Moreover, Khatua group demonstrated that 
human cytidine deaminase APOBEC3G (A3G), a cellular defense system against human 
immunodeficiency virus type 1 (HIV-1) and other retroviruses, can be secreted in exosomes, 
conferring an antiviral phenotype to target cells and limiting replication of the virus in recipient 
cells (Khatua, 2009).  
 Thanks to their potential role in drug delivery, EVs have been also taken in consideration sa 
vaccine technologies. For instance, Bacteria outer membrane vesicles (OMV) could be used as 
natural vaccines (van der Pol, 2015). However, one of their main limitations is related to their 
poor productivity and unreliable safety. To overcome these problems, protoplast derived 
nanovesicles (PDNVs), are arousing a lot of interest as a valid alternative to OMVs (Kim, 
2015). They are small nano-vesicles derived from the protoplast (a bacteria cell deprived of its 
cell wall) of bacteria cells, which are free from all the toxic and dangerous elements present in 
the cell wall. Thanks to their non-toxic nature, PDNVs may be promising OMVs substitutes, 
bypassing all the potential harmful effects that OMVs could give (Kim O. , 2017).  
 Beyond their therapeutic power, EVs can be also used as potent biomarkers in the detection of 
several pathological conditions (Barile, 2017). For instance, EVs carrying viral components 
can inform the host organism about the presence of a viral infection, even if the virus has 
already eluded the immune system response (Rodrigues M. , 2018).  
 In cancer diagnosis, most current cancer biomarkers are tissue-based and invasive biopsies 
(Ayala, 1983). However, liquid biopsies may provide a valid alternative to the traditional solid 
biopsies and, recently, EVs have also arisen attention for their use in this sense (Diaz, 2014) 
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(Pang, 2020). EVs present in body fluids are non-invasive and easy to access, as respect to solid 
biopsies. Hence, they could be used to check the progression of the disease, or its response to 
therapy (Lee C. , 2018). However, there are some limitations in their use, since in vivo systems 
also release EVs from non-cancer related cells. Many kinds of mouse models have been used 
for the identification of new EVs cancer biomarkers (Moon, 2016) and many research groups 
have also evaluated EVs from different body fluids [e.g. plasma (Liu W. , 2019), serum (Morio, 
2018), urine (Matsuzaki, 2017), cerebral spinal fluid (Akers J. , 2017), saliva (Chiabotto, 2019)] 
for the same purpose.  
 Characteristics of EVs that may be taken in consideration as potential cancer biomarkers 
comprehend their concentration in body fluids and their cargo. As regard cargo, different types 
of RNAs (mRNA, microRNA, Long non-coding RNA) and DNA molecules have been taken 
into account, since their levels seem to increase in cancer-EVs (Endzeliņš, 2018) (Vagner, 
2018). Indeed, DNA within EVs includes mtDNA and genomic DNA, that can reflect the 
mutation status of the parental cells (Sansone, 2017). Even proteins have been also proposed as 
potential EV derived biomarkers, based on their abundance and their role in the progression of 
the disease (Hurwitz, 2016). Another possibility could be the analysis of EV derived lipids and 
metabolites, even if only few studies have been currently performed (Puhka, 2017).  
 Similarly to cancer-EVs, in infarcted patients it could be useful monitoring of endothelial EVs 
levels, which may be used as tools for the analysis of early biomarkers for the development of 
cardiovascular diseases (Bei, 2017). 
 As regard neurodegenerative diseases, it has been shown that dendritic cell derived EVs may 
act as an immunotherapeutic tool for the modulation of antigen-specific immune responses 
(Wahlund, 2017), also overcoming those previous drawbacks related to the use of dendritic 
cells (i.e. delicacy of the cells during freezing procedures) (Babatz, 2003). Therefore, a better 
characterization of neuronal EVs could be used as a potential tool for the diagnosis of 
neurological diseases. Neurodegenerative diseases generally do not develop immediately, but 
slowly evolve after several years, thus affecting levels of potential neurodegenerative proteins 
on EVs. Hence, neural EVs could be taken into account as a source of biomarkers for these 
conditions, especially because the diagnosis of neurodegenerative diseases is very difficult in 
the living patients (Karnati, 2019).  
 However, one of the main limitations in these studies is strongly linked to the isolation methods 
used for the investigation of biomarker profiles, since the most common methods currently used 
result in possible protein contaminants that precipitate with EVs (Cvjetkovic, 2014) (Taylor, 
2015). Currently, the most used EVs come from mesenchymal stromal cells, which are able to 
target different cell types and act in a large spectrum of diseases (Mendt, 2019). For instance, 
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it has been demonstrated that they may have positive effects in models of stroke (Yang J. , 
2017), as well as in traumatic brain injury (Williams, 2019), in glioma (Munoz, 2013) and 
Alzheimer's diseases (Wang S. , 2018). Despite the way they exert their beneficial effects is not 
fully understood, it may be that the molecules they carry (e.g. growth factors, cytokines, RNAs) 
could trigger some disease-modifications.  
 However, EVs may have controversial effects on health and diseases; for instance, in cancer 
progression some of them can prevent tumor development (Naseri, 2018) (Rosenberger, 2019), 
while others provide a communication system between tumor cells and the surrounding tissues 
(Haga, 2015) (Keklikoglou, 2019). Moreover, one of the principal obstacles for their clinic 
application is limited to their final yield from donor cells, which is often very poor and strongly 
related to the protocol of isolation (Van Deun, 2014). Hence, in the last few years, researchers 
have also started to combine exosomes with synthetic nanoparticles, developing engineered 
carriers that seem to be more efficient than their natural counterparts. For instance, in order to 
control and modify the performance of exosomal nanocarriers, some researchers realized hybrid 
exosomes fusing them with polyethylene glycol (PEG) liposomes (Sato, 2016). They showed 
that these modifications facilitated cellular uptake of the PEG modified exosomes, reducing 
also their circulation time in the blood.  
 To overcome some limitations related to the biology of extracellular vesicles, the bio-
nanotechnology sector has also recently focused on the production of fully artificial vesicles 
(Garcìa-Manrique, 2018). The fabrication of these kinds of particles may occurs in two main 
ways: top-down and bottom-up approaches (Figure 4).  
 
Figure 4 -  Types of artificial EVs 
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 Top-down methodologies rely on the production of nano-sized materials starting from bigger 
and complex units (such as cells) which are sequentially broken into smaller parts. In this case, 
artificial EVs develop from cultured cells, that are gradually fragmented into vesicles of 
increasingly smaller diameters (Jang, 2013). 
Two of the most relevant strategies involve: extrusion over polycarbonate membrane filters 
(method used to reduce the mean size and homogenize the size distribution of colloidal systems) 
and microfluidic systems (Senthilkumar, 2018) (Qingfu, 2018). For instance, researchers 
created exosome-mimetic nano-vesicles by serial extrusions through polycarbonate membranes 
with pore sizes of 10, 5, and 1 µm, for their utilization in tissue repair and regeneration. These 
exosome-mimetic nanovesicles (NVs) had a final yield almost 100 times higher than exosomes 
and promoted cell proliferation and liver regeneration similar to that induced by exosomes (Wu 
J. , 2018). However, these methods have some drawbacks since, in extrusion methods, cargo 
sorting lacks selectivity due to the passive encapsulation of the surrounding medium during 
membrane fragment self-assembly.  
 By contrast, bottom-up techniques create complex structures starting from molecular 
components, that are manipulated through the variation of their physical and chemical 
properties, using similar methods to those of liposomes formulation. The self-assembled 
synthetic bilayer can be then functionalized with selected proteins to mimic the desired 
exosomal functions (Garcìa-Manrique, 2018).  
 Another way to mimic exosomes could be to use plasma membrane phospholipids as starting 
material for the assembling of the exosomes-like particles. In this case, starting molecules are 
not artificial, but natural components of the plasma membrane of the cells used. These vesicles, 
called proteo-liposomes, can be easily functionalized with specific proteins (Pollet, 2018). 
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2. Aim of the project 
 
This thesis is part of a previous project PRIN 2012, concerning the role of endurance training 
in mice models Balb/c with neoplastic cachexia. During those experiments, the research group, 
led by Prof. Di Felice, has discovered natural nanoparticles (exosomes) able to mimic, in vitro, 
the effects of endurance training, consisting in the overexpression of Hsp60 protein and the 
activation of the mitochondrial biogenesis pathway, to which the PGC-1 co-factor belongs. The 
purpose of the current project mainly focused on the engineering of a stable transfected C2C12 
cell line, overexpressing Hsp60 protein, as well as on the isolation and characterization of 
extracellular vesicles harvested from cell culture medium of C2C12 murine myoblasts. 
 The project was divided in three phases:  
• the first part focused on the engineering of  cells (through their transfection with a 
plasmid containing the gene sequence of Hsp60 protein) capable of producing large 
quantities of vesicles carrying Hsp60; this latter, as a protein, is not able to easily cross 
the cell membrane, but can enhance the activation of PGC-1 when it is transported 
through extracellular vesicles;  
• the second part of the project was carried out in Prof. Mülthoff’s laboratories, in 
Germany, where large volumes of cell culture medium were harvested and processed 
for extracellular vesicle characterization;  
• the last part of the project was executed in collaboration with Nanovector srl company, 
in Turin, where vesicles were further characterized using the same techniques used for 
the analysis of synthetic lipid nanoparticles.  
Understanding the morpho-functional characteristics of these vesicles will allow the design of 
engineered nanoparticles, able of mimicking the effects of endurance training. 
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3. Material and Methods 
3.1. Cell Culture Methods 
3.1.1. Mammalian Cell culture 
C2C12 mouse adherent myoblasts (from ATCCH CRL-1772TM) were grown in high glucose 
Dulbecco Modified Eagle Medium (DMEM) 4.5 g/l glucose supplemented with 10% heat-
inactivated Fetal Bovine Serum (FBS), 1000 UI/ml penicillin, 1000 UI/ml streptomycin and 2 
mM L-Glutamine at 37 °C, in humidified atmosphere containing 5% CO2.  
3.1.2. Plasmid Used 
The cloning vector pCMV6-Entry (Cat. PS100001, Origen) is a plasmid composed by several 
strong promoters (i.e. CMV and T7) that allow the high expression of the target gene. 
 As illustrated in figure 5, from left to right, the plasmid carry: i) the Kozak sequence, 
recognized by the pre-initiation complex of translation in eukaryotes; ii) the multiple cloning 
site (MCS), with several recognition sites for different restriction enzymes, important for the 
insertion of the target gene; iii) c-tag Myc-DDK, a tag protein added to the target protein using 
the DYKDDDDK motif of the sequence (where D= aspartic acid, Y= tyrosine and K= lysine); 
iv) Neo/ Kan, the genes for antibiotic selection of E. Coli bacterial cells and eukaryotic cells 
respectively; v) SV40 ori, the origin of the replication, important for the synthesis of Kanamycin 
and Neomycin genes, that confer antibiotic resistance to bacteria and eukaryotic cells that 
acquired the plasmid (Figure 5). 
 
Figure 5 - (A) Plasmid map of pCMV6-Entry backbone, 4,9 kb; (B) Plasmid map of pCMV6-Entry-HSPD1, 6,6 
kb (Cat. MR222671, Origene) 
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 The gene HSPD1, coding for murine HSP60, is inserted within the site MCS, creating the 
plasmid pCMV6-Entry-HSPD1. The resulting molecule is a fusion protein between HSP60 and 
the tag Myc-DDK. HSPD1 used sequence for the synthesis of this new vector, is published on 
the website of https://www.ncbi.nlm.nih.gov/nuccore/NM_010477, in the database of the 
National Institute of Heath (NIH).  
 As regard the other cloning vector pIRES-hrGFP-1a, it is a plasmid composed by: i) a promoter 
CMV, that allows the expression of the gene of interest; ii) a diastronic cassette, in which MCS 
is followed by an EMCV-IRES sequence, linked to the hrGFP sequence. EMCV-IRES is the 
internal ribosomal entry site, derived by the encephalomyocarditis virus, a characteristic 
nucleotide sequence, able to recruit the ribosomal subunit, thus triggering the translation of the 
mRNA through a cap-indipendent mechanism; iii) hrGFP sequence, which is merged to the 
gene target and codes for the recombinant human GFP protein, allowing an easy visualization 
of the gene of interest after its expression; iv) 3x FLAG, a tag protein added to the target protein, 
with the same sequence of c-tag-Myc, used in tandem (DYKDHD-G-DYKDHD-I-
DYKDDDDK) with a final tag coding for a restriction site for the enterokinase, the enzyme 
involved in the removing of the tag from the target protein; v) SV40 pA, a DNA sequence able 
to add a poliA tail to the transcript, avoiding its degradation; vi) pUC ori, the prokaryotic 
plasmid replication origin; vii) f1 ori, the replication origin of bacteria infected with fagi, 
important for the synthesis of a single DNA vector; viii) LoxP sequences, derived from the 
bacteriophage P1 and recognized from Cre recombinase, for the recombination of Cre-Lox; ix) 
ampicillin, the selection gene of E. Coli cells (Figure 6). 
 
Figure 6 - Plasmid map of pIRES-hrGFP-1a 
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3.1.3. Bacterial transformation 
XL10-Gold ultra competent cells (Agilent technologies 200315) are designed for the 
transformation of DNA molecules with high efficiency.  
Briefly, bacterial cells were placed on ice and a cellular aliquot of 100 µl was gently mixed into 
a pre-chilled tube, with 4 µl of the ß-mercaptoethanol (ß-ME) mix provided with these bacterial 
batches. Cells were first incubated on ice for 10 minutes and gently swirled every 2 minutes; 
after, 50 ng of the experimental DNA were added to the bacterial aliquot and incubated for 30 
minutes. The mixture was then heat-pulsed at 42 °C, in a water bath, for 30 seconds and passed 
on ice for other 2 minutes. Subsequently, 0.9 ml of preheated (42 °C) LB-broth were added to 
the mix and incubated at 37 °C for 1 hour under continuous shaking, at 225-250 rpm.  
 After the incubation, 150 µL of this transformation mixture was plated on LB agar plates 
containing the appropriate antibiotic kanamycin (for pCMV6-Entry-HSPD1), or ampicillin (for 
pcDNA 3.1-mok, pIRES-hrGFP-1a-Hyg and pIRES-hrGFP-1a) and incubated at 37 °C 
overnight. Once the colonies in the Petri dish have grown, a pure colony was isolated, with the 
help of a sterile loop, selected and inoculated in a glass flask with 5mL of LB Broth + the 
specific antibiotic of selection, for 8 hours at 37 °C and 300 rpm continuous shaking. 
 Then, 150 µL of the starter culture were transferred to a glass flask with 100 mL of LB Broth 
+ antibiotic and incubated for further 14 hours, at 37 °C and under constant shaking at 300 rpm.  
3.1.4. Plasmid Extraction 
  After the incubation, plasmid DNA was extracted from bacterial colonies with the QIAGEN 
EndoFree Plasmid Maxi Kit (Cat. 12163), following manufacturer’s instructions. 
 This kit provides rapid anion-exchange-based endotoxin-free plasmid DNA purification, 
thanks to the 2x CsCl gradient centrifugation that drastically reduce the levels of endotoxins. 
Hence, the purified DNA is highly pure and free from endotoxin, that could significantly reduce 
transfection efficiencies in endotoxin sensitive cell lines.  
 The extracted plasmid DNA was washed two times with EtOH 70%, dissolved in 250 µL of 
TE buffer (provided by QIAGEN kit), read at Nanodrop ND-2000 and used for the transfection 
of C2C12 cells.  
3.1.5. C2C12 transfection via Lipofectamine® 2000 
Plasmids were transfected using Lipofectamine® 2000 Reagent according to the manufacturer’s 
instructions, with some modifications.  
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 Briefly, C2C12 cells were plated one day before the transfection in 6-well dishes (5x 104 
cell/well) in DMEM antibiotic free in order to reach a confluence of 70% the day of the 
transfection. The second day, 3.5 μg/well plasmid DNA [pCMV6-Entry-HSPD1] for the over 
expression of Hsp60 (OriGene Technologies Inc., Rockville, MD, USA), and his negative 
control pcDNA 3.1. plasmid, were diluted in 150 μL of Opti-MEM Medium (without FBS, L-
glutamine, penicillin or streptomycin) and incubated for 5 minutes at room temperature (RT). 
 Similarly, Lipofectamine (in ratio 1:1) was diluted in 150 μL/well of Opti-MEM and incubated 
for 5 minutes. The mixture was then incubated for 20 minutes and added to growing cells.  
 After 7-8 h, Opti-MEM medium supplemented with 20% FBS was added to a final volume of 
2 mL/well and incubated for 48 hours. Different ratio DNA: Lipofectamine were tried [3.5 
μg:mL, 5 μg:mL and 8.75 μg:mL] in order to check which one was the most suitable for a good 
percentage of transfected cells. After the incubation, transfected cells were selected for 4-5 
weeks by using DMEM supplemented with antibiotic G418 in a final concentration range of 4-
17 mg/mL. For each well and week, a chamber slide was made, in order to follow the evolution 
of the transfected cells. 
 In a different protocol, C2C12 cells were transfected immediately after trypsinization, during 
the replating (Escobedo, 2003). In this case, the DNA-Lipofectamine complex was added to the 
cells the same day of the trypsinization, while they were still in suspension.  
3.1.6. C2C12 transfection via Electroporation 
C2C12 cells were transfected using the Electoroporator Neon Transfection System (Thermo 
Fisher Scientific, Waltham, Massachusetts, USA) according to the manufacturer’s instructions, 
using the Neon 100 μl Transfection System (Cat. n. MPK10025, Thermo Fisher Scientific, 
Waltham, Massachusetts, USA).  
Briefly, for pCMV6-Entry-HSPD1 transfection, C2C12 cells were plated 1 day before the 
experiment; on the day of the transfection (70-90% of confluence), they were washed with 
DPBS without calcium and magnesium, harvested using 10% Trypsin/EDTA (Cat. n. 
15400054, Gibco - Thermo Fisher Scientific, Waltham, Massachusetts, USA) and 36 μg of 
concentrated DNA, 100 μl Buffer R, 1650 pulse voltage, 10 ms pulse width, 2 pulses, were used 
according to the manufacturer’s instructions. After electroporation, cells were plated into 6-
well dishes with complete DMEM medium, without antibiotics/anti-mycotics.  
Three days after transfection cells were plated into chamber slides for Confocal analysis (5x 
103 cells/well). 
 For pIRES-hrGFP-1a-Hyg plasmid transfection, C2C12 cells were plated in a T75 cm2 flask 
with fresh medium. On the day of the transfection (70-90% of confluence), cells were harvested 
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with DPBS without calcium and magnesium and trypsinized with 10% Trypsin/EDTA (Cat. n. 
15400054, Gibco - Thermo Fisher Scientific, Waltham, Massachusetts, USA). 5x 104 cells/well, 
5 µg of pIRES-hrGFP-1a-Hyg and 100 µL of Buffer R were electroporated following different 
optimization protocols shown in the table below (Table 3). 
 After being electroporated, cells were transferred in 6 well plate and incubated at 37 °C with 2 
mL of fresh completed DMEM (Cat. 41966052, Gibco, USA), supplemented with 15 % of FBS 
(Cat. 16000044, Gilbo) without antibiotic/anti-mycotics. After 48 h, transfected cells were 
observed and checked under confocal microscopy. 
 
Table 3 - Table representing various combination of parameters for better transfection efficiency 
3.1.7. Total DNA isolation 
Due to the impossibility to follow pCMV6-Entry-HSPD1 transfection with a microscope, 
plasmid DNA was extracted from the transfected cells using Norgen kit for Genomic DNA 
Isolation (Cat. 24700, 24750) according to the manufacturer’s instructions. The DNA was 
further analyzed by standard PCR and checked by agarose gel electrophoresis (data not shown).  
3.1.8. Flow cytometry analysis 
     Flow cytometry was performed to analyze the percentage of positive GFP cells post pIRES-
hrGFP-1a-Hyg plasmid transfection, using a BD FACSVerse ™ (Cat. 651153, BD Biosciences) 
flow cytometry. Unstained cells, used as negative control, were prepared following 
manufacturer’s instructions of LIVE/DEAD® Viability/Cytotoxicity kit, while fluorescence was 
detected using FITC filters, at 488 nm.  
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3.2. Methods of Extracellular vesicles isolation and characterization 
3.2.1. Ultracentrifugation 
One day before the isolation, C2C12 cells were trypsinized, counted and plated in T175 flasks 
(1x 106 cell/flask) with 20 mL of completed DMEM and incubated at 37 °C in a humidified 
atmosphere with 5% CO2.  
 The day after, once they reached a confluence of 70-80%, the complete medium was removed 
and three washes in DPBS were made to remove any trace of vesicles from FBS. Then, 20 
mL/flask of DMEM without FBS were added in each flask and incubated for others 24 h. The 
next day, the medium was collected and subject to different centrifugations, while cells were 
trypsinized and counted to be used as cell lysate control for Western Blot analysis.  
 For EVs isolation, the supernatant was first centrifuged at 300 x g, for 10 minutes at 4 °C, in 
order to remove the presence of any death cells; then, the supernatant was recovered and further 
centrifuged at 2,000 x g, 10 minutes at 4 °C, to remove cell debris; the pellet was removed and 
the supernatant was centrifuged at 15,000 x g, for 45 minutes at 4 °C, to remove microvesicles.  
 The resulting pellet (EVs larger than 150 nm) was stored at -80 °C for further analysis. At the 
end of this step, the supernatant was collected and ultracentrifuged for 2 hours, at 110,000 x g 
at 4 °C, using a micro-ultracentrifuge Sorvall® Discovery M120 with a S55-A rotor. After 
ultracentrifugation, the supernatant was discarded, while the pellet was washed in DPBS and 
ultracentrifuged for 2 hours at 110,000 x g at 4 °C, using a S555-A rotor to concentrate the 
sample. At the end of this step, the supernatant was discarded and the pellet (exosomes, EVs 
smaller than 150 nm) was resuspended in 30µL of RIPA buffer for protein quantification using 
BCA protein assay (Ref: 23225, Thermo Scientific), or stored at -80 °C. 
3.2.2. Size Exclusion Chromatography (SEC) 
Briefly, cell culture medium containing extracellular vesicles was firstly harvested from T175 
cm2 flasks and centrifuged at 300 x g and 2,000 x g, to remove dead cells. The supernatant was 
then concentrated with 50 mL Stirred Cell Ultrafiltration system (cat. No 5122), mounted with 
a nitrocellulose filter of 44.5 mm and a nominal molecular weight limit (NMWL) of 100,000 
Da (Millipore Cat. No. 14422AM). Up to 10 mL were collected as retentate and further 
concentrated with a 10 mL stirred Cell Ultrafiltration (cat. No 5121), mounted with an ultracel® 
regenerated cellulose (RC) disc of 25 mm and a nominal molecular weight limit (NMWL) of 
100 kDa (Millipore Corporation, Cat. No. PLHK02510).  
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 A final volume of 2 mL of retentate were harvested and further concentrated with Amicon® 
Ultra centrifugal Filters (100,000 NMWL of  regenerated cellulose), for 15 minutes at 15,000 
x g, at 4 °C. The final retentate (500µL) was finally loaded onto a Size Exclusion 
Chromatography Column (IZON, qEV Original, 70 nm).  
 Before proceeding with SEC isolation, the column was placed in a holder, left equilibrate at 
room temperature and then washed with 10-20 mL of 0.2 µm degassed DPBS. Meanwhile, 20 
empty plastic vials of 1,5 mL each, were weighed. Once equilibrated the column, with the lower 
cap still on, excess of DPBS was pipetted out from the top filter and 500 µL of sample were 
loaded. The lower cap was removed and 20 fractions of 0,5 mL each were collected in 1,5 mL 
plastic vials.  
 Each plastic vial, containing the eluate, was weighed and read at the Zetasizer Instrument. 
Fractions containing vesicles, specifically fraction 7-8-9-10-11, were pooled together and 
concentrated through Amicon® Ultra centrifugal Filters of 100,000 NMWL regenerated 
cellulose, for 15 minutes at 15,000 x g, at 4 °C. The final retentate was then used for tunable 
resistive pulse sensing analysis (where possible) or stored at -20 °C for further analysis. 
3.2.3.  Tangential Flow Filtration (TFF) 
 
 As in SEC, cell culture medium containing extracellular vesicles was initially centrifuged at 
300 x g and 2,000 x g, in order to remove dead cells. The supernatant was then concentrated 
and washed through VIVAFLOW 50 Tangential Flow Filtration system (100,000 Da MWCO); 
specifically, the retentate was firstly concentrated up to 10 mL, washed 8 times in PBS (to 
reduce interfering substances present in the medium) and finally recovered in a total volume of 
5 mL. This latter, was further concentrated with Amicon® VIVASPIN Ultra centrifugal Filters 
of 100,000 Da NMWL regenerated cellulose, for 15 minutes at 15,000 x g and 4 °C.  
 The final concentrate was  then used for Zetasizer analysis and tunable resistive pulse sensing 
(where possible), or stored at -20 °C for further analysis. 
3.2.4. Total exosome isolation kit  
Total Exosome Isolation (Invitrogen by Life technology; Cat. No 4478359) reagent forces less-
soluble components (i.e. exosomes) out of solution, by bounding water molecules and allowing 
their collection after short and low-speed centrifugation. Here, vesicles were isolated as 
manufacturer’s instructions.  
 Briefly, cell culture medium (CCM) without serum was harvested from T150 flasks 
(containing 24 hours starving C2C12 cells) and centrifuged at 2,000 x g, for 30 minutes (in 
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order to remove cells and debris), at 4 °C. Then, the supernatant was concentrated up to 1mL 
through VIVASPIN 20 centrifugal concentrator filters (Sartorius, 10,000 MWCO PES, 
REF_VS2001) at 8,000 x g, for 16 minutes, at 4 °C, and incubated overnight with 0.5 mL of 
the total exosome isolation reagent, at 4 °C.  
 The day after, sample was centrifuged at 10,000 x g, 1 hour at 4 °C, after which the supernatant 
was discarded and the pellet was resuspended with sterile and filtered DPBS or RIPA buffer. 
3.2.5. Dinamic Light Scattering (DLS) 
Dynamic light scattering determinations of extracellular vesicles was performed with a 
Zetasizer Nano instrument (Malvern Nano-Zetasizer, λ=532 laser wavelength) and the size data 
refer to the scattering intensity distribution (z-average). Briefly, extracellular vesicles obtained 
from different protocols (Ultracentrifugation, SEC and TFF), were resuspended in 0.2 µm 
filtrate DPBS and 40 µL of undiluted sample-DPBS mix was analyzed at 25 °C, using a 
precision ultra-micro Quarz Suprasil® cell for low volumes (ZEN2112) for samples isolated 
with ultracentrifugation, while samples isolated through SEC or TFF were  read undiluted in a 
total volume of ˜300 µL, using a UV-transparent disposable cuvettes (Sarstedt, Germany). 
3.2.6.  Tunable Resistive Pulse sensing (TRPS) 
 
 TRPS is a method used for the characterization of nanoparticles without the use of laser. Here, 
a voltage is applied across a pore that is filled with an electrolyte solution for the establishment 
of an ionic current. As particles cross the pore, they briefly increase the electrical resistance, 
creating a resistive pulse, which is proportional to the particle volume. The rate flow of particles 
is proportional to the particle concentration, thus obtaining also a particle number estimation. 
Using this principle, concentration and diameter of extracellular vesicles (EVs) isolated through 
SEC and TFF were analyzed using Nanopores-NP 200 and 80 nm, at three different pressures: 
-5,-7 and -10 mbar.  
 Briefly, samples purified with SEC and TFF were previously concentrated with Amicon® 
VIVASPIN Ultra centrifugal Filters to a final volume of 20-40 µL, after which they were diluted 
with 0.22 µm filtered PBS in a final dilution of 1:2 or 1:4 sample-PBS.  
 Then, a baseline current was established with 75 µL and 40 µL of 0.22 µm filtered PBS, which 
were respectively loaded in the lower and upper fluid cells. After, the PBS was removed from 
the upper fluid cell and 40µL of the diluted sample were loaded on it. Two different kinds of 
nanopores were used: NP-200 (size range 80-400 nm) and NP-80 (size range 40-255 nm). 
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Sample was read at three different pressures (10, 7 and 5 mbar) and compared to a standard 
IZON calibrator specific for each nanopore (SKP 200E for NP200 and CPC100 for NP80).  
3.3. Microscopy  
3.3.1. Immunofluorescence  
Immunofluorescence was performed after transfection of C2C12 cells with pCMV6-Entry-
HSPD1, in order to evaluate the efficiency post-transfection.  
 Briefly, transfected cells in chamber slides (5x 103/well) were washed twice in DPBS, for 5 
minutes and then fixed for 30 minutes in cold Methanol, under ice. After, methanol was 
removed and cells were washed again in DPBS two times, for 5 minutes, after which they were 
incubated with Sodium Citrate, 10 minutes at room temperature. After the incubation, fixed 
cells were washed twice in DPBS, for 5 minutes and blocked with 3% of bovine serum 
albumin/phosphate buffer saline (BSA/DPBS), for 30 minutes at room temperature. Primary 
antibodies anti-DDK (OTI4C5) and anti-Hsp60 were added overnight, in a dilution of 1:200 
and stored at 4 °C, after which samples were washed twice with DPBS, for 5 minutes, and the 
secondary antibody has been added for 1 hour, at room temperature. 
 After the incubation, chamber slide was washed two times with DPBS, for 5 minutes, and 4′,6-
diamidino-2-phenylindole (DAPI), diluted 1:1000 in DPBS, was added for 15 minutes. Then, 
fixed cells were washed again twice in DPBS, for 5 minutes, and assembled with a cover glass 
for Confocal microscopy visualization. 
3.3.2. Transmission Electron Microscopy in 3D Cultures  
After 3 days of differentiation in DMEM enriched in 5% Horse serum (HS, Cat. n. 16050130, 
Gibco - Thermo Fisher Scientific, Waltham, Massachusetts, USA) as previously described 
(23523921), cells were cultured embedded into collagen I (rat tail, Cat. n. 354236, BD 
Biosciences, Franklin Lakes, New Jersey, USA) on 24-well plate inserts (200,000 cells/insert; 
BD Biosciences, BD Biosciences, Franklin lakes, New Jersey, USA).  
 After 24 hours, inserts were fixed in PFA 4% for 6 hours and washed in Phosphate Buffer 
Saline (PBS) overnight. After two rapid washes in PBS, inserts were dehydrated in alcohol 
30%, 50%, and 70% and embedded into liquid LR-White Medium Grade Resin (Cat. n. 14380, 
Electron Microscopy Sciences, Hatfield, Pennsylvania, USA) before inclusion into gelatin 
capsules (Cat. n. 70115, Electron Microscopy Sciences, Hatfield, Pennsylvania, USA). Samples 
were then cut into 70 nm-thick ultra-thin sections, layered onto Formavar coated gold grids 
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(FCF100-Au-50,Electron Microscopy Sciences, Hatfield, Pennsylvania, USA) and 
immunogold labelled. 
 For staining, grids were rinsed on drops of water for 10 min, incubate in citrate buffer pH 6.0 
for 40 minutes and blocked in 3% BSA-c (Cat. n. 900099, Electron Microscopy Sciences, 
Hatfield, Pennsylvania, USA) in T-PBS for 30 min. Grids were then incubated with the primary 
antibody (anti-Alix, 1A12, sc-53540, Santa Cruz Biotechnology, Dallas, Texas, USA, diluted 
1:10) overnight at 4 °C inside a microplate, washed two times for 5 min in T-PBS, incubated 
with AuroProbe EM secondary antibody (RPN425, Amersham Biosciences, Little Chalfton, 
UK, diluted 1:25 in 0.3% BSA-c in T-PBS) for 1 h. The grids, washed twice in T-PBS, were 
post-fixed with 2% glutaraldehyde in PBS. Washed again were contrasted using conventional 
techniques. Grid-mounted preparations were stained with uranyl acetate and lead citrate for 5 
min, and subsequently observed under the JEM-1220 (Jeol) electron microscope examined at 
120 kV. 
3.4. Immunoblotting  
1 x 107 C2C12 cells were homogenized by centrifuging them at 300 x g, 5 minutes at 4 °C; the 
pellet was resuspended in 1 mL DPBS and centrifuge twice at 300 x g, 5 minutes at 4 °C. Then, 
200 μL of lysis buffer RIPA (150 mM NaCl (Roth), 0.5% Sodium Deoxycholate 
(SigmaAldrich), 1% Triton X-100 (SigmaAldrich), 50 mM Tris, pH 8.0 (Roth), 0.1% SDS 
(Roth), supplemented with Protease Inhibitor Cocktail (cOmplete ULTRA Tablets, Mini, 
EDTA-free, EASYpack by Roche) was added to the pellet for 1 hour on ice, by vortexing at the 
beginning and at the end of the incubation. Then, the homogenates were centrifuged at 20,000 
x g for 20 minutes at 4 °C and supernatant fractions were stored at -20 °C, or immediately used.  
 For Extracellular Vesicles, three ultracentrifugation pellets from three independent 
experiments were pooled together (˜ 500 mL total of medium), resuspended in a total volume 
of 80 µL of RIPA buffer and proteins were extracted as mentioned above with cells. Vesicular 
and cellular proteins were then quantified spectrophotometrically according to Pierce™ BCA 
protein Assay Kit manufacturer’s instructions (Ref: 23225, Thermo Scientific). 
 Cellular and cellular-vesicle proteins were then denatured in 4X SDS protein Sample Buffer 
(40% Glicerol, 240 nM Tris/HCl pH 6.8, 8% SDS, 0.04% bromophenol Blue, 5% beta-
mercaptoethanol), diluted to a final concentration of 1X, for 5 min at 95 °C and loaded onto a 
10% SDS-PAGE gel (30 µg protein/sample).  
 After Electrophoresis, proteins were blotted onto a nitrocellulose membrane (Nitrocellulose 
Membrane Filter Paper Sandwich 0.45 µm Pore Size by NOVEX), checked with Red Ponceau, 
and blocked for 1 hour at room temperature, with 5% Milk in Tris-buffered saline/0.05% 
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Tween20. The membrane was then cut and incubated overnight at 4 °C, and in gentle shaking, 
with the antibodies anti-Alix diluted 1:1000 (1А12, sc166028 Santa Cruz), anti-beta-actin 
diluted 1:5000 (AC-74 SigmaAldrich), anti-Hsp70 diluted 1:1000 (gently provided by 
Mülthoff’s laboratories), anti-Hsp60 diluted 1:1000, and anti-Rab5 diluted 1:1000 (R4654 
SigmaAldrich), all diluted in 5% Milk in T-TBS. Polyclonal Rabbit anti-Mouse 
Immunoglobulins/HRP (Ref: PO260, DAKO) and Polyclonal Swine anti-Rabbit 
Immunoglobulins/HRP (Ref: PO217, DAKO) diluted 1:2000 in 5% Milk in T-TBS were used 
as Secondary Antibodies.  
 The signal was detected by using a PierceTM ECL Western Blotting Substrate (Ref: 32106 
Thermo Scientific) and captured by ChemiDoc, or manually in a dark room. 
3.5. Proteomic analysis  
Aliquots of 30 µg of Exo and EVs extracts were firstly dialyzed, lyophilized and then purified 
from PlusOne 2-D Clean-Up Kit (GE Healthcare Life Sciences, Milan, Italy), according to 
manufacturer's intructions. The obtained pellets were then resuspended in 100 μL of 50 mM 
ammonium bicarbonate (pH 8.3) and incubated on ice for 15 min. After, 100 μL of 0.2% 
RapiGest SF (Waters, Milan, Italy) in 50 mM ammonium bicarbonate (pH 8.3) were added and 
incubated on ice for other 30 min.  
 Protein concentration was then determined by Qubit Protein Assay kit with the Qubit 1.0 
Fluorometer (ThermoFisher Scientific, Milan, Italy) (Higa-Nakamine, 2015). A final 
concentration of respectively 0.33 and 0.47 μg/μL for Exo and EVs samples was quantified and 
0.2 µg of yeast Enolase were added as internal standard to each sample. The reduction was 
carried out by adding 20.35 μg (Exo sample) and 29.3 μg (EVs sample) of DTT dissolved in 
the same buffer. The solutions were kept in the dark, for 3 hours, at 25 °C.  
 Subsequently, alkylation was performed by addition of iodoacetamide, at the same molar ratio 
over total thiol groups, for 1 hour, in the dark, at 25 °C. Finally, reduced and alkylated proteins 
were subjected to digestion using modified porcine trypsin (Promega, Milan, Italy), in 
ammonium bicarbonate (pH 8.3) and at an enzyme-substrate ratio of 1:50 (37 °C overnight) 
(Saletti, 2018) (Saletti, 2017). The protein digests were dried under vacuum, redissolved in 40 
μL 5% FA (final concentration 250 ng/μL). 
 Mass spectrometry (MS) data were acquired using an Orbitrap Fusion Tribrid (Q-OT-qIT) 
mass spectrometer (ThermoFisher Scientific, Bremen, Germany) equipped with a 
ThermoFisher Scientific Dionex UltiMate 3000 RSLCnano system (Sunnyvale, CA). An 
aliquot of 1 μL of the in-solution digestion was loaded onto an Acclaim ®Nano Trap C18 
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column (100 μm i.d. × 2 cm, 5 μm particle size, 100Å). After washing the trapping column with 
solvent A (H2O + 0.1% FA) for 3 min at a flow rate of 7 μL/min, peptides were eluted from the 
trapping column onto a PepMap ® RSLC C18 EASY-Spray, 75 μm × 50 cm, 2 μm, 100 Å 
column and were separated by elution at a flow rate of 0.25 μL/min at 40 °C, with a linear 
gradient of solvent B (CH3CN + 0.1% FA) in A, 5% for 3 min, followed by 5% to 20% in 32 
min, 20% to 40% in 30 min, 40% to 60% in 20 min and 60% to 98% in 15 min.  
 The eluted peptides were ionized by a nanospray (Easy-spray ion source, Thermo Scientific) 
using a spray voltage of 1.7 kV and introduced into the mass spectrometer through a heated ion 
transfer tube (275 °C). Survey scans of peptide precursors in the m/z range 400–1600 were 
performed at resolution of 120,000 (@ 200 m/z) with an AGC target for Orbitrap survey of 4.0 
× 105 and a maximum injection time of 50 ms.  
 Tandem MS was performed by isolation at 1.6 Th with the quadrupole, and high-energy 
collisional dissociation (HCD) was performed in the ion routing multipole (IRM), using a 
normalized collision energy of 35 and rapid scan MS analysis in the ion trap. Only precursors 
with charge state 2–4 and an intensity above the threshold of 5∙103 were sampled for MS2. The 
dynamic exclusion duration was set to 60 sec with a 10 ppm tolerance around the selected 
precursor and its isotopes. Monoisotopic precursor selection was turned on. AGC target and 
maximum injection time (ms) for MS/MS spectra were 10,000 and 100, respectively. The 
instrument was run in top speed mode with 3 sec cycles, meaning the instrument continuously 
performed MS2 events until the list of non-excluded precursors diminishes to zero or 3 sec, 
whichever occurred soonest. MS/MS spectral quality was enhanced enabling the parallelizable 
time option (i.e., by using all parallelizable time during full scan detection for MS/MS precursor 
injection and detection). Each sample was injected in triplicate, in order to assess the 
reproducibility of the MS data. MS calibration was performed using the Pierce ® LTQ Velos 
ESI Positive Ion Calibration Solution (Thermo Fisher Scientific). MS data acquisition was 
performed using the Xcalibur v. 3.0.63 software (Thermo Fisher Scientific).  
 LC–MS/MS data were processed by PEAKS software v. X (Bioinformatics Solutions Inc., 
Waterloo, ON, Canada). The data were searched against the 17449 "Mus musculus" SwissProt 
database (release February 2019) to whom yeast enolase 1 (P00924) sequence was added. 
Tryptic peptides with a maximum of three missed cleavage sites were subjected to an in silico 
search. Cysteine carboxyamidomethylation was set as fixed modification, whereas oxidation of 
methionine and transformation of N-terminal glutamine and N-terminal glutamic acid residues 
in the form of pyroglutamic acid were included as variable modifications. The precursor mass 
tolerance threshold was 10 ppm and the maximum fragment mass error was set to 0.6 Da. 
Peptide spectral matches (PSM) were validated using Target Decoy PSM Validator node based 
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on q-values at a 1% False Discovery Rate (FDR). Only proteins identified in at least two 
replicates with a minimum of two peptides matched were considered. Proteins containing the 
same peptides which could not be differentiated based on MS/MS analysis alone were grouped 
to satisfy the principles of parsimony. Label-free quantification data were obtained using 
PEAKS Q software, which detected the reference sample and automatically aligned the sample 
runs. Enolase tryptic peptides internal standards were employed as normalization factor. 
Proteins present in distinctly different concentration between the two samples were identified 
by a statistical analysis tool set with the following filters: protein fold change ≥ 2, protein 
significance ≥ 20, unique peptides ≥ 2, average area <1∙104 and P value < 0.005 The data have 
been displayed in a volcano plot format for ready visualization. 
Raw MS data files, unfiltered protein groups and peptides tables are available at 
ProteomeXchange (www.proteomexchange.org, accession: 30395289). 
3.6. Lipidomic analysis 
EVs samples isolated through ultracentrifugation have been further subjected to lipidomic 
analysis. Briefly, pellet of frozen samples (EVs pelleted at 15,000 x g and EVs pelleted at 
110,000 x g) were first recovered in 100 µL of a solution constituted by 70% of an aqueous 
solvent (A), made of ACN:H2O:Ammonium formate (6:4:1), with 0.1% FA, and 30% of an 
organic solvent (B), composed by Isopropanolo:ACN (9:1), with 0.1% FA. 
 Once resuspended in this running solvent, samples were vortexed for 30 sec, transferred in 
glass reducers of 250 µL each, and further placed in vials for the analysis. Then, 10 µL of 
sample were injected inside a chromatographic column, Phenomenex Luna C18 3 µm 100 Å 
150 x 2.00 mm, using a gradient of an acqueous solvent (A) and an organic solvent (B) (Table 
4), at a flow speed of 200 µL/min, with a temperature of the sample compartment of 10 °C. 
Retention time (min) %A %B 
0 70 30 
5 70 30 
45 0 100 
50 0 100 
55 70 30 
70 70 30 
 
Table 4 - Table representing the gradient of solvents 
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 Samples were analyzed through the FTMS LTQ Orbitrap mass analyzer, with a mass range 
m/z of 100-1500. Full scan and dependent scan MS2-MS3 experiments were conducted and 
positive and negative polarity of samples was examined. Lipid masses were then evaluated 
through Lipid Maps® software. 
3.7. Formulation of synthetic lipid micro-nano emulsions 
 Two types of synthetic nano-systems have been synthesized, with a diameter of around 400 
nm and 100 nm respectively. B-I312-H1 microemulsion (of 300 nm) was prepared from: fatty 
acid MCT oil, fatty acid lauric acid, monoglyceride Imwitor 312, phospholipid Lipoid S75, 
detergent TWEEN 20 and water. TPM-A1-T5 microemulsion (of 100 nm) was composed of a 
mix of phosphatidilcolines, triglycerides, PEG-40 monostearate, Ethanol and short-chain 
alcohols. In both cases, warm microemulsion method was used for the preparation of 
nanoparticles, patented by Nanovector s.r.l. (Gasco M. , 1989).  
 Briefly, all reagents have been weighed and poured in two empty glass vials, one containing  
the oily phase (with all the lipophilic reagents) and the other one including the water phase 
(with the hydrophilic surfactants). Then, the two vials have been warmed at 65 °C under 
magnetic agitation (heating/stirring module, Reacti-ThermTM, PIERCE) and, once the oily 
phase was completely melted, the water phase was added to it, forming the oil in water 
microemulsion (O/W). Then, the two phases were poured in a large volume of water (dispersing 
phase) and mixed under mechanical agitation (1800 rpm), allowing the diffusion of the newly 
formed microemulsion.  
 The final products were then evaluated for their chemical-physical properties through Dynamic 
Light Scattering (DLS) and TRPS technologies, using Zetasizer Nano ZS (Malvern Instruments 
Ltd.) and qNano instruments (from IZON). All DLS measurements have been acquired at 25 
°C, with a final dilution of 1:100 in milliQ water, while TRPS evaluation was performed using 
nanopores NP400 and NP200 respectively, at three different pressures: 5, 7 and 10 mbar. 
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4. Results 
4.1. Transfection of C2C12 cells with pCMV-6-Entry-HSPD1 enhances the 
expression of Hsp60 and DDK proteins 
 As already demonstrated in mice models with neoplastic cachexia (Barone, 2016), endurance 
training seems to stimulate muscle specific expression of Hsp60 chaperonin, which in turn 
triggers the activation of PGC-1 co-factor, the main regulator of mitochondria biogenesis. To 
further investigate the role of Hsp60 in mitochondria biogenesis, an in vitro model of C2C12 
murine myoblast cells was transfected with a plasmid over expressing for Hsp60 protein 
(pCMV6-Entry-HSPD1). Results shown that, after transfection, these cells were able to release 
more Hsp60, also associated to a concomitant raise of PGC-1 protein. Since the chaperonine 
alone was not able to induce PGC-1 protein expression and mitochondria biogenesis, it has been 
speculated that Hsp60 protein may have acted as a paracrine factor transported within small 
nano-vesicles, able to activate all those molecules involved in mitochondria biogenesis (Barone, 
2016). This latter mechanism is of such importance for muscle cells, since mitochondria are the 
energetic house of the cell and they are therefore used to provide large energy requirement for 
all those muscle functions, such as movement of the body. 
 Based on these preliminary data, we decided to focus on the engineering of a stable transfected 
cell line, which could be able to mimic those beneficial effects that physical exercise excerted 
to cells (Barone, 2016).  
 So, C2C12 cells were transfected by electroporation with the pCMV-6-Entry-HSPD1 plasmid 
expressing the HSP60 var1 mouse gene, and the corresponding empty negative control plasmid 
pCMV-6-Entry, previously mentioned in materials and methods section. After 72 h from 
transfection, cells were plated in chamber slides and immunofluorescence for Hsp60 and DDK-
tag proteins was performed. Confocal microscopy analysis of transfected cells confirmed the 
presence of cells expressing a higher quantity of Hsp60 (green) and Myc-DDK tag (red) in 
samples transfected with pCMV-6-Entry-HSPD1, with a minor expression in those samples 
transfected with empty pCMV-6-Entry plasmid. This indicated that tranfection occurred, 
however we always reached a very low amount of positive tranfected cells that affected 
transfection efficiency (Figure 7).  
 Due to the low electroporation efficiency, we also tried different methods of transfection, in 
order to increase the final number of positive transfected cells. Therefore, C2C12 were further 
seeded in a 6-well plate and transfected through Lipofecatime® 2000, a method based on the 
use of cationic lipids, which are able to form positive liposome complexes that bind the negative 
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phosphate groups of DNA molecules, thus facilitating transport and the cellular uptake. Once 
transfected, C2C12 cells were further selected through the treatment with the antibiotic of 
selection G-418 geneticin (at a maximum concentration of 17 mg/mL) for 12 days, and 
constantly monitored under optical microscope. As shown below, among 6, 7 and 12 days of 
treatment, cells became numerous after each week, developing resistance to the antibiotic used 
(Figure 8). 
                                                                               
Figure 7 - Immunofluorescence images of C2C12 myoblasts cell line transfected with pCMV6-Entry-HSPD1 
vector (up) and untreated control cells (down). The expression of the tag Myc-DDK demonstrates the presence of 
the plasmid inside the cell and the expression of the protein, whose sequence has been introduced in the system by 
the vector. 
 
Figure 8 - Optical microscopy of C2C12 transfected with lipofectamine in presence of 17 mg/mL of G-418 
antibiotic. (A, C, E) Cells transfected with the negative control pCMV6-Entry plasmid, after 6, 7 and 12 days, 
respectively. (B, D, F) Cells transfected with pCMV6-Entry-HSPD1 after 6, 7 and 12 days, respectively. 
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4.2. Sensitivity of C2C12 cells to hygromycin B antibiotic and their 
transfection through the new plasmid pIRES-hrGFP-1a-Hyg 
 C2C12 cells transfected with the pCMV-6-Entry-HSPD1 plasmid were selected for 4 weeks 
with the antibiotic of selection G-418 geneticin (gene sequence expressing for the antibiotic 
was contained within the plasmid), in order to create a stable cell line overexpressing for Hsp60 
chaperonin; however, after only few weeks of treatment cells became more abundant and 
proliferative (Figure 8). Therefore, we speculated that cells may have lost the plasmid but not 
the gene of antibiotic selection, suggesting some kind of resistance to the antibiotic used. 
 So, due to this potential acquired resistance of transfected C2C12 cells to the G-418 selection 
antibiotic, we decided to design a new plasmid carrying Hygromycin B, a different kind of 
antibiotic of selection. However, before proceeding with the transfection of cells, it was first 
evaluated the sensitivity of C2C12 to this latter antibiotic using different serial dilutions of 
hygromycin B, up to a final concentration of 500 µg/mL. The Optical microscopy observation 
of C2C12 after 7 days of treatment revealed that the sensitivity of cells increased proportionally 
to the increase of hygromicin concentration, improving the number of dead cells in suspension 
(Figure 9). 
 
Figure 9 - Optical microscopy of C2C12 treated with different concentrations of hygromycin B, after 7 days of 
treatment. (A) Non treated C2C12. (B) C2C12 treated with 0,98 μg/ml of Hygromycin, with cells still alive. (C) 
Cells aggregates, treated with 250 μg/ml of hygromycin. (D) Dead cells in suspension after 500 μg/ml of 
hygromycin 
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 Sensitivity to hygromicyn B was further evaluated through MTT test, at 48 and 72 hours post 
treatment. As shown in the figure below, the trend curve was similar in both the analyzed 
situations, with an initial cell viability of around 50 % at a concentration of 7.81 µg/mL of 
antibiotic, that further decreased as the antibiotic concentration increased (Figure 10). 
 
Figure 10 - MTT test of C2C12 sensitivity to hygromycin B. C2C12 cells were treated with decreasing 
concentrations of antibiotic, starting from 1 mg/mL to 0,48 µg/mL, after 48h and 72h and MTT test was performed 
and read under spectrophotometer at an OD570 nm. 
 On the basis of these preliminary results, hygromycin B seemed to be more efficient than G-
418, hence we decided to change the antibiotic of selection and use HygB for the selection of 
positive transfected cells. 
 So, the hygromycin resistance gene was inserted inside the plasmid pIRES-hrGFP-1a (8,1 Kb 
and devoid of HSPD1 gene) and C2C12 cells were transfected through electroporation, using 
the system Neon® Transfection System. This latter, is an electroporation device that uses the 
tip of a special pipet as an electroporation chamber for the transfection of cells. In general, 
electroporation occurs through the exposure to a short high voltage electrical impulse, which 
transiently generate pores on the cell membranes, allowing the introduction of the DNA of 
interest. The efficacy of electroporation depends on three different parameters: voltage, 
amplitude and pulse number. 
 To optimize transfection efficiency of C2C12 cells, a pre-set protocol was used in four 6 well 
plates, in which all the 24 conditions of the electroporation protocol were tested, changing one 
or two parameters each time. After 48 h, transfected cell were observed under Fluorescent 
microscope using a FITC filter, since the plasmid DNA carries the hrGFP gene for an easy 
recognition of transfeted cells. Overall, even if the transfection efficiency was still very low, 
visible green cells were detected, suggesting that pIRES-hrGFP-1a plasmid was uptaken from 
cells (Figure 11). 
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Figure 11 - Fluorescence images of C2C12 transfected with pIRES-hrGPF-1a-Hyg plasmid. (A-B) C2C12 
electroporated following optimization protocols B3 shown in table 1 of material and methods; (C-D) condition A5 
and B6 respectively 
 After 72 h of electroporation, C2C12 previously subjected to 24 different electroporation 
protocols (table 1 in material and methods) were also analyzed through flow cytometry, to 
evaluate the efficiency of transfection. So, from all the 24 conditions used with 5 µg of plasmid 
pIRES-hrGFP-1a-Hyg and 5x 105 cell/well, only conditions C3 (1300 V, 20 °A, 2) and D2 
(1150 V, 30 °A, 2) gave efficiency higher than 5 %, with a percentage of 7,22 % and 7,21 %, 
respectively (Table 5). 
 
Table 5 - Flow Cytometry of transfected C2C12 with 24 electroporation conditions 
 Once defined the best electroporation protocol, 5 x105 cells/well and 5 µg of plasmid pIRES-
hrGFP-1a-Hyg were further transfected in a 6 well plate, using only conditions C3 and D2. 
After the electroporation, 500 µL of cell suspension were harvested from each well and seeded 
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in a chamber slide for Confocal microscopy analysis. As shown below (Figure 12), pIRES-
hrGFP-1a-Hyg plasmid seemed to be slightly toxic, given the presence of cells under mitotic 
division (Figure 12B); however, the efficiency of transfection was still low and needs some 
modifications to increase the final yield. 
 
Figure 12 - Fluorescence images of C2C12 transfected with pIRES-hrGPF-1a-Hyg plasmid. (A-C) C2C12 
electroporated using condition D2 from the optimization protocol scheme shown in table 1 of material and 
methods. 
4.3. C2C12 cells release extracellular vesicles in cell culture medium 
 Based on previous studies concerning the role of endurance training in mice models with 
neoplastic cachexia, it has been discovered that physical activity enhances the release of natural 
nano-particles able to carry the Hsp60 chaperonin, a protein involved in the mitochondrial 
biogenesis pathway, to which the PGC-1 co-factor belongs. The study has further highlighted 
a potential active role of Hsp60 only when transported inside EVs, since the protein alone was 
not able to trigger the activation of PGC-1 co-factor (Barone, 2016). It could be that, thanks to 
their capability of easily crossing the plasma membrane of the cells, extracellular vesicles may 
help molecules with low solubility to reach specific targets within the cells. 
 So, to demonstrate the presence of nano-vesicles in culture medium, C2C12 cells were cultured 
in T175 cm2 flasks and kept in starvation for 24 h, after which the supernatant was collected for 
the isolation of EVs; in parallel, cells were first analyzed for viability through trypan blue assay, 
and then collected for the production of cell lysate extracts (Figure 13). As shown in the figure 
below, the viability of cells before and after starvation (absence of serum for 24 h) was more 
than 95%, with only a slight increase of dead cells post-starvation, as compared to those of pre-
starvation (Figure 13). On the other hand, cell culture medium supernatant was harvested and 
processed for the isolation of extracellular vesicles using different isolation protocols: 
ultracentrifugation, size exclusion chromatography, tangential flow filtration and total exosome 
isolation kit. 
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Figure 13 - Trypan Blue cell viability of C2C12 myoblasts before and after starvation. Black bars: live and dead 
cells pre-starvation; Gray bars: live and dead cells post-starvation 
 As regard ultracentrifugation, vesicles were first isolated through serial centrifugation (300 g 
for 10 min, 2,000 g for 10 min, 15,000 g for 45 min, and 110,000 g for 2 h, all carried out at 4 
°C) and then evaluated with Zetasizer instrument (by Malvern) under dynamic light scattering 
analysis for size distribution evaluations.  
 Dynamic light scattering (DLS) is a non-invasive technique that investigates the hydrodynamic 
size of nanoparticles. This technology relies on particle size measurement, through the 
estimation of Brownian motion of particles within the sample (this phenomenon occurs when 
particles suspended in a liquid randomly move due to the collisions with the molecules of the 
liquid that surrounds the particle). Particles are illuminated with a laser and further analyzed as 
the intensity fluctuations in the scattered light. Particles speed is then used to determine their 
size: small particles move quickly and scatter less light, while bigger particles move slowly and 
scatter much more light than smaller ones. The size distribution generated by the instrument is 
mainly an intensity distribution, which can be also converted to a volume distribution and a 
number distribution.  
 This latter is an important parameter to take in consideration when performing DLS analysis, 
since it gives an idea of the number of particles, within the sample, with a specific size. For 
instance, if we consider a sample containing only two sizes of particles (5 nm and 50 nm) with 
equal numbers of each size particle, the peaks of number distribution, as expected, are of the 
same size (1:1) as there are equal number of particles. On the other hand, when measuring the 
intensity distribution, the area of the peak for the 50 nm particles would be 1,000,000 times 
larger than the peak for the 5 nm (1:1,000,000 ratio), because large particles scatter much more 
light than small particles (Malvern, 2009). 
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 Two types of EVs were evaluated: those pelleted at 15,000 g and 110,000 g, corresponding to 
microvesicles and large/small EVs, respectively. On the fractions thus obtained, the Z-Average 
(d.nm) size distribution by intensity and number of microvesicles was respectively 301,2 nm, 
while for large/small extracellular vesicles, the Z-Average (d.nm) was of 108,2 nm (Figure 14-
15).  
   
Figure 14 - Zetasizer images of C2C12 myoblasts derived vesicles isolated with ultracentrifugation protocol at 
15,000 g. Left: extracellular vesicles size distribution by intensity, with a main peak at 180,3 nm (95,8 % of the 
total population), Right: extracellular vesicles size distribution by number, with a main peak at 126,1 nm (99,4 % 
of the total population) 
   
Figure 15 - Zetasizer images of C2C12 myoblasts derived vesicles isolated with ultracentrifugation protocol at 
110,000 g. Left: EVs size distribution by intensity, with a main peak at 132 nm (95,8 % of the total population). 
Right: EVs size distribution by number, with a main peak at 56,70 nm (100% of the population) 
 To further demonstrate the presence of nano-vesicles in the C2C12 culture medium, cells were 
cultured for 3 days in presence of horse serum, after which they were detached and placed in 
three-dimensional cultures, in presence of collagen-I (derived from the rat tail) for other 24 h. 
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This type of procedure is generally used to create a suitable sample for electron microscopy 
analysis, as well as in order to prevent the dispersion of nano-vesicles in the culture medium 
(Romancino, 2013).  
 Electron microscopy images of partially differentiated C2C12 cells, revealed the presence of 
EVs with a range diameter between 50 to 120-140 nm, situated close to the cell membranes 
(Figure 16 A), as it was also previously demonstrated from Romancino et al. (Romancino, 
2013). Moreover, as shown in the figure below (Figure 16 B-C), specific antibodies anti-Alix 
revealed the presence of some nano-vesicles aggregates enriched in Alix protein.  
 
Figure 16 – C2C12 cells release nano-vesicles. (A) Electron microscopy analysis of 3D cultures of C2C12 cells 
show the presence of budding intermediates (nascent vesicles) at the plasma membrane or already budded vesicles 
with an average diameter of 80 nm (see scale bar for reference). (B - C) Transmission electron microscopy shows 
immunogold labeling of Alix (a known marker of exosomes) in the nanovesicles from 3D cultures of C2C12 
myoblasts (10 nm gold particles). The two panels B and C show nano-vesicles released in the collagen gel of the 
3D culture (ECM = extra-cellular matrix) (see scale bar for reference)  
 Ultracentrifuged samples, from the two fractions 15,000 g and 110,000 g, were further lysed 
for proteins quantification and used to evaluate the presence of classic EVs protein markers. 
Western blotting analysis of the EVs obtained from 15,000 g and 110,000 g fractions, as well 
their whole cell lysate, shown that the 110,000 g fraction contains a significant enrichment of 
classical exosomes proteins such as Alix, Hsp70 and RAB5, while 15,000 g fraction mainly 
contains RAB5 and Hsp70, with a less abundance in Alix protein (Figure 17). Moreover, total 
cell lysate (used as a control of the corresponding vesicles) presented smaller quantities of Alix 
and RAB5 proteins (Figure 17).  
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Figure 17 - Western blot of EVs isolated by ultracentrifugation protocol. Left: red ponceau of 
microvesicles at 15,000 g, exosomes at 110,000 g and total lysates from C2C12 cells (30 μg of proteins 
per lane). Right: expression bands of Alix, HSP70, HSP60 and RAB5 proteins. β-Actin was used to verify 
the correct protein loading 
 Despite the presence of some of the most common EVs markers, Hsp60 protein band was 
detected only in microvesicles and cell lysate protein samples, but not in EVs pelleted at 
110,000 g. This may be due to the very low presence of the protein within the entire protein 
content of EVs pelleted at 110,000 g. Indeed, although western blot for Hsp60 was negative, 
proteomic results revealed its presence in both samples, 15,000 g and 110,000 g. 
 For proteomic analysis, EVs isolated from 15,000 g and 110,000 g fractions were further 
subjected to RP-nUHPLC/nESI-MS/MS analyses and subsequent database search against the 
Mus musculus UniProt database. Respectively, a total of 1531 proteins were identified from 
samples of EVs isolated at 15.000 g and 1355 in EVs isolated at 110.000 g, including also 
human ENO1 used as internal standard to quantify relative protein abundance.  
 A label free based comparative approach was employed to analyse the differential protein 
content between the two samples. According to the analysis, 389 proteins showed differences 
greater than 2-fold changes and T-test P-value < 0.05 in relative abundances, including 168 up 
regulated and 227 down regulated proteins in Exo. 560 proteins were identified as common to 
both samples with differences in relative abundance lower than 2-fold; 405 proteins were 
exclusively present in Exo and 581 in EVs respectively (Figure 18).  
 Figure 18 shows a volcano plot of the significantly differentially expressed proteins between 
Evs and Exo samples. Hsp60 (Uniprot Acc. P63038) was identified among the differentially 
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accumulated protein with higher abundances in EVs isolated at 15.000 g, as respect to EVs 
isolated at 110.000 g (25-fold change).  
    
Figure 18 - Venn diagram and Volcano Plot showing the identified proteins (unique, common and up/down 
regulated) between EVs and Exo. Left: 560 proteins were identified as common to both samples with differences 
in relative abundance lower than 2-fold; 405 proteins were exclusively present in EVs pelleted at 15.000 g, while 
581 were unique of EVs isolated at 110.000 g. Right: Volcano plot of significantly differentially expressed proteins 
between Evs and Exo samples. X-axis is the fold change of differentially accumulated proteins represented with 
the ratio (Evs/Exo), and Y axis is the corresponding significance. Fold change >= 2 and T-test P-value < 0.05 
were set as the significant threshold for differential expression. Green color represent down-regulated proteins 
and red color represent up-regulated proteins (15.000 g EVs/ 110.000 g EVs) 
 Proteomic data confirmed the results obtained from western blot analysis concerning the 
expression of exosomes markers such as Alix, (Uniprot Acc. Q9WU78) identified among the 
differentially accumulated protein, with lower abundances in microvesicles as respect to 
exosomes (0.12-fold change).  
 Hsp70 (Uniprot Acc. P17879 and P16627) and RAB5 (Uniprot Acc. P35278 and Q9CQD1) 
were identified in both EVs fractions (15,000 g  and 110,000 g) without any relative difference 
in relative abundances. This apparent discrepancy between the western blot analysis may be 
due by the higher sensibility of the spectrometric analysis. Interesting among the list of top 100 
proteins that are often identified in exosomes (derived from exocarta) 44 proteins were also 
identified in our experiments.  
 Moreover, the gene interaction network analysis, performed by Fun-Rich (Figure 19) showed 
that both EVs proteins isolated at 15,000 g and 110,000 g are significantly interconnected with 
Ubc, Eed, Mib and Foxp3 proteins, while only EVs proteins obtained at 110,000 g, significantly 
associated with Hdac1. The list of total proteins identified in EVs pelleted ad 15,000 g A) and 
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EVs pelleted at 110,000 g B) was uploaded and interaction analysis tool was used to obtain the 
diagrams. Green and Red spheres indicate interacting and selected genes, respectively.  
   
Figure 19 - Interaction diagrams of EVs pelleted at 15.000 g and 110.000 g identified proteins performed by 
Fun-Rich 
4.4. Lipid composition of ultracentrifuged EVs 
Lipidomic analysis were carried out to investigate the lipid composition of ultracentrifuged EVs 
fractions obtained at 15,000 g and 110,000 g.  
 Overall, as shown in the figure below, both microvesicles and small/large EVs are composed 
by similar categories of lipids, mainly represented by: glycerolipids (GL), sphingolipids (SP), 
glycerophospholipids (GP), fatty acyls (FA) and sterols (ST). Lipid composition of fractions 
was slightly different between microvesicles (15,000 g) and small/large EVs (110,000 g), with 
a decrease in abundance of some glycerolipids (GL) and an increase of sphingolipids (SP), 
some fatty acyl (FA) and glycerophospholipids (GP) observed in microvesicles as compared to 
small/large EVs (Figure 20). On contrary, small/large EVs seemed to be mainly composed of 
some triradylglycerols, secosteroids, glycerophosphoserines, glycerophosphoethanolamines 
and some fatty amides (figure 20).  
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Figure 20 – Lipidomic analysis of microvesicles pelleted at 15.000 g (red) and small/large EVs pelleted at 
110.000 g (light blue)   
4.5. Size exclusion chromatography (SEC) and tangential flow filtration 
(TFF) as alternative EVs isolation protocols 
 Currently, standard differential centrifugation/density-gradient ultracentrifugation is the most 
used protocol for the isolation of extracellular vesicles; however, it may be challenging, since 
it tends to co-isolate proteins and other contaminant together with vesicles of interest. To 
overcome this problem, we decided to work on the evaluation of different protocols of isolation 
(free of any ultracentrifugation step), mainly using techniques based on the separation of 
particles by different diameters, such as size exclusion chromatography (SEC) and tangential 
flow filtration (TFF).  
 Before proceeding with EVs purification, the two techniques were first set through the aid of 
two different synthetic lipid nano-emulsions of a similar size from that of natural vesicles: 100 
nm TPM-A1-T5 formulation for exosomes and 350 nm B-I312-H1 formulation for 
microparticles. So, the two types of synthetic lipid nanoparticles were first formulated through 
the technique of warm microemulsion, further purified by using TFF (data not shown) and SEC 
protocols and finally characterized by the use of DLS and TRPS technologies. 
 As regard SEC purification, 20 fractions of 500 µL each of TPM-A1-T5 formulation were first 
collected and subsequently characterized by DLS; size distribution of the most relevant 
fractions (7, 8, 9 and 10) shown a Z-Average of 127 nm (Figure 21). 
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Figure 21 - Zetasizer size distribution by intensity and by number of synthetic lipid nanoparticles TPM-A1-T5 
purified with SEC. Left: size distribution by intensity of TPM-A1-T5 nanoparticles purified with SEC, with a main 
peak of 150,5 nm (99,7 %). Right: size distribution by number of TPM-A1-T5, with a main peak of 74,82 nm (100 
%), respectively. Average of 3.  
 To emulate the diameter of microvesicles, B-I312-H1 formulation (of  around 300-350 nm) 
was first prepared, purified through TFF (data not shown) and SEC and finally characterized 
by DLS and TRPS technologies. DLS analysis of post-SEC fractions 7, 8, 9 and 10 shown a Z-
Average (d.nm) of 336,6 nm, with a main peak of 403,8 nm (99, 4 %) and 304,7 nm (82,4 %) 
for intensity and number distribution respectively (Figure 22). 
 
Figure 22 - Zetasizer size distribution by intensity and by number of synthetic lipid nanoparticles B-I312-H1 
purified with SEC. Left: size distribution by intensity of B-I312-H1 fractions (7-10) after SEC purification. Right: 
size distribution by number of B-I312-H1 fractions (7-10) after SEC purification. Average of 3. 
 To better understand the percentage of recovery after SEC purification, we also decided to 
evaluate, for each SEC fraction of each formulation, the correlation between the size Z-average 
distribution and the number of particles read as derived count rate (DCR). This latter, is a 
parameter representative of the scattering intensity measured in the absence of the laser 
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attenuation filter; it gives a qualitative analysis of the quantity of read particles and is calculated 
with the formula: Derived count rate= (Measured Count Rate)/(Attenuation Factor). 
 As shown in the graphs below, the highest percentage of recovery was in fractions 8-10, for 
both formulations, with a percentage of almost 50 % for TPM-A1-T5 and up to 15 % for B-
I312-H1 (Figure 23). These data were also in line with qEVoriginal column data sheet, which 
suggests an elution profile in fraction 7-10  for 500 µL sample loading. 
  
Figure 23 - Graphic representation of Z-average vs % Recovery of the lipid nanoemulsions TPM-A1-T5 fractions 
(left) and B-I312-H1 (right) after SEC purification. Correlation between the diameter of particles (Z-Average) in 
each fraction (blue bars) and the number of particles read at Zetasizer as Derived Count Rate (red and orange 
lines respectively). Left Y-axis: Z-Average distribution; right Y-axis: percentage of recovery; X-axis: SEC fractions 
 To have a comparison with DLS obtained data, synthetic nanoparticles isolated with TFF (data 
not shown) and SEC protocols, were further evaluated by using tunable resistive pulse sensing 
technique (TRPS). Unlike DLS, in TRPS system no laser are involved, but a voltage is applied 
across a pore that is filled with an electrolyte solution for the establishment of an ionic current. 
As particles cross the pore, they briefly increase the electrical resistance, creating a resistive 
pulse called blockade event, which is proportional to the particle volume. The rate of flow of 
particles is proportional to the particle concentration, thus obtaining also a particle number 
estimation (IZON, 2014). Therefore, larger particles produce a higher resistance and a larger 
blockade magnitude, while smaller particles generate a lower resistance with a smaller blockade 
magnitude (Figure 24).  
 TRPS instrument has 5 main components: a fluid cell (where electrodes and sample are 
located) further divided in upper cell (upper electrode) and lower cell (lower electrode), a 
nanopore (a polyurethane membrane with a central hole where the sample pass through), a 
shielding cap (to isolate the electrodes from external interferences), a variable pressure module-
VPM (used for concentration measurement, particle mobility and surface charge analysis of the 
particles) and a base instrument hosting a handle to adjust the nanopore stretch (Figure 24). 
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Figure 24 -  qNano instrument. Left: individual components. Right: Generation of blockade event (yellow peaks) 
 To use TRPS instrument, a non-conductive nanopore was placed on the 4 arms of the machine 
and a voltage (dependent on the size of the nanopore) was applied. Then, an electric baseline 
current was established, filling the two upper and lower fluid cells electrodes with filtered and 
degassed PBS. For TPM-A1-T5 formulation, a nanopore-NP 200 (with a size range of 85-500 
nm) was used, and three different measurements were performed at 4 different pressures: 13, 
10, 7 and 5 mbar respectively. Overall, all the measurements conducted shown a similar trend, 
with an abundance of nanoparticles in the range of 100-150 nm (Figure 25). As concern B-
I312-H1 formulation, a nanopore-NP 400 (size range of 185-1500 nm) was used, and three 
different measurements were performed at three different pressures: 10, 7 and 5 mbar 
respectively. Since in larger nanopores the electrokinetic forces are less than smaller nanopores, 
we decided to use only three pressure values, rather than the four values used for TPM-A1-T5 
formulation (IZON, 2014). Overall, the measurements conducted shown a similar trend, with 
an enrichment of nanoparticles in the range of 200-350 nm (Figure 25).  
  
Figure 25 – Group report histogram of particle diameter vs concentration of TPM-A1-T5 (7, 8 and 9) and B-
I312-H1 (7, 8, 9 and 10) formulations fractions post SEC, using nanopores of 200 nm and 400 nm, respectively. 
Left: size histogram of particle diameter (˜100-300 nm) vs concentration (4,00 E+12) of TPM-A1-T5 fractions. 
Right: size histogram of particle diameter (˜250-800 nm) vs concentration (2,00 E+11) of B-I312-H2 fractions. 
Image representative of three measurements at four and three different pressures (13, 10, 7, and 5 mbar), 
respectively. 
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4.6. EVs isolation through size exclusion chromatography (SEC) and 
tangential flow filtration (TFF) 
 Once having set TFF and SEC isolation protocols with the aid of synthetic nanoparticles, we 
further decided to investigate their purification efficiency for the isolation of EVs, evaluating 
their possible use as alternative technologies to the common ultracentrifugation. This is 
primarily due by the fact that EVs isolation through differential centrifugation/density-gradient 
ultracentrifugation may be a challenge, primarily because of the presence of proteins and other 
contaminant which tend to co-isolate with the vesicles of interest.  
 For both protocols, C2C12 cell culture medium was first collected from cell flasks and 
centrifuged by low differential centrifugations to remove dead cells, after which it was 
processed by TFF and SEC protocols. 
 As concern SEC, pre-purified cell culture medium was washed, concentrated up to 500 µL and 
finally loaded to a commercial qEVoriginal column of 70 nm range (provided by IZON Science 
Ltd.). Then, a total of 20 fractions of 500 µL each were collected and subjected to morpho-
dimensional analysis through DLS and TRPS techniques. DLS analysis of isolated fractions 
demonstrated that most of the recovery was in fractions 7, 8 and 9, with a particle size range of 
150-200 nm (Figure 26).  
   
Figure 26 - Zetasizer images of C2C12 myoblasts derived vesicles, isolated with SEC protocol. Left: EVs size 
distribution by intensity of fractions 7, 8 and 9 in PBS, with a Z-Average (d.nm) of 166,7 nm and a main peak of 
207,2 nm (99,3 %). Right: EVs size distribution by number of fraction 7, 8 and 9 in PBS, with a Z-Average (d.nm) 
of 166,7 nm and a main peak of 46,76 nm (100 %). Average of three measurements. 
 The percentage of recovery for biological nanovesicles, examined by the correlation between 
the Z-average size distribution and the number of particles read as derived count rate (DCR) in 
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each SEC fraction, seemed to be in fractions 7, 8 and 9, with just over 20 % of particles 
recovered (Figure 27).  
 
Figure 27 - Z-Average distribution vs Derived Count Rate (DCR) of SEC Fractions 7-18. Correlation between 
the Z-Average distribution by size (blue bars) and the number of particles read as Derived Count Rate (orange 
line), in each fraction.  
These data were also in line with qEVoriginal column data sheet, which suggests that typical 
elution profile of 500 µL sample should be in fractions 7-10. However, the Z-average 
distribution was not decreasing by increasing the number of eluted fraction, as one would expect 
when using SEC technology, probably due by the presence of some aggregates or interfering 
molecules within the PBS.  
 Purified SEC fractions were further characterized by tunable resistive pulse sensing (TRPS) 
technique using qNano instrument (provided by IZON Science Ltd.). However, when 
performing TRPS analysis, one should keep in mind that the overall size distribution of 
biological vesicles is widely heterogeneous, with a higher polydispersion index as compared to 
synthetic nanoparticles; therefore, measuring EVs in biological samples may often result in 
nanopore clogging, with interruptions of particle rate plot and generation of inaccurate EVs 
concentration estimations.  
 For the analysis of EVs fractions (7, 8 and 9)  post SEC, a non-conductive nanopore-NP 80 
(size range 40-255 nm) was placed on the 4 arms of the machine, stretched at 49,50 mm and a 
voltage (dependent on the size of the nanopore) was applied. The instrument was first set 
through the establishment of an electric baseline current (generated by filling the two upper and 
lower fluid cells electrodes with filtered and degassed PBS), and two different measurements 
were performed at 84,30 nA, using pressure values of: 10, 7 and 5 mbar, respectively. It was 
not possible to perform the third measurement, due to the presence of very large particles that 
they were clogging the nanopore (probably resulting from non-sterile PBS), thus affecting all 
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the analysis. However, the overall trend of data collected revealed a particle diameter mean and 
mode of around 160 nm and 110 nm respectively, with an abundance of nanoparticles in the 
range of 100-150 nm (Figure 28). 
 
Figure 28 - Group report histogram of EVs fractions post SEC (7, 8 and 9), using a nanopore-NP 80 at pressures: 
5, 7 and 10 mbar. X-axis: particle diameter (nm); Y-axis: particle concentration (particle/mL). Image 
representative of two measurements. 
 Similarly to SEC, biological vesicles were also purified with TFF and further characterized 
through DLS and TRPS technologies. As shown in the figure below, DLS analysis revealed 
that most of the recovered particles had a size range between 200-250 nm (Figure 29). 
   
Figure 29 - Zetasizer images of C2C12 myoblasts derived vesicles, isolated with TFF protocol. Left: EVs size 
distribution by intensity with a Z-Average (d.nm) of 213,5 nm and a main peak of 252,9 nm (97,6 %). Right: EVs 
size distribution by number with a Z-Average (d.nm) of 213,5 nm and a main peak of 178,3 nm (67,1 %). Average 
of three measurements.   
 On the basis of DLS results, we decided to use a nanopore-NP 200 (size range 85-500 nm) for 
TRPS analysis of purified TFF vesicles, which was stretched at 47,26 mm and three different 
measurements were performed at 69,67 nA, at pressures: 10, 7 and 5 mbar, respectively.  
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 We noticed that, unlike SEC protocol, TFF purified EVs were more spread (Figure 30). 
Overall, all measurements conducted had a similar trend, with an abundance of nanoparticles 
in the range of 200 nm, and a particle diameter mean and mode of around 250 nm and 190 nm 
respectively (Figure 30). This could be explained by the fact that in TFF we have all population 
sorted, while when using SEC protocol, particles population is sorted on the basis of its different 
size. 
   
Figure 30 - Groups report histogram of EVs isolated through TFF. X-axis: particle diameter (nm); Y-axis: 
particle concentration (particle/mL). Image representative of three measurements. 
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5. Discussion 
Skeletal muscle tissue plays an important role in human function, being involved in vital 
processes such as locomotion and respiration. Generally, muscle mass is balanced from a 
continuous cycle of protein synthesis and protein degradation; however, if this homeostasis is 
altered, it may lead to the development of specific myopathies, such as sarcopenia and cachexia 
(Bowen, 2015).  
 This latter, is a multifactorial syndrome represented by different pathological conditions, such 
as weight loss, anorexia, loss of muscle mass, systemic inflammation and insulin resistance, 
which lead to a global functional decline (Fearon, 2011). Despite its gravity, there is still a lack 
in successful therapeutic interventions, since most of the treatments used so far, resulted not 
effective, thus provoking its underestimation (Tazi, 2010).  
 Currently, most used therapeutic approaches are based on pharmacological therapies, mainly 
focused on the use of appetite stimulants (e.g. megestrol acetate, L-carnitine and melatonin), 
anti-inflammatory drugs (thalidomide and pentoxyphylline), monoclonal antibodies and ghrelin 
agonist anamorelin (Von Haehling, 2014). However, most of these drugs demonstrated 
conflicting results, showing only few auspicious results (Table 6). 
 
Table 6 – Efficiency of the different anti-cachexia treatments (Argilés, 2010) 
 Despite these limitations, recent literature suggested exercise as a positive modulator of 
cachexia and other cancer-associated disorders. Indeed, growing evidences proposed chronic 
exercise as a low-cost and safe defensive tool against systemic inflammations, which positively 
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modulates muscle metabolism (Lira, 2014). Overall, it promotes the attenuation of some of 
those signalling pathways related with protein degradation (e.g. FoxO, myostatin and ROS 
pathways), as well as the activation of specific molecules involved in protein synthesis and 
mitochondrial biogenesis (i.e. IGF-1 and PGC-1α transcriptor factor) (Belloum, 2017). 
However, despite its well-documented beneficial effects in the treatment of muscle wasting, 
only few studies focused on the effect of exercise training in cancer cachexia (Pin, 2015) 
(Ranjbar, 2019) (Padrão, 2017). For instance, our group of research has recently demonstrated 
a positive role of endurance training in the treatment of cachectic mice, which stimulated the 
expression of the mitochondrial chaperonine Hsp60, followed by a further increase of PGC-1α 
levels (Barone, 2016).  
 In line with these previous results, the aim of the PhD project focused on the execution of 
preliminary experiments for the development of a biological drug, based on natural, or 
engineered, nanovesicles against cachexia. In particular, the group have already isolated 
biological nanovesicles able to stimulate, in murine myoblast cells, one of the effects induced 
by endurance training performed by healthy mice. They demonstrated that cell culture medium 
of C2C12 cells, an immortalized myoblast cell line that simulates the characteristics of muscle 
cells, transfected with the plasmid pCMV-6-Entry-HSPD1, promote the activation of the 
mitochondrial biogenesis pathway, to which PGC-1α co-factor belongs (Barone, 2016). 
Physiactisome, the name of this new drug, aims to be the first direct drug on the treatment of 
muscle wasting, with the potential to be customizable, since it can be developed directly from 
muscle stem cells of the patient.  
 As shown in a recent research, cancer cells are able to release HSP60 protein through lipid raft-
exosome pathway; in this alternative secretion mechanism, the chaperonine, previously 
accumulated in the cytoplasm of the cells, translocates to the periphery of the cells, where it 
interacts with the lipid rafts of the membrane and localizes on exosome vesicles (Caruso 
Bavisotto, 2017). Moreover, it was shown that the medium of C2C12 cells transfected with a 
plasmid overexpressing for Hsp60 protein was able, in vitro, to trigger the transcription of PGC-
1α and its isoform PGC-1α1, probably thanks to the activity of Hsp60 chaperonine (Barone, 
2016). Therefore, on the basis of these evidences, we presumed that the secretion of Hsp60 
protein may occur within exocytic vesicles, keeping in mind that Hsp60 protein may be also 
released in a free active form in the extracellular space.  
 So, to prove our hypothesis, C2C12 cells were transfected with both pCMV6-Entry-HSPD1 
plasmid (expressing for murine HSP60), and its negative control pCMV6-Entry plasmid (empty 
plasmid). Confocal microscopy analysis confirmed the presence of positive transfected cells, 
which were positive not only for Myc-DDK tag, (a small oligonucleotide coding for a protein 
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kinase), present in both plasmids, but also for HSP60 (present only in pCMV6-Entry-HSPD1 
plasmid) (Figure 7). However, the antibiotic selection of positive C2C12 transfected clones has 
not given the desired results, since non- transfected cells acquired antibiotic resistance 
characteristics, even using high concentration of antibiotic (Figure 8); indeed, cells continued 
to grow and, more importantly, positive clones lost the plasmid or died, since we couldn’t no 
longer see the expression signal for either HSP60 and Myc-DDK tag (data not shown). So, we 
speculated that cells tend reject the plasmid, while maintaining the gene for antibiotic 
resistance, as they continued to grow.  
 To solve the problem, we decided to design a new plasmid with a different resistance gene, 
able to facilitate the selection of positive transfected cells, hoping to achieve better results. 
Among all the possible selection antibiotics, the choice fell on Hygromycin B, an 
aminoglycoside able of inhibiting protein synthesis of different cells, thus provoking its death 
in about 48 hours. Once proved the efficacy of free Hygromycin B on C2C12 cells (Figure 9), 
we further decided to modify and design a new plasmid pIRES-hrGFP-1a-Hyg, (already 
available at the Human Anatomy laboratories of the Polyclinic of Palermo) in which it was 
inserted the gene module for hygromycin antibiotic. Unlike the previous plasmid pCMV6-
Entry, pIRES-hrGFP-1a-Hyg plasmid was also equipped with green fluorescent human protein 
(hrGFP), allowing the direct observation of transfected cells under fluorescence microscopy, 
thus avoiding time-consuming and unreliable methods of fixing cells methods. The hrGFP 
coding sequence is placed in a distant area from MCS site within pIRES-hrGFP-1a-Hyg 
plasmid, avoiding the production of a fusion GFP protein, which was instead important in the 
sequence DDK-tag of pCMV6-Entry plasmid.  
 The transfection of C2C12 cells with the new plasmid occurred by using an electroporator, an 
instrument able to generate high voltage electrical impulses, provoking the temporary formation 
of cell membrane channels (permeabilization), thus allowing the cellular uptake of various 
molecules which could not spontaneously cross the plasma membrane under physiological 
conditions. So, C2C12 were first electroporated with the empty control pIRES-hrGFP-1a-Hyg 
plasmid (with no HSP60 sequence), using different electroporation optimization protocols 
(Table 3), in order to evaluate the best transfection condition able to give the highest 
transfection efficiency. Flow cytometry analysis of these transfected cells, revealed that only 
conditions C3 (1300 V, 2 pulses, 30 °A) and D2 (1150 V, 2 pulses, 30 °A) seem to be the best 
options for the highest efficiency (Table 5). Overall, the new plasmid resulted less toxic as 
compare to the old one, also confirmed by the confocal microscopy images, in which dividing 
positive green transfected cells were observed (Figure 12). Despite these preliminary results, in 
the next experiments it will be necessary to clone Hsp60 gene (HSPD1 sequence) inside the 
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pIRES-hrGFP-1a-Hyg plasmid, for its insertion within C2C12 cells and the production of high 
levels of extracellular vesicles bearing Hsp60 protein. 
 Currently, physiactisome drug is at the preclinical phase, at the level of animal testing phase, 
and its production is based on the engineering of muscle cells (transfected with a plasmid 
expressing for Hsp60 protein) able to release high amounts of extracellular vesicles carrying 
Hsp60. These tiny vesicles may be then used as a delivery system able to bind to the plasma 
membrane of muscle cells, activating muscle cells repair in all those chronic conditions 
responsible for muscle atrophy (e.g. cancer, Alzheimer’s and heart dysfunction). Physiactisome 
may be a promising biological drug, able to increase the quality of life of patients, also 
improving the effectiveness of other therapies. Since the production of this innovative drug is 
based on biological vesicles, we also focused our attention at some isolation and 
characterization protocols currently used for the recovery of extracellular vesicles, in order to 
better study their characteristics to use in the design of engineered nanoparticles, similar to 
those already discovered.  
 It was first demonstrated that, even in basal conditions, cultured non transfected C2C12 cells 
are able to release extracellular vesicles of 50-250 nm in the cell culture medium (Figure 14-
16), containing some of their most characteristic biomarkers, such as Alix and Rab5 (proteins 
involved in the biogenesis of EVs), as well as Hsp70, as confirmed by western blotting analysis. 
These data were also in line with the previous work of Romancino and his collaborators, who 
have confirmed the presence of Alix protein in C2C12 nanovesicles (Romancino, 2013). 
Moreover, the work of Guescini and colleagues also demonstrated the presence of extracellular 
vesicles with an average diameter of 90-99 nm (therefore only exosomes) in the culture medium 
of C2C12 cells both normal and treated with hydrogen peroxide (Guescini, 2017).  
 However, despite western blot analysis of ultracentrifuged extracellular vesicles were negative 
for Hsp60 protein (Figure 17), label free quantitative proteomic data detected its presence, with 
an abundance 25 folds  higher in microvesicles than exosomes (Figure 18). Moreover, 
proteomic analysis have identified many and common protein profiles between microvesicles 
and exosomes (Figure 18).  
 Studies of interaction network, revealed a considerable interconnection with the ubiquitin 
protein (Ubc), for both exosome and the rest of nano-vesicle proteins (Figure 19). This 
molecule is involved in the degradation of altered proteins, through its interaction with the 
ubiquitin-proteasome system (UPS), one of the major proteolytic machinery systems activated 
during cachexia (Khal, 2005). In addition, a considerable association was also identified 
between EVs proteins and two important epigenetic regulators: embryonic ectoderm 
development (Eed) and histone deacetylase 1 (Hdac1). These genes encode for important 
82 
 
proteins involved in the regulation of chromatin structure, as well as in the control of cell 
development and differentiation during embryogenesis. For instance, HDAC1 as a component 
of the histone deacetylase complex, may play an important role in those gene alterations that 
trigger the development of muscle wasting processes (Tseng, 2015). 
 Despite the growing interest in the use of EVs as diagnostic and therapeutic tool of pathologies, 
understanding their physical composition is still a concern, and most of the current researches 
primarily focused on proteic and nucleic acid characterization of EVs, leaving aside studies on 
their lipid composition. Indeed, only a few EVs lipidomic studies have been performed so far, 
also due by the lack of specific standardized isolation methods and the difficulties in the 
evaluation of pure EVs samples. Moreover, the choice of the lipidomic protocol to use, as well 
as the competence of the operators using these methods, may affect the interpretation of final 
data.  Nonetheless, despite all these limitations, it is now known that lipid composition of  most 
derived cultured cells EVs is mainly represented by cholesterol, sphingomyelin, 
glycosphingolipids, and phosphatidylserines (Table 7). 
 
Table 7 - Lipid composition of exosomes released by individual cell types (Skotland, 2019) 
 In line with most of the data presented in the scientific literature, lipidomic analysis of 
ultracentrifugated EVs (microvesicles and small-EVs) reported the presence of five main lipid 
categories: glycerophospholipids (GP), glycerolipids (GL), sphingolipids (SP), fatty acyls (FA) 
and steroids (ST). Nonetheless, there were no substantial differences between the lipid 
composition of microvesicles and small-EVs, except for some glycerophospholipids, which 
were more abundant in microvesicles rather than exosomes, as well as glycerolipids, which 
were more represented in small-EVs fraction rather than in microvesicles (Figure 20). 
Moreover, the online evaluation through XCMS software confirmed that some of the most 
identified lipids belonged to Phosphatidylcholines (PC), an important component of plasma 
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membranes, despite the presence of this lipid should be less abundant in EVs than their parent 
cells (Skotland, 2017). This could be due by the fact that EVs isolation by ultracentrifugation 
could have also co-isolated some other lipid contaminants, such as lipid droplets or other plasma 
membrane fragments  (Yuana, 2014).  
 Therefore, the choice of a specific isolation method is an important variable to assess when 
characterizing these vesicles, since it may influence the efficacy of EVs isolation (Patel G. , 
2019). Based on this, we also decided to evaluate other different EVs isolation methods, in 
order to better understand their biological properties and compare obtained data in terms of EVs  
purity and quality. So, size exclusion chromatography, tangential flow filtration and Invitrogen 
total exosome isolation kit (data not shown) methods were also investigated as alternative 
isolation methods to the classic ultracentrifugation protocol, after having set the protocols with 
synthetic lipid nanoparticles of similar size to that of EVs, previously formulated by the 
technique of warm microemulsion (Gasco M. , 1989). 
 Size Exclusion Chromatography (SEC), is a technology widely used for the separation of 
heterogeneous samples based on their size, constituting one of the most promising isolation 
methods in the field of extracellular vesicles (Benedikter, 2017). Indeed, as compared to the 
classical ultracentrifugation technology, SEC is easy to perform, do not need specific 
equipments (e.g. ultracentrifuge) and provide a higher quality of isolated EVs, keeping their 
shape intact, which can instead be damaged by centrifuge force. Nowadays, various group of 
research have already widely used this technology, demonstrating its ability to obtain sorted 
purer vesicles subpopulations than ultracentrifugation (Benedikter, 2017) (Mol, 2017). 
However, one of its main drawbacks is that it dilutes the initial sample, causing its dispersion 
in several fractions, thus influencing the final yield and subsequent EVs analysis. 
 On the basis of DLS analysis performed in previous ultracentrifuged samples (Figure 14-15), 
a commercial 10 mL qEVoriginal column of 70 nm range (provided by IZON Science Ltd.) 
was used for the isolation of pre-centrifuged vesicles. However, this type of columns are only 
suitable for small sample volumes of about 0.5 ml, hence pre-centrifuged cell culture medium 
was further concentrated through stirred cell device, using a 100 kDa filter. DLS analysis 
confirmed that the majority of isolated EVs had a size range between 50 and 300 nm in diameter 
(Figure 26-27). To have an idea of the concentration value of isolated EVs, fractions containing 
vesicles (F7, F8 and F9) were further analyzed through tunable resistive pulse sensing, an 
innovative technology able to characterize size, concentration and Z-potential of biological 
vesicles (Figure 28). TRPS technology allows the investigation of small sample size in a short 
time and without the need to manipulate the sample. The only prerequisite for successful 
measurement is to maintain the same conditions between calibration and sample particles (i.e. 
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same sample buffers, instrument settings, nanopore size, voltage and applied pressure) (Maas, 
2014). Nonetheless, one of its main limitations is due by the lack of an exact mechanism for the 
setting of the pressure VPM device, which frequently causes minor differences in applied 
pressure between samples. Moreover, evaporation of fluid in the VPM may provoke pressure 
differences if measuring at different time points.  
 Despite these downsides, C2C12 SEC fractions 7, 8 and 9 were pooled together, concentrated 
and further analyzed through qNano instrument (provided by IZON Science Ltd.). Overall, the 
size distribution of EVs was in the range of 100-300 nm (Figure 28). However, unlike synthetic 
nanoparticles (Figure 21-25), biological samples were more polydisperse, made by different 
size of vesicles that had often clogged the nanopore membrane, especially when using smaller 
nanopores where the electrokinetic forces increased. Moreover, sample contaminants (e.g. 
sugars, lipids, proteins and other larger debris present in cell culture medium) could have also 
influenced measurement conditions, affecting the quality of results. Nonetheless, the use of 
larger nanopores could eliminate the problem, although we noticed that increasing the diameter 
of the hole in the nanopores may affect the measurement of smaller vesicles, which would pass 
through it and would be read as background noise. Another possible solution could be filtration 
of the sample, but the results obtained would not reflect the real concentration value of the 
sample, since most of the vesicles would remain blocked in the filter, decreasing the final yield 
(Konoshenko, 2018).    
 Extracellular vesicles were also purified using tangential flow filtration (TFF), an alternative 
method of membrane filtration originally used for concentrating and desalting dissolved 
molecules (Zahka, 1985), but recently adapted in EVs isolation to improve their final yield 
(Haraszti, 2018). Here, cell culture medium is both concentrated and filtered, in one step, only 
using a peristaltic system, that can process large volume of medium, thus making the system 
scalable. Overall, membrane filtration technology can use direct flow filtration (DFF), also 
known as dead-end filtration, or and Tangential Flow Filtration (TFF). In the first case, the flow 
of the fluid is perpendicular to the membrane face (Iritani, 1995), while in TFF the feed stream 
passes parallel to the filter and is recirculated back to the feed reservoir (Figure 31).  
 
Figure 31 – Dead end filtration vs tangential flow filtration 
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 So, similarly to SEC, tangential flow filtration was evaluated as an alternative size-based EV 
concentration method able of processing scalable volumes of biological fluids. C2C12 pre-
centrifuged cell culture medium was purified through VIVAFLOW 50 Tangential Flow 
Filtration system (100,000 MWCO) and further characterized through DLS ant TRPS analysis. 
As confirmed in other studies (Busatto, 2018), the size distribution of isolated EVs ranged from 
200-250 nm (Figure 29), with broader EVs peak diameters, as compared to ultracentrifugation 
and SEC methods. These data were further confirmed through tunable resistive pulse sensing 
measurements (Figure 30), where it was necessary to use a nanopore with a larger diameter 
than the nanopore used in SEC isolation. This could be explained by the fact that in TFF 
technology all EVs population are recovered, unlike SEC and ultracentrifugation, where only 
specific population are sorted. Therefore, standing to these results, we concluded that TFF 
technology often requires a second process of purification, often constituted by filtration, size-
exclusion chromatography, or a sucrose density gradient, in order to achieve the optimal purity 
and yield. However, for a complete comparison among all these isolation methods, biochemical 
analysis focused on the identification of specific EVs biomarkers for the identification of the 
sub-type of isolated vesicles are needed, and are still under investigation. 
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6. Conclusions 
Given the beneficial effects of physical activity on the general state of cachectic patients, 
Physiactisome® could represent the first customizable anti-cachectic drug able to act directly 
on skeletal muscle cells, thus mimicking the effects of exercise. Moreover, it could also improve 
the lifespan of cancer patients allowing, in parallel, the evaluation of other possible cancer 
therapies, which are often denied in terminal patients.  
 We found that in vitro transfection of cells was able to reproduce the positive effects of exercise 
in trained cachectic mice, as suggested by the overexpression of HSP60 protein and the 
activation of PGC-1α, both regulators of mitochondria biogenesis and muscle homeostasis. 
However, the efficiency of transfection was always very low, and we still need to design a 
stable cell line in order to obtain high quantities of product. In addition, since the drug should 
be based on biological vesicles, further studies are needed to better isolate and characterize 
these tiny particles. Extracellular vesicles can be isolated through different methods and, the 
choice of the best method depends on the characteristics of the initial sample. In addition, 
isolation step is often tricky, especially if the starting cells are under physiological conditions, 
since they tend to release lower levels of nanovesicles, making their analysis very difficult and 
linked to the volumes of medium harvested.  
 
 
 
 
 
 
 
 
 
 
 
 
87 
 
7. References 
Aatonen, M. (2014). Isolation and characterization of platelet-derived extracellular vesicles. J 
Extracell Vesicles. doi:10.3402/jev.v3.24692 
Abid Hussein, M. (2005). Cell-derived microparticles contain caspase 3 in vitro and in vivo. J Thromb 
Haemost., 3(5):888-96. doi:10.1111/j.1538-7836.2005.01240.x 
Abramowicz, A. (2019). Ionizing radiation affects the composition of the proteome of extracellular 
vesicles released by head-and-neck cancer cells in vitro. Journal of Radiation Research, 289–
297. doi:10.1093/jrr/rrz001 
Ahmadi Badi, S. (2017). Microbiota-Derived Extracellular Vesicles as New Systemic Regulators. Front 
Microbiol., 8:1610. doi:10.3389/fmicb.2017.01610. 
Akbarzadeh, A. (2013). Liposome: classification, preparation, and applications. Nanoscale Res Lett, 
102. doi:10.1186/1556-276X-8-102 
Akers, J. (2013). Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like 
vesicles, and apoptotic bodies. J Neurooncol., 1-11. doi: 10.1007/s11060-013-1084-8 
Akers, J. (2017). A cerebrospinal fluid microRNA signature as biomarker for glioblastoma. 
Oncotarget., 8(40):68769-68779. doi:10.18632/oncotarget.18332. 
Almiñana, C. (2020). Extracellular vesicles: Multi-signal messengers in the gametes/embryo-oviduct 
cross-talk. Theriogenology., S0093-691X(20)30090-X. 
doi:10.1016/j.theriogenology.2020.01.077. 
Al-Samadi, A. (2017). Crosstalk between tongue carcinoma cells, extracellular vesicles, and immune 
cells in in vitro and in vivo models. Oncotarget., 8(36): 60123–60134. 
doi:10.18632/oncotarget.17768 
Altan-Bonnet, N. (2016). Extracellular vesicles are the Trojan horses of viral infection. Curr Opin 
Microbiol, 77-81. doi:10.1016/j.mib.2016.05.004 
Alvarez-Erviti, L. (2011). Delivery of siRNA to the mouse brain by systemic injection of targeted 
exosomes. Nat. Biotechnol, 341–345. doi:10.1038/nbt.1807 
Amabile, N. (2005). Circulating endothelial microparticles are associated with vascular dysfunction in 
patients with end-stage renal failure. J Am Soc Nephrol., 16(11):3381-8. 
doi:10.1681/ASN.2005050535 
Anthony, T. (2016). Mechanisms of protein balance in skeletal muscle. Domest Anim Endocrinol., S23-
32. doi:10.1016/j.domaniend.2016.02.012. 
Antonescu, C. (2011). Phosphatidylinositol-(4,5)-bisphosphate regulates clathrin-coated pit initiation, 
stabilization, and size. Mol Biol Cell., 22(14): 2588–2600. doi:10.1091/mbc.E11-04-0362 
Antonucci, F. (2012). Microvesicles released from microglia stimulate synaptic activity via enhanced 
sphingolipid metabolism. EMBO J, 1231–1240. doi:10.1038/emboj.2011.489 
Antunes, D. (2014). Molecular insights into mitochondrial dysfunction in cancer-related muscle 
wasting. Biochim Biophys Acta., 1841(6):896-905. doi:10.1016/j.bbalip.2014.03.004 
Ardies, C. (2002). Exercise, cachexia, and cancer therapy: a molecular rationale. Nutr Cancer., 
42(2):143-57. doi:10.1207/S15327914NC422_1 
88 
 
Argilés, J. (2005). Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia 
versus sarcopenia. Int J Biochem Cell Biol, 37(5):1084-104. doi:10.1016/j.biocel.2004.10.003 
Argilés, J. (2010). Optimal management of cancer anorexia-cachexia syndrome. Cancer Manag Res, 
27-38. doi:10.2147/cmar.s7101 
Aryani, A. (2016). Exosomes as a nanodelivery system: a key to the future of neuromedicine? . Mol. 
Neurobiol , 818–834. doi:10.1007/s12035-014-9054-5 
Atkin-Smith, G. (2015). A novel mechanism of generating extracellular vesicles during apoptosis via a 
beads-on-a-string membrane structure. Nat. Commun., 6:7439. doi:10.1038/ncomms8439 
Aversa, Z. (2017). Cancer-induced muscle wasting: latest findings in prevention and treatment. Ther 
Adv Med Oncol, 9(5): 369–382. doi:10.1177/1758834017698643 
Ayala, A. (1983). Primary bone tumors: percutaneous needle biopsy. Radiologic-pathologic study of 
222 biopsies. Radiology., 149(3):675-9. doi:10.1148/radiology.149.3.6580673 
Babatz, J. (2003). Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic 
cells for cancer immunotherapy: a phase I study. J Hematother Stem Cell Res., 12(5):515-23. 
doi:10.1089/152581603322448222 
Babst, M. (2011). MVB Vesicle Formation: ESCRT-Dependent, ESCRT-Independent and Everything in 
Between. Curr Opin Cell Biol, 452–457. doi:10.1016/j.ceb.2011.04.008 
Bache, K. (2003). Hrs regulates multivesicular body formation via ESCRT recruitment to endosomes. J 
Cell Biol., 162(3): 435–442. doi:10.1083/jcb.200302131 
Badimon, L. (2016). Role of Platelet-Derived Microvesicles As Crosstalk Mediators in 
Atherothrombosis and Future Pharmacology Targets: A Link between Inflammation, 
Atherosclerosis, and Thrombosis. Front Pharmacol., 7: 293. doi:10.3389/fphar.2016.00293 
Bagatolli, L. (2000). Giant phospholipid vesicles: comparison among the whole lipid sample 
characteristics using different preparation methods: A two photon fluorescence microscopy 
study. Chemistry and Physics of Lipids. doi:10.1016/S0009-3084(00)00118-3 
Baietti, M. (2011). Syndecan–syntenin–ALIX regulates the biogenesis. Nature Cell Biology, 677-85. 
doi:10.1038/ncb2502 
Bank, I. (2015). The diagnostic and prognostic potential of plasma extracellular vesicles for 
cardiovascular disease. Expert Rev Mol Diagn., 15(12):1577-88. 
doi:10.1586/14737159.2015.1109450 
Barile, L. (2017). Exosomes: Therapy delivery tools and biomarkers of diseases. Pharmacol Ther, 63-
78. doi:10.1016/j.pharmthera.2017.02.020. 
Barone, R. (2016). Skeletal muscle Heat shock protein 60 increases after endurance training and 
induces peroxisome proliferator-activated receptor gamma coactivator 1 α1 expression. Sci 
Rep, 6:19781. doi:10.1038/srep19781 
Batrakova, E. (2015). Using exosomes, naturally-equipped nanocarriers, for drug delivery. J Control 
Release, 396-40. doi:10.1016/j.jconrel.2015.07.030 
Beere, H. (2004). "The stress of dying": the role of heat shock proteins in the regulation of apoptosis. 
J Cell Sci, 2641-51. doi:10.1242/jcs.01284 
89 
 
Beez, C. (2019). Cardiac Extracellular Vesicles (EVs) Released in the Presence or Absence of 
Inflammatory Cues Support Angiogenesis in Different Manners. Int J Mol Sci., 20(24): 6363. 
doi:10.3390/ijms20246363 
Bei, Y. (2017). Extracellular Vesicles in Cardiovascular Theranostics. Theranostics., 7(17): 4168–4182. 
doi:10.7150/thno.21274 
Belizário, J. (2001). Cleavage of caspases-1, -3, -6, -8 and -9 substrates by proteases in skeletal 
muscles from mice undergoing cancer cachexia. Br J Cancer, 1135–1140. 
doi:10.1054/bjoc.2001.1700 
Belloum, Y. (2017). Cancer-induced cardiac cachexia: Pathogenesis and impact of physical activity 
(Review). Oncol Rep, 2543-2552. doi:10.3892/or.2017.5542 
Benedikter, B. (2017). Cigarette smoke extract induced exosome release is mediated by depletion of 
exofacial thiols and can be inhibited by thiol-antioxidants. Free Radic Biol Med, 334-344. 
doi:10.1016/j.freeradbiomed.2017.03.026 
Benedikter, B. (2017). Ultrafiltration combined with size exclusion chromatography efficiently 
isolates extracellular vesicles from cell culture media for compositional and functional 
studies. Sci. Rep, 7:15297. doi:10.1038/s41598-017-15717-7 
Benedikter, B. (2019). Proteomic analysis reveals procoagulant properties of cigarette smoke-induced 
extracellular vesicles. J Extracell Vesicles, 1585163. doi:10.1080/20013078.2019.1585163 
Berckmans, R. (2001). Cell-derived microparticles circulate in healthy humans and support low grade 
thrombin generation. Thromb Haemost., 85(4):639-46. 
Bergsmedh, A. (2001). Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proc Natl 
Acad Sci U S A., 98(11):6407-11. doi:10.1073/pnas.101129998 
Besterman, J. (1983). Endocytosis: a review of mechanisms and plasma membrane dynamics. 
Biochem J., 210(1):1-13. doi:10.1042/bj2100001 
Bettscheider, M. (2012). Optimized analysis of DNA methylation and gene expression from small, 
anatomically-defined areas of the brain. J Vis Exp, (65):e3938. doi:10.3791/3938 
Bewicke-Copley, F. (2017). Extracellular vesicles released following heat stress induce bystander 
effect in unstressed populations. J Extracell Vesicles., 6(1):1340746. 
doi:10.1080/20013078.2017.1340746 
Bhatia, S. (2016). Nanoparticles Types, Classification, Characterization, Fabrication Methods and Drug 
Delivery Applications. Natural Polymer Drug Delivery Systems. doi:10.1007/978-3-319-41129-
3_2 
Bianchi, E. (2014). Izumo meets Juno: preventing polyspermy in fertilization. Cell Cycle., 13(13):2019-
20. doi:10.4161/cc.29461. 
Bianchi, E. (2014). Juno is the egg Izumo receptor and is essential for mammalian fertilization. 
Nature., 508(7497):483-7. doi:10.1038/nature13203. 
Bick, R. (1992). Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost., 
18(4):353-72. doi:10.1055/s-2007-1002575. 
Bielaszewska, M. (2017). Host cell interactions of outer membrane vesicle-associated virulence 
factors of enterohemorrhagic Escherichia coli O157: Intracellular delivery, trafficking and 
mechanisms of cell injury. PLoS Pathog., 13(2):e1006159. doi:10.1371/journal.ppat.1006159. 
90 
 
Bitto, N. (2017). Bacterial membrane vesicles transport their DNA cargo into host cells. Sci Rep., 
7(1):7072. doi:10.1038/s41598-017-07288-4. 
Blanco, E. (2015). Principles of nanoparticle design for overcoming biological barriers to drug 
delivery. Nat Biotechnol. doi:10.1038/nbt.3330 
Bloom, A. (1990). Physiology of blood coagulation. Haemostasis., 1:14-29. doi:10.1159/000216159 
Bode-Böger, S. (1998). L-arginine-induced vasodilation in healthy humans: pharmacokinetic-
pharmacodynamic relationship. Br J Clin Pharmacol., 46(5):489-97. doi:10.1046/j.1365-
2125.1998.00803.x 
Böing, A. (2014). Single-step isolation of extracellular vesicles by size-exclusion chromatography. J 
Extracell Vesicles. doi:10.3402/jev.v3.23430 
Borroto-Escuela, D. (2015). The role of transmitter diffusion and flow versus extracellular vesicles in 
volume transmission in the brain neural-glial networks. Philos Trans R Soc Lond B Biol Sci., 
20140183. doi:10.1098/rstb.2014.0183 
Boukouris, S. (2015). Exosomes in bodily fluids are a highly stable resource of disease biomarkers. 
Proteomics Clin Appl., 9(3-4):358-67. doi:10.1002/prca.201400114. 
Boulanger, C. (2001). Circulating microparticles from patients with myocardial infarction cause 
endothelial dysfunction. Circulation., 104(22):2649-52. doi:10.1161/hc4701.100516 
Boulanger, C. (2017). Extracellular vesicles in coronary artery disease. Nat Rev Cardiol., 14(5):259-
272. doi:10.1038/nrcardio.2017.7 
Bowen, T. (2015). Skeletal muscle wasting in cachexia and sarcopenia: Molecular pathophysiology 
and impact of exercise training. journal of Cachexia, Sarcopenia and Muscle, 197-207. 
doi:10.1002/jcsm.12043 
Brahmer, A. (2019). Platelets, endothelial cells and leukocytes contribute to the exercise-triggered 
release of extracellular vesicles into the circulation. J Extracell Vesicles., 8(1):1615820. 
doi:10.1080/20013078.2019.1615820 
Briggs, J. (2003). Structural organization of authentic, mature HIV-1 virions and cores. EMBO J, 1707–
1715. doi:10.1093/emboj/cdg143 
Brock, C. (2019). Stem cell proliferation is induced by apoptotic bodies from dying cells during 
epithelial tissue maintenance. Nat Commun., 1044. doi:10.1038/s41467-019-09010-6 
Brouwers, J. (2013). Distinct lipid compositions of two types of human prostasomes. Proteomics, 
1660-6. doi:10.1002/pmic.201200348 
Brown, P. (2017). Polymer-Based Purification of Extracellular Vesicles. Methods Mol Biol, 91-103. 
doi:10.1007/978-1-4939-7253-1_8 
Brown, S. (2017). Basics of Skeletal Muscle Function and Normal Physiology. Cardioskeletal 
Myopathies in Children and Young Adults, 21-38. doi:org/10.1016/B978-0-12-800040-
3.00002-9 
Bulbake, U. (2017). Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics, E12. 
doi:10.3390/pharmaceutics9020012 
Busatto, S. (2018). Tangential Flow Filtration for Highly Efficient Concentration of Extracellular 
Vesicles from Large Volumes of Fluid. Cells, E273. doi:10.3390/cells7120273 
91 
 
Busatto, S. (2019). Organotropic drug delivery: Synthetic nanoparticles and extracellular vesicles. 
Biomed Microdevices, 46. doi:10.1007/s10544-019-0396-7 
Cai, J. (2013). Extracellular vesicle-mediated transfer of donor genomic DNA to recipient cells is a 
novel mechanism for genetic influence between cells. J Mol Cell Biol., 5(4):227-38. 
doi:10.1093/jmcb/mjt011. 
Caldwell, R. (2018). Arginase: A Multifaceted Enzyme Important in Health and Disease. Physiol Rev., 
98(2):641-665. doi:10.1152/physrev.00037.2016. 
Campanella, C. (2012). The Odyssey of Hsp60 from Tumor Cells to Other Destinations Includes 
Plasma Membrane-Associated Stages and Golgi and Exosomal Protein-Trafficking Modalities. 
PLoS ONE. doi:10.1371/journal.pone.0042008 
Cantaluppi, V. (2015). Endothelial progenitor cell-derived extracellular vesicles protect from 
complement-mediated mesangial injury in experimental anti-Thy1.1 glomerulonephritis. 
Nephrol Dial Transplant., 30(3):410-22. doi:10.1093/ndt/gfu364 
Cantó, C. (2009). PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy 
expenditure. Current Opinion in Lipidology, 98-105. doi:10.1097/MOL.0b013e328328d0a4 
Caruso Bavisotto, C. (2017). Exosomal HSP60: a potentially useful biomarker for diagnosis, assessing 
prognosis, and monitoring response to treatment. Expert Rev Mol Diagn, 815-822. 
doi:10.1080/14737159.2017.1356230 
Catchpoole, D. R. (1995). Formation of apoptotic bodies is associated with internucleosomal DNA 
fragmentation during drug-induced apoptosis. Exp. Cell Res., 216 169–177. 
doi:10.1006/excr.1995.1021 
Cavalli, R. (2007). THE EFFECT OF ALCOHOLS WITH DIFFERENT STRUCTURES ON THE FORMATION OF 
WARM O/W MICROEMULSIONS. Journal of Dispersion Science and Technology, 717-734. 
doi:10.1080/01932699608943535 
Cerezo-Magaña, M. (2019). The pleiotropic role of proteoglycans in extracellular vesicle mediated 
communication in the tumor microenvironment. Semin Cancer Biol., S1044-579X(19)30162-
2. doi:10.1016/j.semcancer.2019.07.001. 
Chandra, D. (2003). Mitochondrially localized active caspase-9 and caspase-3 result mostly from 
translocation from the cytosol and partly from caspase-mediated activation in the organelle. 
Lack of evidence for Apaf-1-mediated procaspase-9 activation in the mitochondria. J Biol 
Chem, 278(19):17408-20. doi:10.1074/jbc.M300750200 
Chargaff, E. (1946). The biological significance of the thromboplastic protein of blood. J Biol Chem., 
166(1):189-97. 
Cheung, W. (2010). Inflammation and cachexia in chronic kidney disease. Pediatr Nephrol, 711–724. 
doi:10.1007/s00467-009-1427-z 
Chiabotto, G. (2019). Salivary Extracellular Vesicle-Associated exRNA as Cancer Biomarker. Cancers 
(Basel), 11(7): 891. doi:10.3390/cancers11070891 
Chin, E. (2004). The role of calcium and calcium/calmodulin-dependent kinases in skeletal muscle 
plasticity and mitochondrial biogenesis. Proc Nutr Soc, 63(2):279-86. 
doi:10.1079/PNS2004335 
92 
 
Chinsomboon, J. (2009). The transcriptional coactivator PGC-1alpha mediates exercise-induced 
angiogenesis in skeletal muscle. Proc Natl Acad Sci U S A, 106(50):21401-6. 
doi:10.1073/pnas.0909131106 
Chistiakov, D. (2015). Extracellular vesicles and atherosclerotic disease. Cell. Mol., 2697–2708. 
doi:10.1007/s00018-015-1906-2 
Chistiakov, D. (2017). α-Synuclein-carrying extracellular vesicles in Parkinson’s disease: deadly 
transmitters. Acta Neurol Belg, 43–51. doi:10.1007/s13760-016-0679-1 
Chivet, M. (2012). Emerging Role of Neuronal Exosomes in the Central Nervous System. Front Physiol, 
3: 145. doi:10.3389/fphys.2012.00145 
Choi. (2017). Structural Analysis of Exosomes Using Different Types. Apllied Microscopy, 171-175. 
doi:10.9729/AM.2017.47.3.171 
Choi, D. (2014). Extracellular vesicles shed from gefitinib‐resistant nonsmall cell lung cancer regulate 
the tumor microenvironment. Proteomics, 14(16):1845-56. doi:10.1002/pmic.201400008. 
Choi, D. (2015). Isolation of extracellular vesicles for proteomic profiling. Methods Mol Biol, 167-77. 
doi:10.1007/978-1-4939-2550-6_14 
Ciregia, F. (2017). Extracellular Vesicles in Brain Tumors and Neurodegenerative Diseases. Front Mol 
Neurosci., 10:276. doi:10.3389/fnmol.2017.00276. 
Cocucci, E. (2015). Ectosomes and exosomes: shedding the confusion between extracellular vesicles. 
Trends Cell Biol., 25 364–372. doi:10.1016/j.tcb.2015.01.004 
Coleman, M. (2001). Membrane blebbing during apoptosis results from caspase-mediated activation 
of ROCK I. Nat. Cell Biol., 3 339–345. doi:10.1038/35070009 
Colombo, M. (2013). Analysis of ESCRT functions in exosome biogenesis, composition and secretion 
highlights the heterogeneity of extracellular vesicles. J Cell Sci, 5553-65. 
doi:10.1242/jcs.128868 
Colombo, M. (2014). Biogenesis, secretion, and intercellular interactions of exosomes and other 
extracellular vesicles. Annu Rev Cell Dev Biol., 255-89. doi:10.1146/annurev-cellbio-101512-
122326 
Costelli, P. (1993). Tumor Necrosis Factor-a Mediates Changes in Tissue Protein Turnover. J Clin 
Invest, 92(6):2783–2789. doi:10.1172/JCI116897 
Costelli, P. (2001). Activation of Ca2+-dependent proteolysis in skeletal muscle and heart in cancer 
cachexia. Br J Cancer, 84(7): 946–950. doi:10.1054/bjoc.2001.1696 
Costelli, P. (2005). Ca(2+)-dependent proteolysis in muscle wasting. Int J Biochem Cell Biol., 
37(10):2134-46. doi:10.1016/j.biocel.2005.03.010 
Costelli, P. (2006). IGF-1 is downregulated in experimental cancer cachexia. Am J Physiol Regul Integr 
Comp Physiol, 291(3):R674-83. doi:10.1152/ajpregu.00104.2006 
Cuenca, A. (2006). Emerging implications of nanotechnology on cancer diagnostics and therapeutics. 
Cancer, 459-66. doi:10.1002/cncr.22035 
Currow, D. (2018). Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with 
Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia—Review and Expert Opinion. Int 
J Mol Sci, 19(11): 3471. doi:10.3390/ijms19113471 
93 
 
Cvjetkovic, A. (2014). The influence of rotor type and centrifugation time on the yield and purity of 
extracellular vesicles. J Extracell Vesicles. doi:10.3402/jev.v3.23111 
D’Souza, R. (2014). Rab4 Orchestrates a Small GTPase Cascade for Recruitment of Adaptor Proteins 
to Early Endosomes. Curr Biol., 24(11):1187-98. doi:10.1016/j.cub.2014.04.003. 
Dalli, J. (2008). Annexin 1 mediates the rapid anti-inflammatory effects of neutrophil-derived 
microparticles. Blood, 2512-2519. doi:10.1182/blood-2008-02-140533 
Dalwadi, G. (2007). Purification of PEGylated Nanoparticles Using Tangential Flow Filtration (TFF). 
Drug Development and Industrial Pharmacy, 1030-9. doi:10.1080/03639040601180143 
Davis, C. (2019). The importance of extracellular vesicle purification for downstream analysis: A 
comparison of differential centrifugation and size exclusion chromatography for helminth 
pathogens. PLoS Negl Trop Dis, e0007191. doi:10.1371/journal.pntd.0007191 
de Toledo, M. (2019). Extracellular Vesicles in Fungi: Composition and Functions. Curr Top Microbiol 
Immunol, 45-59. doi:10.1007/82_2018_141 
Del Conde, I. (2005). Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated 
platelets to initiate coagulation. Blood., 106(5):1604-11. doi:10.1182/blood-2004-03-1095 
Diaz, L. (2014). Liquid Biopsies: Genotyping Circulating Tumor DNA. J Clin Oncol., 32(6): 579–586. 
doi:10.1200/JCO.2012.45.2011 
Diaz-Hidalgo, L. (2016). Transglutaminase type 2-dependent selective recruitment of proteins into 
exosomes under stressful cellular conditions. Biochim Biophys Acta., 1863(8):2084-92. 
doi:10.1016/j.bbamcr.2016.05.005 
Dickens, A. (2017). Astrocyte-shed extracellular vesicles regulate the peripheral leukocyte response 
to inflammatory brain lesions. Sci Signal, eaai7696. doi:10.1126/scisignal.aai7696 
Dinarello, C. (1986). Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces 
production of interleukin 1. J Exp Med, 163(6): 1433–1450. doi:10.1084/jem.163.6.1433 
Ding, M. (2018). Comparison of commercial exosome isolation kits for circulating exosomal microRNA 
profiling. Anal Bioanal Chem, 3805-3814. doi:10.1007/s00216-018-1052-4 
Dipak, K. (2005). Engineering of Nanoemulsions for Drug Delivery. Current Drug Delivery. 
doi:10.2174/156720105774370267 
Drummond, I. (1987). The role of oxidative stress in the induction of Drosophila heat-shock proteins. 
Exp Cell Res, 439-49. doi:10.1016/0014-4827(87)90284-9 
Du, J. (2004). Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in 
catabolic conditions. J Clin Invest, 113(1): 115–123. doi:10.1172/JCI200418330 
Dua, J. (2012). LIPOSOME: METHODS OF PREPARATION AND APPLICATIONS. International Journal of 
Pharmaceutical Studies and Research, 14-20. 
Egan, B. (2010). Exercise intensity-dependent regulation of peroxisome proliferator-activated 
receptor coactivator-1 mRNA abundance is associated with differential activation of 
upstream signalling kinases in human skeletal muscle. J Physiol, 588(Pt 10):1779-90. 
doi:10.1113/jphysiol.2010.188011 
Eguchi, A. (2016). Circulating adipocyte-derived extracellular vesicles are novel markers of metabolic 
stress. J Mol Med., 1241–1253. doi:10.1007/s00109-016-1446-8. 
94 
 
Eguchi, A. (2019). Circulating Extracellular Vesicles and Their miR "Barcode" Differentiate Alcohol 
Drinkers With Liver Injury and Those Without Liver Injury in Severe Trauma Patients. Front 
Med (Lausanne)., 6:30. doi:10.3389/fmed.2019.00030 
Eldh, M. (2010). Exosomes communicate protective messages during oxidative stress; possible role of 
exosomal shuttle RNA. PLoS One., 5(12):e15353. doi:10.1371/journal.pone.0015353. 
Elizondo, E. (2011). Liposomes and other vesicular systems: structural characteristics, methods of 
preparation, and use in nanomedicine. Prog Mol Biol Transl Sci, 1-52. doi:10.1016/B978-0-12-
416020-0.00001-2 
Endzeliņš, E. (2017). Detection of circulating miRNAs: comparative analysis of extracellular vesicle-
incorporated miRNAs and cell-free miRNAs in whole plasma of prostate cancer patients. BMC 
Cancer., 17(1):730. doi: 10.1186/s12885-017-3737-z 
Endzeliņš, E. (2018). Extracellular Vesicles Derived from Hypoxic Colorectal Cancer Cells Confer 
Metastatic Phenotype to Non-metastatic Cancer Cells. Anticancer Res., 38(9):5139-5147. 
doi:10.21873/anticanres.12836. 
Escobedo, J. (2003). Improved transfection technique for adherent cells using a commercial lipid 
reagent. Biotechniques, 936-8. doi:10.2144/03355bm06 
Escola, J. (1998). Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular 
endosomes and on exosomes secreted by human B-lymphocytes. J Biol Chem, 20121-7. 
doi:10.1074/jbc.273.32.20121 
Eva, P. (2016). Aerobic Exercise and Pharmacological Treatments Counteract Cachexia by Modulating 
Autophagy in Colon Cancer. Scientific Reports, 6:26991. doi:10.1038/srep26991 
Fares, J. (2017). Syntenin: Key player in cancer exosome biogenesis and uptake? Cell Adh Migr, 124–
126. doi:10.1080/19336918.2016.1225632 
Fearon, K. (2011). Definition and classification of cancer cachexia: an international consensus. Lancet 
Oncol, 489-95. doi:10.1016/S1470-2045(10)70218-7 
Feng, D. (2010). Cellular internalization of exosomes occurs through phagocytosis. Traffic, 675–687. 
doi:10.1111/j.1600-0854.2010.01041.x 
Fernandez-Marcos, P. (2011). Regulation of PGC-1α, a nodal regulator of mitochondrial biogenesis. 
Am J Clin Nutr, 93(4): 884S–890S. doi:10.3945/ajcn.110.001917 
Fernández-Messina, L. (2015). Immunomodulatory role of microRNAs transferred by extracellular 
vesicles. Biol Cell., 107(3):61-77. doi:10.1111/boc.201400081 
Fili, N. (2006). Compartmental signal modulation: Endosomal phosphatidylinositol 3-phosphate 
controls endosome morphology and selective cargo sorting. Proc Natl Acad Sci U S A., 
103(42): 15473–15478. doi:10.1073/pnas.0607040103 
Finck, B. (2006). PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. 
J Clin Invest, 116(3): 615–622. doi:10.1172/JCI27794 
Fitzner, D. (2011). Selective transfer of exosomes from oligodendrocytes to microglia by 
macropinocytosis. J Cell Sci, 447-58. doi:10.1242/jcs.074088 
Fleisher, T. (1997). Apoptosis. Ann Allergy Asthma Immunol., 245-250. doi:10.1016/S1081-
1206(10)63176-6 
95 
 
Freeman, D. (2018). Altered Extracellular Vesicle Concentration, Cargo, and Function in Diabetes. 
Diabetes., 67(11):2377-2388. doi:10.2337/db17-1308. 
Friand, V. (2015). Syntenin and syndecan in the biogenesis of exosomes. Biol Cell, 331-41. 
doi:10.1111/boc.201500010. Epub 2015 Jun 30 
Friedman, J. (2013). Endoplasmic reticulum–endosome contact increases as endosomes traffic and 
mature. Mol Biol Cell., 24(7): 1030–1040. doi:10.1091/mbc.E12-10-0733. 
Frühbeis, C. (2013). Extracellular vesicles as mediators of neuron-glia communication. Front Cell 
Neurosci, 7: 182. doi:10.3389/fncel.2013.00182 
Frühbeis, C. (2013). Neurotransmitter-Triggered Transfer of Exosomes Mediates Oligodendrocyte–
Neuron Communication. PLoS Biol, e1001604. doi:10.1371/journal.pbio.1001604 
Frühbeis, C. (2015). Physical exercise induces rapid release of small extracellular vesicles into the 
circulation. J Extracell Vesicles, 4:28239. doi:10.3402/jev.v4.28239 
Frühbeis, C. (2019). Oligodendrocyte-derived exosomes promote axonal transport and axonal long-
term maintenance. bioRxiv. doi:10.1101/2019.12.20.884171 
Gamez-Valero, A. (2016). Size-exclusion chromatography-based isolation minimally alters 
extracellular vesicles’ characteristics compared to precipitating agents. Sci. Rep, 6:33641. 
doi:10.1038/srep33641 
Gao, X. (2017). Extracellular Vesicles from Adipose Tissue-A Potential Role in Obesity and Type 2 
Diabetes? Front Endocrinol (Lausanne)., 8:202. doi:10.3389/fendo.2017.00202 
Garbuz, D. (2017). The evolution of heat shock genes and expression patterns of heat shock proteins 
in the species from temperature contrasting habitats. Genetika, 12-30. 
doi:10.1134/S1022795417010069 
Garcia, N. (2016). Cardiomyocyte exosomes regulate glycolytic flux in endothelium by direct transfer 
of GLUT transporters and glycolytic enzymes. Cardiovasc Res., 109(3):397-408. 
doi:10.1093/cvr/cvv260. 
Garcìa-Manrique, P. (2018). Fully Artificial Exosomes: Towards New Theranostic Biomaterials. Trends 
Biotechnol, 10-14. doi:10.1016/j.tibtech.2017.10.005 
Garcìa-Manrique, P. (2018). Therapeutic biomaterials based on extracellular vesicles: classification of 
bioengineering and mimetic preparation routes. J Extracell Vesicles, 1422676. 
doi:10.1080/20013078.2017.1422676 
Garzetti, L. (2014). Activated macrophages release microvesicles containing polarized M1 or M2 
mRNAs. J Leukoc Biol., 95(5):817-825. doi:10.1189/jlb.0913485 
Gasco, M. (1989). Microemulsions as topical delivery vehicles: ocular administration of timolol. J 
Pharm Biomed Anal, 433-9. doi:10.1016/0731-7085(89)80030-5 
Gasco, M. (2009). Chapter 10 - Solid lipid nanoparticles and microemulsions for drug delivery The 
CNS. Prog Brain Res., 181-92. doi:10.1016/S0079-6123(08)80010-6 
Gener Lahav, T. (2019). Melanoma-derived extracellular vesicles instigate proinflammatory signaling 
in the metastatic microenvironment. Int J Cancer., 145(9):2521-2534. doi:10.1002/ijc.32521. 
Gercel-Taylor, C. (2012). Nanoparticle analysis of circulating cell-derived vesicles in ovarian cancer 
patients. Anal Biochem, 44-53. doi:10.1016/j.ab.2012.06.004 
96 
 
Gheldof, D. (2017). Procoagulant activity of extracellular vesicles as a potential biomarker for risk of 
thrombosis and DIC in patients with acute leukaemia. J Thromb Thrombolysis, 224–232. 
doi:10.1007/s11239-016-1471-z 
Ghossoub, R. (2014). Syntenin-ALIX exosome biogenesis and budding into multivesicular bodies are 
controlled by ARF6 and PLD2. Nat Commun, 3477. doi:10.1038/ncomms4477 
Gill, M. (2019). Placental Syncytiotrophoblast-Derived Extracellular Vesicles Carry Active NEP 
(Neprilysin) and Are Increased in Preeclampsia. Hypertension., 73(5):1112-1119. 
doi:10.1161/HYPERTENSIONAHA.119.12707. 
Gkretsi, V. (2018). Cell Adhesion and Matrix Stiffness: Coordinating Cancer Cell Invasion and 
Metastasis. Front Oncol., 8:145. doi:10.3389/fonc.2018.00145. 
Glebov, O. (2006). Flotillin-1 defines a clathrin-independent endocytic pathway in mammalian cells. 
Nat Cell Biol., 46–54. doi:10.1038/ncb1342 
Gleyzer, N. (2005). Control of mitochondrial transcription specificity factors (TFB1M and TFB2M) by 
nuclear respiratory factors (NRF-1 and NRF-2) and PGC-1 family coactivators. Mol Cell Biol, 
25(4):1354-66. doi:10.1128/MCB.25.4.1354-1366.2005 
Gnopo, Y. (2017). Designer outer membrane vesicles as immunomodulatory systems - 
Reprogramming bacteria for vaccine delivery. Adv Drug Deliv Rev., 114:132-142. 
doi:10.1016/j.addr.2017.05.003. 
Goettsch, C. (2016). Sortilin mediates vascular calcification via its recruitment into extracellular 
vesicles. J Clin Invest., 126(4):1323-36. doi:10.1172/JCI80851 
Gomari, H. (2018). Targeted cancer therapy using engineered exosome as a natural drug delivery 
vehicle. Onco Targets Ther, 5753–5762. doi:10.2147/ott.s173110 
Göran Ronquist, K. (2019). Extracellular vesicles and energy metabolism. Clin Chim Acta., 488:116-
121. doi:10.1016/j.cca.2018.10.044. 
Gould, D. (2013). Cancer cachexia prevention via physical exercise: molecular mechanisms. J Cachexia 
Sarcopenia Muscle, 111–124. doi:10.1007/s13539-012-0096-0 
Groot Kormelink, T. (2018). The role of extracellular vesicles when innate meets adaptive. Semin 
Immunopathol., 40(5):439-452. doi:10.1007/s00281-018-0681-1. 
Guescini, M. (2017). Extracellular Vesicles Released by Oxidatively Injured or Intact C2C12 Myotubes 
Promote Distinct Responses Converging toward Myogenesis. Int J Mol Sci, E2488. 
doi:10.3390/ijms18112488 
Guix, F. (2018). Detection of Aggregation-Competent Tau in Neuron-Derived Extracellular Vesicles. Int 
J Mol Sci, E663. doi:10.3390/ijms19030663 
Gupta, A. (2004). Detection of fetal DNA and RNA in placenta-derived syncytiotrophoblast 
microparticles generated in vitro. Clin Chem., 50(11):2187-90. 
doi:10.1373/clinchem.2004.040196. 
Gupta, S. (2018). An improvised one-step sucrose cushion ultracentrifugation method for exosome 
isolation from culture supernatants of mesenchymal stem cells. Stem Cell Res Ther, 9(1):180. 
doi:10.1186/s13287-018-0923-0 
Gutierrez-Vazquez, C. (2013). Transfer of extracellular vesicles during immune cell-cell interactions. 
Immunol. Rev., 125–142. doi:10.1111/imr.12013 
97 
 
Ha, D. (2016). Exosomes as therapeutic drug carriers and delivery vehicles across biological 
membranes: current perspectives and future challenges. Acta Pharm. Sin. , 287–296. 
doi:10.1016/j.apsb.2016.02.001 
Haga, H. (2015). Tumour cell-derived extracellular vesicles interact with mesenchymal stem cells to 
modulate the microenvironment and enhance cholangiocarcinoma growth. J. Extracell. 
Vesicles, 4:24900. doi:10.3402/jev.v4.24900 
Hahn, G. (1991). Mammalian stress proteins HSP70 and HSP28 coinduced by nicotine and either 
ethanol or heat. Mol Cell Biol, 6034–6040. doi:10.1128/mcb.11.12.6034 
Haldar, S. (2015). Chaperonin-Assisted Protein Folding: Relative Population of Asymmetric and 
Symmetric GroEL:GroES Complexes. J Mol Biol, 2244-55. doi:10.1016/j.jmb.2015.04.009 
Han, C. (2019). Syncytiotrophoblast-Derived Extracellular Vesicles in Pathophysiology of 
Preeclampsia. Front Physiol., 10:1236. doi:10.3389/fphys.2019.01236. 
Han, J. (2018). Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue 
lipolysis and browning. Lipids Health Dis, 17: 14. doi:10.1186/s12944-018-0657-0 
Handschin, C. (2008). The role of exercise and PGC1α in inflammation and chronic disease. Nature, 
463-9. doi:10.1038/nature07206 
Haney, M. (2015). Exosomes as drug delivery vehicles for Parkinson’s disease therapy. J. Control. 
Release, 18–30. doi:10.1016/j.jconrel.2015.03.033 
Hanson, P. (2012). Multivesicular body morphogenesis. Annu Rev Cell Dev Biol, 337-62. 
doi:10.1146/annurev-cellbio-092910-154152 
Haraszti, R. (2016). High-resolution proteomic and lipidomic analysis of exosomes and microvesicles 
from different cell sources. J Extracell Vesicles, 5:32570. doi:10.3402/jev.v5.32570 
Haraszti, R. (2018). Exosomes Produced from 3D Cultures of MSCs by Tangential Flow Filtration Show 
Higher Yield and Improved Activity. Mol Ther, 2838-2847. doi:10.1016/j.ymthe.2018.09.015 
Hartl, F. (1992). Protein folding in the cell: the role of molecular chaperones Hsp70 and Hsp60. Annu 
Rev Biophys Biomol Struct, 293-322. doi:10.1146/annurev.bb.21.060192.001453 
Hasegawa, J. (2017). PI5P and PI(3,5)P2: Minor, but Essential Phosphoinositides. Cell Struct Funct., 
42(1): 49–60. doi:10.1247/csf.17003 
Hessvik, N. (2018). Current knowledge on exosome biogenesis and release. Cell. Mol. Life Sci, 193–
208. doi:10.1007/s00018-017-2595-9 
Heydenreich, A. (2003). Preparation and purification of cationic solid lipid nanospheres—effects on 
particle size, physical stability and cell toxicity. International Journal of Pharmaceutics, 83-7. 
doi:10.1016/S0378-5173(02)00688-9 
Higa-Nakamine, S. (2015). Involvement of Protein Kinase D1 in Signal Transduction from the Protein 
Kinase C Pathway to the Tyrosine Kinase Pathway in Response to Gonadotropin-releasing 
Hormone. J Biol Chem, 25974-85. doi:10.1074/jbc.M115.681700 
Hirata, E. (2017). Tumor Microenvironment and Differential Responses to Therapy. Cold Spring Harb 
Perspect Med., 7(7): a026781. doi:10.1101/cshperspect.a026781 
Hisada, Y. (2019). Cancer cell-derived tissue factor-positive extracellular vesicles. Current Opinion in 
Hematology, 349-356. doi:10.1097/MOH.0000000000000521 
98 
 
Hope, M. (1986). Generation of multilamellar and unilamellar phospholipid vesicles. Chemistry and 
Physics of Lipids. doi:10.1016/0009-3084(86)90065-4 
Horváth, I. (2008). Membrane-associated stress proteins: More than simply chaperones. Biochim 
Biophys Acta, 1653-64. doi:10.1016/j.bbamem.2008.02.012 
Huang, J. (1998). Role of calpain in skeletal-muscle protein degradation. Proc. Natl. Acad. Sci. USA, 
12100–12105. doi:10.1073/pnas.95.21.12100 
Huber, V. (2018). Tumor-derived microRNAs induce myeloid suppressor cells and predict 
immunotherapy resistance in melanoma. The Journal of Clinical Investigation, 128(12):5505-
5516. doi:10.1172/JCI98060 
Huotari, J. (2011). Endosome maturation. EMBO J., 30(17): 3481–3500. doi:10.1038/emboj.2011.286 
Hurwitz, S. (2016). Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein 
cargo and cancer type-specific biomarkers. Oncotarget., 7(52): 86999–87015. 
doi:10.18632/oncotarget.13569 
Hutcheson, J. (2018). Extracellular vesicles in cardiovascular homeostasis and disease. Curr Opin 
Cardiol, 290-297. doi:10.1097/HCO.0000000000000510 
Hyunseok, J. (2016). Size dependent classification of heat shock proteins: a mini-review. J Exerc 
Rehabil, 255–259. doi:10.12965/jer.1632642.321 
Iraci, N. (2017). Extracellular vesicles are independent metabolic units with asparaginase activity. Nat 
Chem Biol., 13(9):951-955. doi:10.1038/nchembio.2422. 
Iritani, E. (1995). Upward Dead-End Ultrafiltration of Binary Protein Mixtures. Separation science and 
technology. doi:10.1080/01496399508013877 
Irrcher, I. (2008). AMP-Activated Protein Kinase-Regulated Activation of the PGC-1α Promoter in 
Skeletal Muscle Cells. PLoS One, 3(10): e3614. doi:10.1371/journal.pone.0003614 
Ishida, R. (2018). Physicochemical Properties of the Mammalian Molecular Chaperone HSP60. 
International Journal of Molecular Sciences. doi:10.3390/ijms19020489 
Iwai, K. (2016). Isolation of human salivary extracellular vesicles by iodixanol density gradient 
ultracentrifugation and their characterizations. J Extracell Vesicles, 5:30829. 
doi:10.3402/jev.v5.30829 
IZON. (2014). qNano training modules.  
Jang, S. (2013). Bioinspired exosome-mimetic nanovesicles for targeted delivery of 
chemotherapeutics to malignant tumors. ACS Nano, 7698-710. doi:10.1021/nn402232g 
Ji, Q. (2020). Primary tumors release ITGBL1-rich extracellular vesicles to promote distal metastatic 
tumor growth through fibroblast-niche formation. Nat Commun, 1211. doi:10.1038/s41467-
020-14869-x 
Jia, Y. (2016). miRNAs in Urine Extracellular Vesicles as Predictors of Early-Stage Diabetic 
Nephropathy. J Diabetes Res., 2016:7932765. doi:10.1155/2016/7932765 
Joffe, L. (2016). Potential Roles of Fungal Extracellular Vesicles during Infection. mSphere, e00099-16. 
doi:10.1128/mSphere.00099-16 
Joseph, A. (2006). Control of gene expression and mitochondrial biogenesis in the muscular 
adaptation to endurance exercise. Essays in Biochemistry, 13–29. doi: 10.1042/bse0420013 
99 
 
Jovic, M. (2010). The early endosome: a busy sorting station for proteins at the crossroads. Histol 
Histopathol., 25(1): 99–112. doi:10.14670/hh-25.99 
Jun, S. (2013). Acinetobacter baumannii outer membrane vesicles elicit a potent innate immune 
response via membrane proteins. PLoS One., 8(8):e71751. 
doi:10.1371/journal.pone.0071751. 
Kalra, H. (2016). Focus on Extracellular Vesicles: Introducing the Next Small Big Thing. Int J Mol Sci., 
17(2):170. doi:10.3390/ijms17020170 
Kang, C. (2013). Extracellular Vesicles Derived from Gut Microbiota, Especially Akkermansia 
muciniphila, Protect the Progression of Dextran Sulfate Sodium-Induced Colitis. PLoS One., 
8(10): e76520. doi:10.1371/journal.pone.0076520 
Karlin, S. (2000). Heat shock protein 60 sequence comparisons: duplications, lateral transfer, and 
mitocondrial ecolution. Proc Natl Acad Sci USA, 11348-53. doi:10.1073/pnas.97.21.11348 
Karnati, H. (2019). Neuronal Enriched Extracellular Vesicle Proteins as Biomarkers for Traumatic Brain 
Injury. J Neurotrauma, 975-987. doi:10.1089/neu.2018.5898 
Kauppi, M. (2002). The small GTPase Rab22 interacts with EEA1 and controls endosomal membrane 
trafficking. J Cell Sci., 115(Pt 5):899-911. 
Kayacan, O. (2006). Impact of TNF-alpha and IL-6 levels on development of cachexia in newly 
diagnosed NSCLC patients. Am J Clin Oncol, 29(4):328-35. 
doi:10.1097/01.coc.0000221300.72657.e0 
Kaye, S. (1988). The multidrug resistance phenotype. Br J Cancer., 58(6): 691–694. 
doi:10.1038/bjc.1988.291. 
Keklikoglou, I. (2019). Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer 
models. Nat. Cell Biol, 190–202. doi:10.1038/s41556-018-0256-3 
Kerr, J. (1972). Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue 
Kinetics. Br J Cancer, 239–257. doi:10.1038/bjc.1972.33 
Kesimer, M. (2009). Characterization of exosome-like vesicles released from human tracheobronchial 
ciliated epithelium: a possible role in innate defense. FASEB J, 1858-68. doi:10.1096/fj.08-
119131 
Kesimer, M. (2015). Physical characterization and profiling of airway epithelial derived exosomes 
using light scattering. Methods, 87:59-63. doi:10.1016/j.ymeth.2015.03.013 
Khal, J. (2005). Expression of the ubiquitin-proteasome pathway and muscle loss in experimental 
cancer cachexia. Br J Cancer, 93(7): 774–780. doi:10.1038/sj.bjc.6602780 
Khatua, A. (2009). Exosomes packaging APOBEC3G confer human immunodeficiency virus resistance 
to recipient cells. J. Virol, 512–521. doi:10.1128/jvi.01658-08 
Kim, D. (2018). Mastocytosis-derived extracellular vesicles exhibit a mast cell signature, transfer KIT 
to stellate cells, and promote their activation. Proc Natl Acad Sci U S A., 115(45):E10692-
E10701. doi: 10.1073/pnas.1809938115 
Kim, M. (2016). Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. 
Nanomedicine., 12(3):655-664. doi:10.1016/j.nano.2015.10.012. 
100 
 
Kim, M. (2019). Delivery of High Mobility Group Box-1 siRNA Using Brain-Targeting Exosomes for 
Ischemic Stroke Therapy. J Biomed Nanotechnol, 2401-2412. doi:10.1166/jbn.2019.2866 
Kim, O. (2015). Bacterial protoplast-derived nanovesicles as vaccine delivery system against bacterial 
infection. Nano Lett., 15(1):266-74. doi:10.1021/nl503508h 
Kim, O. (2017). Bacterial protoplast-derived nanovesicles for tumor targeted delivery of 
chemotherapeutics. Biomaterials, 68-79. doi:10.1016/j.biomaterials.2016.10.037 
Kim, S. (1983). Preparation of multivesicular liposomes. . Biochim Biophys Acta, 339-48. 
doi:10.1016/0005-2736(83)90504-7 
Kisho, O. (2018). HSP-enriched properties of extracellular vesicles involve survival of metastatic oral 
cancer cells. Journal of Cellular Biochemistry, 7350-7362. doi:10.1002/jcb.27039 
Kleijmeer, M. (2001). Antigen loading of MHC class I molecules in the endocytic tract. Traffic., 
2(2):124-37. doi:10.1034/j.1600-0854.2001.020207.x 
Klumperman, J. (2014). The complex ultrastructure of the endolysosomal system. Cold Spring Harb 
Perspect Biol., 6(10):a016857. doi:10.1101/cshperspect.a016857 
Knijff-Dutmer, E. (2002). Elevated levels of platelet microparticles are associated with disease activity 
in rheumatoid arthritis. Arthritis Rheum., 46(6):1498-503. doi:10.1002/art.10312 
Ko, S. (2019). Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, 
bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun Biol., 2:386. 
doi:10.1038/s42003-019-0609-x. 
Kobayashi, Y. (2018). Circulating extracellular vesicles are associated with lipid and insulin 
metabolism. Am J Physiol Endocrinol Metab., 315(4):E574-E582. 
doi:10.1152/ajpendo.00160.2018. 
Koistinen, H. (2002). Regulation of glucose transport in human skeletal muscle. Ann Med, 410-418. 
doi:10.1080/078538902321012351 
Kojima, K. (2014). ESCRT-0 Protein Hepatocyte Growth Factor-regulated Tyrosine Kinase Substrate 
(Hrs) Is Targeted to Endosomes Independently of Signal-transducing Adaptor Molecule 
(STAM) and the Complex Formation with STAM Promotes Its Endosomal Dissociation. J Biol 
Chem, 33296–33310. doi:10.1074/jbc.M114.578245 
Koliha, N. (2016). A novel multiplex bead-based platform highlights the diversity of extracellular 
vesicles. J Extracell Vesicles, 5:29975. doi:10.3402/jev.v5.29975 
Konoshenko, M. (2018). Isolation of Extracellular Vesicles: General Methodologies and Latest Trends. 
Biomed Res Int, 8545347. doi:10.1155/2018/8545347 
Kosanovic, D. (2019). Enhanced circulating levels of CD3 cells-derived extracellular vesicles in 
different forms of pulmonary hypertension. Pulm Circ., 9(3): 2045894019864357. 
doi:10.1177/2045894019864357 
Koukourakis, M. (2006). Oxygen and glucose consumption in gastrointestinal adenocarcinomas: 
correlation with markers of hypoxia, acidity and anaerobic glycolysis. Cancer Sci., 
97(10):1056-60. doi:10.1111/j.1349-7006.2006.00298.x 
Kouwaki, T. (2017). Extracellular Vesicles Deliver Host and Virus RNA and Regulate Innate Immune 
Response. Int. J. Mol. Sci, 666. doi:10.3390/ijms18030666 
101 
 
Kowal, J. (2016). Proteomic comparison defines novel markers to characterize heterogeneous 
populations of extracellular vesicle subtypes. Proc. Natl. Acad. Sci. U.S. A, E968–E977. 
doi:10.1073/pnas.1521230113 
Kraft, J. (2014). Emerging research and clinical development trends of liposome and lipid 
nanoparticle drug delivery systems. J Pharm Sci, 29-52. doi:10.1002/jps.23773 
Kulp, A. (2010). Biological functions and biogenesis of secreted bacterial outer membrane vesicles. 
Annu Rev Microbiol., 64:163-84. doi:10.1146/annurev.micro.091208.073413 
Kurten, R. (2001). Self-assembly and binding of a sorting nexin to sorting endosomes. J Cell Sci., 
114(Pt 9):1743-56. 
Kyrana, E. (2012). Molecular mechanisms of cachexia in chronic disease. Expert Rev Endocrinol 
Metab, 7(1):73-90. doi:10.1586/eem.11.87 
Lakhter, A. (2015). Minireview: Emerging Roles for Extracellular Vesicles in Diabetes and Related 
Metabolic Disorders. Mol Endocrinol., 29(11):1535-48. doi: 10.1210/me.2015-1206. 
Larsson, N. (1998). Mitochondrial transcription factor A is necessary for mtDNA maintenance and 
embryogenesis in mice. Nat Genet, 18(3):231-6. doi:10.1038/ng0398-231 
Lässer, C. (2018). Subpopulations of extracellular vesicles and their therapeutic potential. Mol 
Aspects Med, 1-14. doi:10.1016/j.mam.2018.02.002 
Laulagnier, K. (2004). PLD2 is enriched on exosomes and its activity is correlated to the release of 
exosomes. FEBS Lett, 11-4. doi:10.1016/j.febslet.2004.06.082 
Laulagnier, K. (2018). Amyloid precursor protein products concentrate in a subset of exosomes 
specifically endocytosed by neurons. Cell. Mol. Life Sci, 757–773. doi:10.1007/s00018-017-
2664-0 
Lawson, J. (2017). Selective secretion of microRNAs from lung cancer cells via extracellular vesicles 
promotes CAMK1D-mediated tube formation in endothelial cells. Oncotarget., 8(48): 83913–
83924. doi:10.18632/oncotarget.19996 
Lee, C. (2018). Discovery of a diagnostic biomarker for colon cancer through proteomic profiling of 
small extracellular vesicles. BMC Cancer., 18(1):1058. doi:10.1186/s12885-018-4952-y. 
Lee, E. (2009). Gram-positive bacteria produce membrane vesicles: proteomics-based 
characterization of Staphylococcus aureus-derived membrane vesicles. Proteomics., 
9(24):5425-36. doi:10.1002/pmic.200900338. 
Lee, J. (2013). Staphylococcus aureus Extracellular Vesicles Carry Biologically Active β-Lactamase. 
Antimicrob Agents Chemother., 57(6): 2589–2595. doi:10.1128/AAC.00522-12 
Lemaire, Q. (2019). Isolation of microglia-derived extracellular vesicles: towards miRNA signatures 
and neuroprotection. J Nanobiotechnology, 17: 119. doi:10.1186/s12951-019-0551-6 
Lentz, B. (2003). Exposure of platelet membrane phosphatidylserine regulates blood coagulation. 
Prog Lipid Res., 42(5):423-38. doi:10.1016/s0163-7827(03)00025-0 
Li, M. (2017). Lactobacillus-derived extracellular vesicles enhance host immune responses against 
vancomycin-resistant enterococci. BMC Microbiol, 66. doi:10.1186/s12866-017-0977-7 
Li, W. (2014). Rab27A regulates exosome secretion from lung adenocarcinoma cells A549: 
involvement of EPI64. APMIS, 122(11):1080-7. doi:10.1111/apm.12261. 
102 
 
Li, Y. (2003). Hydrogen peroxide stimulates ubiquitin-conjugating activity and expression of genes for 
specific E2 and E3 proteins in skeletal muscle myotubes. Am J Physiol Cell Physiol., C806-12. 
doi:10.1152/ajpcell.00129.2003 
Li, Z. (2002). Roles of heat-shock proteins in antigen presentation and cross-presentation. Curr Opin 
Immunol, 45-51. doi:10.1016/s0952-7915(01)00297-7 
Liang, G. (2018). Engineered exosome-mediated delivery of functionally active miR-26a and its 
enhanced suppression effect in HepG2 cells. Int. J. Nanomed, 585–599. 
doi:10.2147/ijn.s15445 
Lichtenberg, D. (1984). Structural Characteristics of Phospholipid Multilamellar Liposomes . Journal of 
pharmaceutical sciences. doi:10.1002/jps.2600730134 
Lin, J. (2002). Peroxisome Proliferator-activated Receptor γ Coactivator 1β (PGC-1β), A Novel PGC-1-
related Transcription Coactivator Associated with Host Cell Factor. Journal of Biological 
Chemistry, 1645-1648. doi:10.1074/jbc.C100631200 
Lin, J. (2005). Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab, 
1(6):361-70. doi:10.1016/j.cmet.2005.05.004 
Lin, Y. (2018). Exosome-liposome hybrid nanoparticles deliver CRISPR/Cas9 system in MSCs. . Adv. 
Sci. , 5:1700611. doi:10.1002/advs.201700611 
Lira, F. (2014). Exercise training as treatment in cancer cachexia. Appl Physiol Nutr Metab, 679-86. 
doi:10.1139/apnm-2013-0554 
Liu, P. (2007). Rab-Regulated Interaction of Early Endosomes with Lipid Droplets. Biochim Biophys 
Acta., 1773(6): 784–793. doi:10.1016/j.bbamcr.2007.02.004 
Liu, W. (2019). A novel pan‐cancer biomarker plasma heat shock protein 90alpha and its diagnosis 
determinants in clinic. Cancer Sci., 110(9): 2941–2959. doi:10.1111/cas.14143 
Liu, Y. (2015). Targeted exosome-mediated delivery of opioid receptor Mu siRNA for the treatment of 
morphine relapse. Sci. Rep, 5:17543. doi:10.1038/srep17543 
Logozzi, M. (2009). High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma 
patients. PLoS One, 4(4):e5219. doi:10.1371/journal.pone.0005219 
Lopes-Rodrigues, V. (2017). Identification of the metabolic alterations associated with the multidrug 
resistant phenotype in cancer and their intercellular transfer mediated by extracellular 
vesicles. Sci Rep., 44541. doi:10.1038/srep44541. 
Lopez-Verrilli, M. (2013). Schwann cell-derived exosomes enhance axonal regeneration in the 
peripheral nervous system. Glia., 61(11):1795-806. doi:10.1002/glia.22558 
Lotvall, J. (2014). Minimal experimental requirements for definition of extracellular vesicles and their 
functions: a position statement from the international society for extracellular vesicles. J. 
Extracell. Vesicles., 3:26913. doi:10.3402/jev.v3.26913 
Lou, G. (2015). Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase 
chemosensitivity of hepatocellular carcinoma. J Hematol Oncol, 122. doi:10.1186/s13045-
015-0220-7 
Luan, X. (2017). Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta 
Pharmacol Sin, 754–763. doi:10.1038/aps.2017.12 
103 
 
Lunavat, T. (2015). Small RNA deep sequencing discriminates subsets of extracellular vesicles 
released by melanoma cells--Evidence of unique microRNA cargos. RNA Biol., 12(8):810-23. 
doi:10.1080/15476286.2015.1056975. 
Lund, P. (2003). The chaperonins: perspectives from the Archaea. Biochem Soc Trans, 681-5. 
doi:10.1042/bst0310681 
Lv, C. (2018). A PEG-based method for the isolation of urinary exosomes and its application in renal 
fibrosis diagnostics using cargo miR-29c and miR-21 analysis. Int Urol Nephrol, 973-982. 
doi:10.1007/s11255-017-1779-4 
Lydic, T. (2015). Rapid and comprehensive 'shotgun' lipidome profiling of colorectal cancer cell 
derived exosomes. Methods, 83-95. doi:10.1016/j.ymeth.2015.04.014 
Maacha, S. (2019). Extracellular vesicles-mediated intercellular communication: roles in the tumor 
microenvironment and anti-cancer drug resistance. Mol Cancer., 18: 55. doi:10.1186/s12943-
019-0965-7 
Maas, S. (2014). Quantification and size-profiling of extracellular vesicles using tunable resistive pulse 
sensing. J Vis Exp, e51623. doi:10.3791/51623 
Macario, A. (2005). Sick chaperones cellular stress and disease. N Engl J Med, 1489-501. 
doi:10.1056/NEJMra050111 
MacDonald, P. (2005). Calcium increases endocytotic vesicle size and accelerates membrane fission 
in insulin-secreting INS-1 cells. J Cell Sci., 118(Pt 24):5911-20. doi:10.1242/jcs.02685 
Machtinger, R. (2016). Extracellular vesicles: roles in gamete maturation, fertilization and embryo 
implantation. Hum Reprod Update., 22(2):182-93. doi:10.1093/humupd/dmv055. 
Madeddu, C. (2009). Medroxyprogesterone acetate in the management of cancer cachexia. Expert 
Opin Pharmacother, 10(8):1359-66. doi:10.1517/14656560902960162 
Maëva, D. (2017). Characterisation of adipocyte-derived extracellular vesicle subtypes identifies 
distinct protein and lipid signatures for large and small extracellular vesicles. J Extracell 
Vesicles., 6(1): 1305677. doi:10.1080/20013078.2017.1305677. 
Malik, M. (2012). Microemulsion method: A novel route to synthesize organic and inorganic 
nanomaterials: 1st Nano Update. Arabian Journal of Chemistry, 397-417. 
doi:10.1016/j.arabjc.2010.09.027 
Malvern. (2009). user manual. England. 
Marcilla, A. (2014). Extracellular vesicles in parasitic diseases. J Extracell Vesicles., 3:25040. 
doi:10.3402/jev.v3.25040. 
Markov, O. (2019). Immunotherapy Based on Dendritic Cell-Targeted/-Derived Extracellular Vesicles-
A Novel Strategy for Enhancement of the Anti-tumor Immune Response. Front Pharmacol., 
10:1152. doi:10.3389/fphar.2019.01152. 
Martínez-Redondo, V. (2015). The hitchhiker's guide to PGC-1α isoform structure and biological 
functions. Diabetologia, 58(9):1969-77. doi:10.1007/s00125-015-3671-z 
Martínez-Redondo, V. (2016). Peroxisome Proliferator-activated Receptor γ Coactivator-1 α Isoforms 
Selectively Regulate Multiple Splicing Events on Target Genes. J Biol Chem, 291(29): 15169–
15184. doi:10.1074/jbc.M115.705822 
104 
 
Mashburn-Warren, L. (2008). Interaction of quorum signals with outer membrane lipids: insights into 
prokaryotic membrane vesicle formation. Mol Microbiol., 69(2):491-502. doi:10.1111/j.1365-
2958.2008.06302.x 
Masiero, E. (2009). Autophagy is required to maintain muscle mass. Cell Metabolism, 507-15. 
doi:10.1016/j.cmet.2009.10.008. 
Matsuzaki, K. (2017). MiR-21-5p in urinary extracellular vesicles is a novel biomarker of urothelial 
carcinoma. Oncotarget., 8(15): 24668–24678. doi:10.18632/oncotarget.14969 
Mc Clements, D. (2012). Nanoemulsions versus microemulsions: terminology, differences, and 
similarities. Soft Matter. doi:10.1039/C2SM06903B 
Mellisho, E. (2017). Identification and characteristics of extracellular vesicles from bovine blastocysts 
produced in vitro. PLoS One., 12(5):e0178306. doi:10.1371/journal.pone.0178306. 
Menay, F. (2017). Exosomes Isolated from Ascites of T-Cell Lymphoma-Bearing Mice Expressing 
Surface CD24 and HSP-90 Induce a Tumor-Specific Immune Response. Front Immunol., 8:286. 
doi:10.3389/fimmu.2017.00286. 
Mendt, M. (2019). Mesenchymal stem cell-derived exosomes for clinical use. Bone Marrow 
Transplant, 789-792. doi:10.1038/s41409-019-0616-z 
Merendino, A. (2010). Hsp60 Is Actively Secreted by Human Tumor Cells. PLoS ONE. 
doi:10.1371/journal.pone.0009247 
Migliano, S. (2018). ESCRT and Membrane Protein Ubiquitination. Prog Mol Subcell Biol, 107-135. 
doi:10.1007/978-3-319-96704-2_4 
Mills, J. (1998). Apoptotic membrane blebbing is regulated by myosin light chain phosphorylation. J 
Cell Biol., 140(3):627-36. doi:10.1083/jcb.140.3.627 
Mimms, L. (1981). Phospholipid vesicle formation and transmembrane protein incorporation using 
octyl glucoside. Biochemistry. doi:10.1021/bi00507a028 
Mincheva-Nilsson, L. (2014). Placenta-derived exosomes and syncytiotrophoblast microparticles and 
their role in human reproduction: immune modulation for pregnancy success. Am J Reprod 
Immunol., 72(5):440-57. doi:10.1111/aji.12311. 
Minciacchi, V. (2015). Extracellular vesicles in cancer: exosomes, microvesicles and the emerging role 
of large oncosomes. Semin Cell Dev Biol., 40:41-51. doi:10.1016/j.semcdb.2015.02.010. 
Mitsuhashi, S. (2016). Luminal Extracellular Vesicles (EVs) in Inflammatory Bowel Disease (IBD) 
Exhibit Proinflammatory Effects on Epithelial Cells and Macrophages. Inflamm Bowel Dis., 
22(7):1587-95. doi:10.1097/MIB.0000000000000840. 
Miura, S. (2008). Isoform-specific increases in murine skeletal muscle peroxisome proliferator-
activated receptor-gamma coactivator-1alpha (PGC-1alpha) mRNA in response to beta2-
adrenergic receptor activation and exercise. Endocrinology, 149(9):4527-33. 
doi:10.1210/en.2008-0466 
Mol, E. (2017). Higher functionality of extracellular vesicles isolated using size-exclusion 
chromatography compared to ultracentrifugation. Nanomedicine, 2061-2065. 
doi:10.1016/j.nano.2017.03.011 
Momen-Heravi, F. (2012). Alternative methods for characterization of extracellular vesicles. Front 
Physiol., 3:354. doi: 10.3389/fphys.2012.00354 
105 
 
Moon, P. (2016). Identification of Developmental Endothelial Locus-1 on Circulating Extracellular 
Vesicles as a Novel Biomarker for Early Breast Cancer Detection. clinical cancer research, 
22(7):1757-66. doi:10.1158/1078-0432.CCR-15-0654 
Morio, H. (2018). Cancer-Type OATP1B3 mRNA in Extracellular Vesicles as a Promising Candidate for 
a Serum-Based Colorectal Cancer Biomarker. Biol Pharm Bull., 41(3):445-449. 
doi:10.1248/bpb.b17-00743. 
Mulcahy, L. (2014). Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles. 
doi:10.3402/jev.v3.24641. 
Müller, I. (2003). Intravascular tissue factor initiates coagulation via circulating microvesicles and 
platelets. FASEB J., 17(3):476-8. doi:10.1096/fj.02-0574fje 
Munoz, J. (2013). Delivery of Functional Anti-miR-9 by Mesenchymal Stem Cell-derived Exosomes to 
Glioblastoma Multiforme Cells Conferred Chemosensitivity. Mol Ther Nucleic Acids, e126. 
doi:10.1038/mtna.2013.60 
Nagano, M. (2019). Rab5-mediated endosome formation is regulated at the trans-Golgi network. 
Commun Biol., 419. doi:10.1038/s42003-019-0670-5 
Narkar, V. A. (2017). PGC1α Promoter Methylation and Nucleosome Repositioning: Insights Into 
Exercise and Metabolic Regulation in Skeletal Muscle. Endocrinology, 158(7): 2084–2085. 
doi:10.1210/en.2017-00439 
Naseri, Z. (2018). Exosome-mediated delivery of functionally active miRNA-142-3p inhibitor reduces 
tumorigenicity of breast cancer in vitro and in vivo. Int. J. Nanomed, 7727–7747. 
doi:10.2147/ijn.s18238 
Nawaz, M. (2018). Extracellular Vesicles and Matrix Remodeling Enzymes: The Emerging Roles in 
Extracellular Matrix Remodeling, Progression of Diseases and Tissue Repair. Cells., E167. 
doi:10.3390/cells7100167. 
Nguyen, D. (2016). Characterization of Microvesicles Released from Human Red Blood Cells. Cell 
Physiol Biochem., 38(3):1085-99. doi:10.1159/000443059 
Nielsen, E. (1999). Rab5 regulates motility of early endosomes on microtubules. Nat Cell Biol., 
1(6):376-82. doi:10.1038/14075 
Nielsen, K. (1999). A Single-Ring Mitochondrial Chaperonin (Hsp60-Hsp10) Can Substitute for GroEL-
GroES In Vivo. J Bacteriol, 5871-5. doi:10.1128/JB.181.18.5871-5875.1999 
Nielsen, M. (2015). Elevated atherosclerosis-related gene expression, monocyte activation and 
microparticle-release are related to increased lipoprotein-associated oxidative stress in 
familial hypercholesterolemia. PLoS One., 10(4):e0121516. 
doi:10.1371/journal.pone.0121516 
Nik, A. (2017). Extracellular Vesicles As Mediators of Cardiovascular Calcification. Front Cardiovasc 
Med., 4: 78. doi:10.3389/fcvm.2017.00078 
Nishida, N. (2006). Angiogenesis in Cancer. Vasc Health Risk Manag., 2(3): 213–219. 
doi:10.2147/vhrm.2006.2.3.213 
Nixon, B. (2019). Proteomic Profiling of Mouse Epididymosomes Reveals their Contributions to Post-
testicular Sperm Maturation. Mol Cell Proteomics., 18(Suppl 1):S91-S108. 
doi:10.1074/mcp.RA118.000946. 
106 
 
Nomura, S. (2017). Extracellular vesicles and blood diseases. Int J Hematol, 392-405. doi: 
10.1007/s12185-017-2180-x 
Nordin, J. (2015). Ultrafiltration with size-exclusion liquid chromatography for high yield isolation of 
extracellular vesicles preserving intact biophysical and functional properties. Nanomedicine, 
879-83. doi: 10.1016/j.nano.2015.01.003 
Nowak, T. J. (1990). 70-kDa heat shock protein and c-fos gene expression after transient ischemia. 
Stroke, 107-11. 
Oda, H. (1995). Interaction of the microtubule cytoskeleton with endocytic vesicles and cytoplasmic 
dynein in cultured rat hepatocytes. J Biol Chem., 270(25):15242-9. 
doi:10.1074/jbc.270.25.15242 
Ofir-Birin, Y. (2017). Pathogen-derived extracellular vesicles coordinate social behaviour and host 
manipulation. Semin Cell Dev Biol, 83-90. doi:10.1016/j.semcdb.2017.03.004 
Ohtani, N. (2013). Roles and mechanisms of cellular senescence in regulation of tissue homeostasis. 
Cancer Sci., 104(5):525-30. doi:10.1111/cas.12118. 
O'Loughlin, A. (2012). Exosomes and the emerging field of exosome-based gene therapy. Curr Gene 
Ther, 262-74. doi:10.2174/156652312802083594 
O'Neill, C. (2019). Role of Extracellular Vesicles (EVs) in Cell Stress Response and Resistance to Cancer 
Therapy. Cancers (Basel)., E136. doi:10.3390/cancers11020136. 
O'Neill, H. (2008). Exosomes secreted by bacterially infected macrophages are proinflammatory. Sci 
Signal., 1(6):pe8. doi:10.1126/stke.16pe8 
Osteikoetxea, X. (2015). Differential detergent sensitivity of extracellular vesicle subpopulations. Org 
Biomol Chem, 9775-82. doi:10.1039/c5ob01451d 
Ostrowski, K. (1999). Pro- and anti-inflammatory cytokine balance in strenuous exercise in humans. J 
Physiol, 287–291. doi:10.1111/j.1469-7793.1999.287ad.x 
P. Y. Che, S. (2017). Tissue Factor-Expressing Tumor-Derived Extracellular Vesicles Activate Quiescent 
Endothelial Cells via Protease-Activated Receptor-1. Front. Oncol. 
doi:10.3389/fonc.2017.00261 
Padrão, A. (2017). Long-term exercise training prevents mammary tumorigenesis-induced muscle 
wasting in rats through the regulation of TWEAK signalling. Acta Physiol (Oxf), 803-813. 
doi:10.1111/apha.12721 
Pagano, A. (2004). In Vitro Formation of Recycling Vesicles from Endosomes Requires Adaptor 
Protein-1/Clathrin and Is Regulated by Rab4 and the Connector Rabaptin-5. Molecular 
Biology of the Cell., 4990–5000. doi:10.1091/mbc.e04-04-0355. 
Palikaras, K. (2014). Mitochondrial homeostasis: the interplay between mitophagy and mitochondrial 
biogenesis. Exp Gerontol., 56:182-8. doi:10.1016/j.exger.2014.01.021 
Pang, B. (2020). Extracellular vesicles: the next generation of biomarkers for liquid biopsy-based 
prostate cancer diagnosis. Theranostics., 2309–2326. doi:10.7150/thno.39486 
Pascua-Maestro, R. (2018). Extracellular Vesicles Secreted by Astroglial Cells Transport 
Apolipoprotein D to Neurons and Mediate Neuronal Survival Upon Oxidative Stress. Front 
Cell Neurosci, 12: 526. doi:10.3389/fncel.2018.00526 
107 
 
Patel, G. (2019). Comparative analysis of exosome isolation methods using culture supernatant for 
optimum yield, purity and downstream applications. Sci Rep, 5335. doi:10.1038/s41598-019-
41800-2 
Patel, H. (2017). TNF-α and cancer cachexia: Molecular insights and clinical implications. Life Sci., 
170:56-63. doi:10.1016/j.lfs.2016.11.033 
Patton, M. (2020). Hypoxia alters the release and size distribution of extracellular vesicles in 
pancreatic cancer cells to support their adaptive survival. J Cell Biochem., 121(1):828-839. 
doi:10.1002/jcb.29328. 
Paul, P. (2010). Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice. J Cell Biol, 
191(7):1395-411. doi:10.1083/jcb.201006098 
Pedersen, K. (2017). Specific and Generic Isolation of Extracellular Vesicles with Magnetic Beads. 
Methods Mol Biol., 1660:65-87. doi:10.1007/978-1-4939-7253-1_7 
Pegtel, D. (2014). Extracellular vesicles as modulators of cell-to-cell communication in the healthy 
and diseased brain. Philos Trans R Soc Lond B Biol Sci, 369(1652): 20130516. 
doi:10.1098/rstb.2013.0516 
Penna, F. (2013). Autophagic Degradation Contributes to Muscle Wasting in. Am J Pathol, 
182(4):1367-78. doi:10.1016/j.ajpath.2012.12.023 
Penna, F. (2019). The Skeletal Muscle as an Active Player Against Cancer Cachexia. Front. Physiol, 10: 
41. doi:10.3389/fphys.2019.00041 
Perut, F. (2019). Extracellular Nanovesicles Secreted by Human Osteosarcoma Cells Promote 
Angiogenesis. Cancers (Basel)., 11(6). doi:10.3390/cancers11060779. 
Pfrieger, F. (2018). Cholesterol and the journey of extracellular vesicles. J. Lipid Res., 2255–2261. 
doi:10.1194/jlr.r084210 
Pierre-Yves, M. (2014). The role of extracellular vesicles in Plasmodium and other protozoan 
parasites. Cell Microbiol, 344–354. doi:10.1111/cmi.12259 
Pilegaard, H. (2003). Exercise induces transient transcriptional activation of the PGC-1alpha gene in 
human skeletal muscle. J Physiol, 546(Pt 3):851-8. doi:10.1113/jphysiol.2002.034850 
Pin, F. (2015). Combination of exercise training and erythropoietin prevents cancer-induced muscle 
alterations. Oncotarget, 43202–43215. doi:10.18632/oncotarget.6439 
Pirkkala, L. (2001). Roles of the heat shock transcription factors in regulation of the heat shock 
response and beyond. FASEB J, 1118-31. doi:10.1096/fj00-0294rev 
Podinovskaia, M. (2018). The Endosomal Network: Mediators and Regulators of Endosome 
Maturation. Progress in Molecular and Subcellular Biology., 1-38. doi:10.1007/978-3-319-
96704-2_1. 
Poliakov, A. (2009). Structural heterogeneity and protein composition of exosome-like vesicles 
(prostasomes) in human semen. Prostate, 159-67. doi:10.1002/pros.20860 
Pollet, H. (2018). Plasma Membrane Lipid Domains as Platforms for Vesicle Biogenesis and Shedding? 
Biomolecules, 8(3): 94. doi:10.3390/biom8030094 
108 
 
Pospichalova, V. (2015). Simplified protocol for flow cytometry analysis of fluorescently labeled 
exosomes and microvesicles using dedicated flow cytometer. J Extracell Vesicles, 4:25530. 
doi:10.3402/jev.v4.25530 
Pugholm, L. (2016). Phenotyping of Leukocytes and Leukocyte-Derived Extracellular Vesicles. J 
Immunol Res., 2016:6391264. doi: 10.1155/2016/6391264 
Puhka, M. (2017). Metabolomic Profiling of Extracellular Vesicles and Alternative Normalization 
Methods Reveal Enriched Metabolites and Strategies to Study Prostate Cancer-Related 
Changes. Theranostics., 7(16): 3824–3841. doi: 10.7150/thno.19890 
Puigserver, P. (1999). Activation of PPARgamma coactivator-1 through transcription factor docking. 
Science, 286(5443):1368-71. doi:10.1126/science.286.5443.1368 
Puppa, M. (2014). Skeletal muscle glycoprotein 130’s role in Lewis lung carcinoma-induced cachexia. 
FASEBJ, 998-1009. doi:28:998-1009 
Qingfu, Z. (2018). Microfluidic Engineering of Exosomes: Editing Cellular Messages for Precision 
Therapeutics. Lab Chip, 1690–1703. doi:10.1039/c8lc00246k 
Raimondo, S. (2015). Chronic myeloid leukemia-derived exosomes promote tumor growth through 
an autocrine mechanism. Cell Commun Signal, 8. doi:10.1186/s12964-015-0086-x. 
Ranjbar, K. (2019). Combined Exercise Training Positively Affects Muscle Wasting in Tumor-Bearing 
Mice. Med Sci Sports Exerc, 1387-1395. doi:10.1249/MSS.0000000000001916 
Reggiori, F. (2001). Sorting of proteins into multivesicular bodies: ubiquitin-dependent and -
independent targeting. EMBO J, 5176-86. doi:10.1093/emboj/20.18.5176 
Rejman, J. (2005). Role of clathrin- and caveolae-mediated endocytosis in gene transfer mediated by 
lipo- and polyplexes. Mol Ther., 12(3):468-74. doi:10.1016/j.ymthe.2005.03.038 
Ribeiro-Rodrigues, T. (2017). Exosomes secreted by cardiomyocytes subjected to ischaemia promote 
cardiac angiogenesis. Cardiovasc Res., 113(11):1338-1350. doi:10.1093/cvr/cvx118 
Richard, J. (2005). Cellular Uptake of Unconjugated TAT Peptide Involves Clathrindependent 
Endocytosis and Heparan Sulfate Receptors. J Biol Chem., 280(15):15300-6. 
doi:10.1074/jbc.M401604200 
Ricklefs, F. (2018). Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. 
Science Advances, eaar2766. doi:10.1126/sciadv.aar2766 
Rink, J. (2005). Rab conversion as a mechanism of progression from early to late endosomes. Cell., 
122(5):735-49. doi:10.1016/j.cell.2005.06.043 
Ritossa, F. (1962). A new puffing pattern induced by temperature shock and DNP in drosophila. 
Experientia, 571–573. doi:10.1007/BF02172188 
Robert, J. (2003). Evolution of heat shock protein and immunity. Dev Comp Immunol., 449-64. 
doi:10.1016/s0145-305x(02)00160-x 
Robinson, M. (1996). Membrane dynamics in endocytosis. Cell., 84(1):13-21. doi:10.1016/s0092-
8674(00)80988-5 
Rock, G. (1997). New concepts in coagulation. Crit Rev Clin Lab Sci., 34(5):475-501. 
doi:10.3109/10408369709006423. 
109 
 
Rodrigues, M. (2013). Vesicular mechanisms of traffic of fungal molecules to the extracellular space. 
Curr Opin Microbiol, 414-20. doi:10.1016/j.mib.2013.04.002 
Rodrigues, M. (2018). Role of Extracellular Vesicles in Viral and Bacterial Infections: Pathogenesis, 
Diagnostics, and Therapeutics. Theranostics, 2709–2721. doi:10.7150/thno.20576 
Romancino, D. (2013). Identification and characterization of the nano-sized vesicles released by 
muscle cells. FEBS Lett, 1379-84. doi:10.1016/j.febslet.2013.03.012 
Rosenberger, L. (2019). Stem cell exosomes inhibit angiogenesis and tumor growth of oral squamous 
cell carcinoma. Sci. Rep, 9:663. doi:10.1038/s41598-018-36855-6 
Roucourt, B. (2015). Heparanase activates the syndecan-syntenin-ALIX exosome pathway. Cell Res, 
412–428. doi:10.1038/cr.2015.29 
Royo, F. (2017). Hepatocyte-secreted extracellular vesicles modify blood metabolome and 
endothelial function by an arginase-dependent mechanism. Sci Rep., 7:42798. 
doi:10.1038/srep42798. 
Russell, A. (2003). Endurance training in humans leads to fiber type-specific increases in levels of 
peroxisome proliferator-activated receptor-gamma coactivator-1 and peroxisome 
proliferator-activated receptor-alpha in skeletal muscle. Diabetes, 52(12):2874-81. 
doi:10.2337/diabetes.52.12.2874 
Russell, M. (2006). Molecular mechanisms of late endosome morphology, identity and sorting. Curr 
Opin Cell Biol., 18(4):422-8. doi:10.1016/j.ceb.2006.06.002 
Saletti, R. (2017). High resolution mass spectrometry characterization of the oxidation pattern of 
methionine and cysteine residues in rat liver mitochondria voltage-dependent anion 
selective channel 3 (VDAC3). Biochim Biophys Acta Biomembr, 301-311. 
doi:10.1016/j.bbamem.2016.12.003 
Saletti, R. (2018). Post-translational modifications of VDAC1 and VDAC2 cysteines from rat liver 
mitochondria. Biochim Biophys Acta Bioenerg, 806-816. doi:10.1016/j.bbabio.2018.06.007 
Salomon, C. (2014). A gestational profile of placental exosomes in maternal plasma and their effects 
on endothelial cell migration. PLoS One., 9(6):e98667. doi:10.1371/journal.pone.0098667. 
Sampaio, N. (2018). Extracellular vesicles from early stage Plasmodium falciparum-infected red blood 
cells contain PfEMP1 and induce transcriptional changes in human monocytes. Cell Microbiol, 
e12822. doi:10.1111/cmi.12822 
Sanders, P. (2005). Angiotensin II directly induces muscle protein catabolism through the ubiquitin–
proteasome proteolytic pathway and may play a role in cancer cachexia. Br J Cancer, 425–
434. doi:10.1038/sj.bjc.6602725 
Sandqvist, A. (2009). Heterotrimerization of heat-shock factors 1 and 2 provides a transcriptional 
switch in response to distinct stimuli. Mol Biol Cell, 1340-7. doi:10.1091/mbc.E08-08-0864 
Sansone, P. (2017). Packaging and transfer of mitochondrial DNA via exosomes regulate escape from 
dormancy in hormonal therapy-resistant breast cancer. Proc Natl Acad Sci U S A., 
114(43):E9066-E9075. doi:10.1073/pnas.1704862114. 
Santamaria-Martos, F. (2019). Comparative and functional analysis of plasma membrane-derived 
extracellular vesicles from obese vs. nonobese women. Clin Nutr., S0261-5614(19)30163-3. 
doi:10.1016/j.clnu.2019.04.008. 
110 
 
Sato, Y. (2016). Engineering hybrid exosomes by membrane fusion with liposomes. Sci. Rep, 6:21933. 
doi:10.1038/srep21933 
Scarpulla, R. (2002). Nuclear activators and coactivators in mammalian mitochondrial biogenesis. 
Biochim Biophys Acta, 1576(1-2):1-14. doi:10.1016/s0167-4781(02)00343-3 
Schaeffer, P. (2004). Calcineurin and calcium/calmodulin-dependent protein kinase activate distinct 
metabolic gene regulatory programs in cardiac muscle. J Biol Chem., 279(38):39593-603. 
doi:10.1074/jbc.M403649200 
Schey, K. (2015). Proteomics characterization of exosome cargo. Methods, 75-82. 
doi:10.1016/j.ymeth.2015.03.018 
Schiro, A. (2015). Elevated levels of endothelial-derived microparticles and serum CXCL9 and SCGF-β 
are associated with unstable asymptomatic carotid plaques. Sci Rep, 16658. 
doi:10.1038/srep16658 
Schneider, D. (2017). Mechanisms and modulation of microvesicle uptake in a model of alveolar cell 
communication. J Biol Chem, 20897-20910. doi:10.1074/jbc.M117.792416 
Schuh, A. (2014). The ESCRT machinery: From the plasma membrane to endosomes and back again. 
Crit Rev Biochem Mol Biol., 49(3): 242–261. doi:10.3109/10409238.2014.881777 
Scott, C. (2011). Ion flux and the function of endosomes and lysosomes: pH is just the start. 
BioEssays., 33(2):103-10. doi:10.1002/bies.201000108. 
Senthilkumar, K. (2018). A New Approach for Loading Anticancer Drugs Into Mesenchymal Stem Cell-
Derived Exosome Mimetics for Cancer Therapy. Front Pharmacol, 1116. 
doi:10.3389/fphar.2018.01116 
Serban, K. (2016). Structural and functional characterization of endothelial microparticles released by 
cigarette smoke. Sci Rep., 6: 31596. doi:10.1038/srep31596 
Silva, K. (2015). Inhibition of Stat3 Activation Suppresses Caspase-3 and the Ubiquitin-Proteasome 
System, Leading to Preservation of Muscle Mass in Cancer Cachexia. J Biol Chem, 290(17): 
11177–11187. doi:10.1074/jbc.M115.641514 
Silverman, J. (2016). Disease Mechanisms in ALS: Misfolded SOD1 Transferred Through Exosome-
Dependent and Exosome-Independent Pathways. Cell Mol Neurobiol, 377–381. 
doi:10.1007/s10571-015-0294-3 
Sitar, S. (2015). Size characterization and quantification of exosomes by asymmetrical-flow field-flow 
fractionation. Anal Chem, 87(18):9225-33. doi:10.1021/acs.analchem.5b01636 
Sivamohan, R. (1999). Liquid chromatography used to size-separate the amphiphilic-molecules 
stabilized nano-particles of cds in the 1–10nm range. Nanostructured Materials, 89-94. 
doi:10.1016/S0965-9773(99)00072-0 
Skotland, T. (2017). Lipids in exosomes: Current knowledge and the way forward. Prog Lipid Res, 30-
41. doi:10.1016/j.plipres.2017.03.001 
Skotland, T. (2019). Exosomal lipid composition and the role of ether lipids and phosphoinositides in 
exosome biology. J Lipid Res, 9-18. doi:10.1194/jlr.R084343 
Skottvoll, F. (2019). Ultracentrifugation versus kit exosome isolation: nanoLC-MS and other tools 
reveal similar performance biomarkers, but also contaminations. Future Sci, OA 5:FSO359. 
doi:10.4155/fsoa-2018-0088 
111 
 
Soekmadji, C. (2019). Extracellular Vesicles in Health and Disease. Tratto da Coursera. 
Sokolova, V. (2011). Characterisation of exosomes derived from human cells by nanoparticle tracking 
analysis and scanning electron microscopy. Colloids Surf B Biointerfaces, 146-50. 
doi:10.1016/j.colsurfb.2011.05.013 
Solans, C. (1997). Surfactants for microemulsions. Current opinion in colloid & interface science, 464-
471. doi:10.1016/S1359-0294(97)80093-3 
Soler, N. (2008). Virus-like vesicles and extracellular DNA produced by hyperthermophilic archaea of 
the order Thermococcales. Res Microbiol., 159(5):390-9. doi:10.1016/j.resmic.2008.04.015. 
Somji, S. (1999). Expression of the constitutive and inducible forms of heat shock protein 70 in 
human proximal tubule cells exposed to heat, sodium arsenite, and CdCl(2). Environ Health 
Perspect, 887–893. doi:10.1289/ehp.99107887 
Sousa, D. (2015). Intercellular Transfer of Cancer Drug Resistance Traits by Extracellular Vesicles. 
Trends Mol Med., 21(10):595-608. doi:10.1016/j.molmed.2015.08.002 
Spinazzola, A. (2009). Mitochondrial diseases: a cross-talk between mitochondrial and nuclear 
genomes. Adv Exp Med Biol, 652:69-84. doi:10.1007/978-90-481-2813-6_6 
Sproviero, D. (2018). Pathological Proteins Are Transported by Extracellular Vesicles of Sporadic 
Amyotrophic Lateral Sclerosis Patients. Front Neurosci., 12:487. 
doi:10.3389/fnins.2018.00487 
Stenmark, H. (2009). Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol., 10(8):513-
25. doi:10.1038/nrm2728 
Stevenson, T. (2018). Immunization with outer membrane vesicles displaying conserved surface 
polysaccharide antigen elicits broadly antimicrobial antibodies. Proc Natl Acad Sci U S A, 
115(14):E3106-E3115. doi:10.1073/pnas.1718341115. 
Suades, R. (2012). Circulating and platelet-derived microparticles in human blood enhance 
thrombosis on atherosclerotic plaques. Thromb Haemost., 108(6):1208-19. 
doi:10.1160/TH12-07-0486 
Suades, R. (2015). High levels of TSP1+/CD142+ platelet-derived microparticles characterise young 
patients with high cardiovascular risk and subclinical atherosclerosis. Thromb Haemost., 
114(6):1310-21. doi:10.1160/TH15-04-0325 
Sullivan, R. (2016). Epididymosomes: Role of extracellular microvesicles in sperm maturation. Front 
Biosci (Schol Ed)., 8:106-14. doi:10.2741/s450. 
Sun, D. (2010). A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin 
is enhanced when encapsulated in exosomes. Mol Ther, 1606-14. doi: 10.1038/mt.2010.105 
Sun, S. (2006). Mechanics of Enveloped Virus Entry into Host Cells. Biophys J, L10–L12. 
doi:10.1529/biophysj.105.074203 
Surman, M. (2017). Deciphering the role of ectosomes in cancer development and progression: focus 
on the proteome. Clin. Exp. Metastasis, 34 273–289. doi:10.1007/s10585-017-9844-z 
Szatanek, R. (2015). Isolation of extracellular vesicles: determining the correct approach. Int. J. Mol. 
Med., 11–17. doi:10.3892/ijmm.2015.2194 
112 
 
Taha, E. (2019). Roles of Extracellular HSPs as Biomarkers in Immune Surveillance and Immune 
Evasion. Int. J. Mol. Sci., E4588. doi:10.3390/ijms20184588 
Taldone, T. (2014). Protein chaperones: a composition of matter. Expert Opin Ther Pat, 501-18. 
doi:10.1517/13543776.2014.887681 
Tardif, N. (2013). Autophagic-lysosomal pathway is the main proteolytic system modified in the 
skeletal muscle of esophageal cancer patients. The American Journal of Clinical Nutrition, 
1485–1492. doi:10.3945/ajcn.113.063859 
Taylor, D. (2015). Methods of isolating extracellular vesicles impact down-stream analyses of their 
cargoes. Methods., 87:3-10. doi:10.1016/j.ymeth.2015.02.019 
Tazi, E. (2010). Treatment of Cachexia in Oncology. Indian J Palliat Care, 16(3): 129–137. 
doi:10.4103/0973-1075.73644 
Théry, C. (2006). Isolation and characterization of exosomes from cell culture supernatants and 
biological fluids. Curr Protoc Cell Biol, Unit 3.22. doi:10.1002/0471143030.cb0322s30 
Théry, C. (2018). Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a 
position statement of the International Society for Extracellular Vesicles and update of the 
MISEV2014 guidelines. J Extracell Vesicles, 1535750. doi: 10.1080/20013078.2018.1535750 
Thomas, G. (2009). Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 
accelerate thrombus formation in vivo. J Exp Med., 206(9):1913-27. 
doi:10.1084/jem.20082297. 
Thompson, A. (2016). Extracellular vesicles in neurodegenerative disease — pathogenesis to 
biomarkers. Nat Rev Neurol, 346–357. doi:10.1038/nrneurol.2016.68 
Thompson, M. (1998). Signalling pathways regulating protein turnover in skeletal muscle. Cell Sign, 1-
11. doi:10.1016/s0898-6568(97)00076-4 
Tian, T. (2018). Surface functionalized exosomes as targeted drug delivery vehicles for cerebral 
ischemia therapy. Biomaterials, 137-149. doi:10.1016/j.biomaterials.2017.10.012 
Tian, Y. (2014). A doxorubicin delivery platform using engineered natural membrane vesicle 
exosomes for targeted tumor therapy. Biomaterials, 2383-90. 
doi:10.1016/j.biomaterials.2013.11.083 
Tijerina, A. (2004). The biochemical basis of metabolism in cancer cachexia. Dimens Crit Care Nurs, 
23(6):237-43. doi:10.1097/00003465-200411000-00001 
Timár, C. (2013). Antibacterial effect of microvesicles released from human neutrophilic 
granulocytes. Blood., 121(3):510-8. doi:10.1182/blood-2012-05-431114. 
Tissot, J. (2013). Blood microvesicles: From proteomics to physiology. ScienceDirect, 38-52. 
doi:10.1016/j.trprot.2013.04.004 
Tixeira, R. (2017). Defining the morphologic features and products of cell disassembly during 
apoptosis. Apoptosis, 475–477. doi:10.1007/s10495-017-1345-7 
Tominaga, N. (2015). Brain metastatic cancer cells release microRNA-181c-containing extracellular 
vesicles capable of destructing blood-brain barrier. Nat Commun., 6:6716. 
doi:10.1038/ncomms7716. 
113 
 
Tracey, K. (1986). Shock and tissue injury induced by recombinant human cachectin. Science, 
234(4775):470-4. doi:10.1126/science.3764421 
Tracey, K. (1988). Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp 
Med, 167(3): 1211–1227. doi:10.1084/jem.167.3.1211 
Tramontano, A. (2010). Circulating Endothelial Microparticles in Diabetes Mellitus. Mediators of 
Inflammation., 1-8. doi:10.1155/2010/250476  
Tricarico, C. (2017). Biology and biogenesis of shed microvesicles. Small GTPases, 220-232. 
doi:10.1080/21541248.2016.1215283 
Tripisciano, C. (2017). Different Potential of Extracellular Vesicles to Support Thrombin Generation: 
Contributions of Phosphatidylserine, Tissue Factor, and Cellular Origin. Sci Rep., 7(1):6522. 
doi:10.1038/s41598-017-03262-2. 
Trotta, M. (1996). Phase behaviour of microemulsion systems containing lecithin and lysolecithin as 
surfactants. International journal of Pharmaceutics. doi:10.1016/S0378-5173(96)04688-1 
Tseng, Y. (2015). Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the 
Treatment of Cancer-Induced Cachexia. J Natl Cancer Inst, djv274. doi:10.1093/jnci/djv274 
Tuena de Gómez-Puyou, M. (1983). Regulation of the synthesis and hydrolysis of ATP by 
mitochondrial ATPase. Role of the natural ATPase inhibitor protein. J Biol Chem, 
258(22):13680-4. 
Tunici, P. (1999). In vivo modulation of 73 kDa heat shock cognate and 78 kDa glucose-regulating 
protein gene expression in rat liver and brain by ethanol. Alcohol Clin Exp Res, 1861-7. 
Turturici, G. (2014). Extracellular membrane vesicles as a mechanism of cell-to-cell communication: 
advantages and disadvantages. Am. J. Physiol. Cell Physiol., 306 C621–C633. 
doi:10.1152/ajpcell.00228.2013. 
Vagner, T. (2018). Large extracellular vesicles carry most of the tumour DNA circulating in prostate 
cancer patient plasma. J Extracell Vesicles., 7(1): 1505403. 
doi:10.1080/20013078.2018.1505403 
Valencia, K. (2014). miRNA cargo within exosome‐like vesicle transfer influences metastatic bone 
colonization. The Journal of Neuroscience, 39(47), 9269–9273. doi:10.1523/jneurosci.0147-
18.2019  
Vallin, J. (2019). The role of the molecular chaperone CCT in protein folding and mediation of 
cytoskeleton-associated processes: implications for cancer cell biology. Cell Stress and 
Chaperones, 17–27. doi:10.1007/s12192-018-0949-3 
van der Pol, L. (2015). Outer membrane vesicles as platform vaccine technology. Biotechnol J, 1689–
1706. doi:10.1002/biot.201400395 
van der Vos, K. (2016). Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to 
microglia/macrophages in the brain. Neuro Oncol., 18(1):58-69. doi:10.1093/neuonc/nov244. 
Van Deun, J. (2014). The impact of disparate isolation methods for extracellular vesicles on 
downstream RNA profiling. J. Extracell. Vesicles, 18:3. doi:10.3402/jev.v3.24858 
Vargas-Roig, L. (1997). Heat shock proteins and cell proliferation in human breast cancer biopsy 
samples. Cancer Detect Prev, 441-51. 
114 
 
Vazirabadi, G. (2003). Epstein-Barr virus latent membrane protein-1 (LMP-1) and lytic LMP-1 
localization in plasma membrane-derived extracellular vesicles and intracellular virions. J Gen 
Virol, 1997-2008. doi:10.1099/vir.0.19156-0 
Veerman, R. (2019). Immune Cell-Derived Extracellular Vesicles - Functions and Therapeutic 
Applications. Trends Mol Med., 25(5):382-394. doi:10.1016/j.molmed.2019.02.003 
Ventura-Clapier, R. (2008). Transcriptional control of mitochondrial biogenesis: the central role of 
PGC-1alpha. Cardiovascular Research, 208-17. doi:10.1093/cvr/cvn098 
Vilasi, S. (2014). Human Hsp60 with Its Mitochondrial Import Signal Occurs in Solution as Heptamers 
and Tetradecamers Remarkably Stable over a Wide Range of Concentrations. PLoS One, 9(5): 
e97657. doi:10.1371/journal.pone.0097657 
Von Haehling, S. (2014). Treatment of Cachexia: An Overview of Recent Developments. J Am Med Dir 
Assoc, 866-72. doi:10.1016/j.jamda.2014.09.007 
Vorkapic, D. (2016). Multifaceted roles of extracellular DNA in bacterial physiology. Curr Genet, 71–
79. doi:10.1007/s00294-015-0514-x 
Vu, L. (2019). Tumor-secreted extracellular vesicles promote the activation of cancer-associated 
fibroblasts via the transfer of microRNA-125b. J Extracell Vesicles., 8(1): 1599680. 
doi:10.1080/20013078.2019.1599680 
Wagner, M. (1999). Induction of stress proteins in human endothelial cells by heavy metal ions and 
heat shock. Am J Physiol, 1026-33. doi:10.1152/ajplung.1999.277.5.L1026 
Wahlund, C. (2017). Exosomes from antigen-pulsed dendritic cells induce stronger antigen-specific 
immune responses than microvesicles in vivo. Scientific Reports, 17095. doi:10.1038/s41598-
017-16609-6 
Wallberg, A. (2003). Coordination of p300-mediated chromatin remodeling and TRAP/mediator 
function through coactivator PGC-1alpha. Mol Cell, 12(5):1137-49. doi:10.1016/s1097-
2765(03)00391-5 
Wandinger-Ness, A. (2014). Rab Proteins and the Compartmentalization of the Endosomal System. 
Cold Spring Harb Perspect Biol., 6(11): a022616. doi:10.1101/cshperspect.a022616 
Wang, S. (2018). Mesenchymal Stem Cell-Derived Extracellular Vesicles Suppresses iNOS Expression 
and Ameliorates Neural Impairment in Alzheimer's Disease Mice. J Alzheimers Dis, 1005-
1013. doi:10.3233/JAD-170848 
Wang, X. (2010). Caspase-3 cleaves specific 19 S proteasome subunits in skeletal muscle stimulating 
proteasome activity. J Biol Chem., 285(28):21249-57. doi:10.1074/jbc.M109.041707 
Wang, Y. (2017). Global scientific trends on exosome research during 2007-2016: a bibliometric 
analysis. Oncotarget, 48460-48470. doi:10.18632/oncotarget.17223 
Wang, Y. (2019). Extracellular Vesicles (EVs) from Lung Adenocarcinoma Cells Promote Human 
Umbilical Vein Endothelial Cell (HUVEC) Angiogenesis through Yes Kinase-associated Protein 
(YAP) Transport. Int J Biol Sci., 15(10):2110-2118. doi:10.7150/ijbs.31605 
Wegele, H. (2004). Hsp70 and Hsp90—a relay team for protein folding. Reviews of Physiology, 
Biochemistry and Pharmacology. doi:10.1007/s10254-003-0021-1 
Weiss, R. (2018). Differential Interaction of Platelet-Derived Extracellular Vesicles with Leukocyte 
Subsets in Human Whole Blood. Sci Rep., 8(1):6598. doi:10.1038/s41598-018-25047-x 
115 
 
Wenz, T. (2009). PGC-1alpha activation as a therapeutic approach in mitochondrial disease. IUBMB 
Life, 1051-62. doi:10.1002/iub.261 
Wenzel, E. (2018). Concerted ESCRT and clathrin recruitment waves define the timing and 
morphology of intraluminal vesicle formation. Nat Commun., 2932. doi:10.1038/s41467-018-
05345-8 
Westerblad, H. (2010). Skeletal muscle: Energy metabolism, fiber types, fatigue and adaptability. 
Experimental Cell Research, 3093-3099. doi:10.1016/j.yexcr.2010.05.019 
Whitley, D. (1999). Heat shock proteins: A review of the molecular chaperones. Journal of Vascular 
Surgery, 748-51. doi:10.1016/s0741-5214(99)70329-0 
Wilcke, M. (2000). Rab11 Regulates the Compartmentalization of Early Endosomes Required for 
Efficient Transport from Early Endosomes to the Trans-Golgi Network. J Cell Biol., 151(6): 
1207–1220. doi:10.1083/jcb.151.6.1207 
Williams, A. (2019). Mesenchymal Stem Cell-Derived Exosomes Provide Neuroprotection and 
Improve Long-Term Neurologic Outcomes in a Swine Model of Traumatic Brain Injury and 
Hemorrhagic Shock. J Neurotrauma, 54-60. doi:10.1089/neu.2018.5711 
Willms, E. (2018). Extracellular vesicle heterogeneity: subpopulations, isolation techniques, and 
diverse functions in cancer progression. Front. Immunol., 9:738. 
doi:10.3389/fimmu.2018.00738 
Wolf, P. (1967). The nature and significance of platelet products in human plasma. Br J Haematol., 
269-88. doi:10.1111/j.1365-2141.1967.tb08741.x 
Wu, C. (2019). Extracellular vesicles derived from natural killer cells use multiple cytotoxic proteins 
and killing mechanisms to target cancer cells. J Extracell Vesicles., 8(1):1588538. 
doi:10.1080/20013078.2019.1588538. 
Wu, G. (2015). Altered microRNA Expression Profiles of Extracellular Vesicles in Nasal Mucus From 
Patients With Allergic Rhinitis. Allergy Asthma Immunol Res., 7(5):449-57. 
doi:10.4168/aair.2015.7.5.449 
Wu, H. (2007). Calpain-calcineurin signaling in the pathogenesis of calcium-dependent disorder. Acta 
Med Okayama, 61(3):123-37. doi:10.18926/AMO/32905 
Wu, J. (2018). Exosome-Mimetic Nanovesicles from Hepatocytes promote hepatocyte proliferation in 
vitro and liver regeneration in vivo. Sci Rep, 2471. doi:10.1038/s41598-018-20505-y 
Xu, D. (2013). The role of exosomes and microRNAs in senescence and aging. Adv Drug Deliv Rev., 
65(3):368-75. doi:10.1016/j.addr.2012.07.010. 
Yang, C. (2019). Effects of extracellular vesicles on placentation and pregnancy disorders. 
Reproduction., 158(5):R189-R196. doi:10.1530/REP-19-0147. 
Yang, J. (2017). Exosome Mediated Delivery of miR-124 Promotes Neurogenesis after Ischemia. Mol 
Ther Nucleic Acids, 278-287. doi:10.1016/j.omtn.2017.04.010 
Yang, L. (2019). Long non-coding RNA HOTAIR promotes exosome secretion by regulating RAB35 and 
SNAP23 in hepatocellular carcinoma. Mol Cancer., 18(1):78. doi:10.1186/s12943-019-0990-6. 
Yang, Y. (2018). Inflammation leads to distinct populations of extracellular vesicles from microglia. J 
Neuroinflammation, 168. doi:10.1186/s12974-018-1204-7 
116 
 
Yarana, C. (2018). Extracellular Vesicles Released by Cardiomyocytes in a Doxorubicin-Induced 
Cardiac Injury Mouse Model Contain Protein Biomarkers of Early Cardiac Injury. Clin Cancer 
Res., 24(7):1644-1653. doi:10.1158/1078-0432.CCR-17-2046 
Yoshida, T. (2015). Mechanisms of Cachexia in Chronic Disease States. Am J Med Sci, 350(4): 250–
256. doi:10.1097/MAJ.0000000000000511 
Yuana, Y. (2013). Extracellular vesicles in physiological and pathological conditions. Blood Rev., 
27(1):31-9. doi:10.1016/j.blre.2012.12.002. 
Yuana, Y. (2014). Co-isolation of extracellular vesicles and high-density lipoproteins using density 
gradient ultracentrifugation. J Extracell Vesicles, 3: 10. doi:10.3402/jev.v3.23262 
Yujun, H. (2007). Proteomics‐based identification of HSP60 as a tumor‐associated antigen in 
colorectal cancer. Proteomic Clinical Applications, 336-42. doi:10.1002/prca.200600718 
Zahka, J. (1985). Practical Aspects of Tangential Flow Filtration in Cell Separations. doi:10.1021/bk-
1985-0271.ch003 
Zeng, F. (2018). Extracellular vesicle-mediated MHC cross-dressing in immune homeostasis, 
transplantation, infectious diseases, and cancer. Semin Immunopathol., 40(5):477-490. 
doi:10.1007/s00281-018-0679-8. 
Zhang, B. (2014). Immunotherapeutic Potential of Extracellular Vesicles. Front Immunol., 5: 518. 
doi:10.3389/fimmu.2014.00518 
Zhang, L. (2017). Skeletal Muscle-Specific Overexpression of PGC-1α Induces Fiber-Type Conversion 
through Enhanced Mitochondrial Respiration and Fatty Acid Oxidation in Mice and Pigs. Int J 
Biol Sci, 13(9): 1152–1162. doi:10.7150/ijbs.20132 
Zhang, Z. (2014). Comparison of ultracentrifugation and density gradient separation methods for 
isolating Tca8113 human tongue cancer cell line-derived exosomes. Oncol. Lett., 1701–1706. 
doi:10.3892/ol.2014.2373 
Zhao, L. (2016). Phosphatidylserine exposing-platelets and microparticles promote procoagulant 
activity in colon cancer patients. J Exp Clin Cancer Res, 35: 54. doi:10.1186/s13046-016-0328-
9 
Zhou, T. (2018). Development and validation of a clinically applicable score to classify cachexia stages 
in advanced cancer patients. J Cachexia Sarcopenia Muscle, 9(2): 306–314. 
doi:10.1002/jcsm.12275 
Zwicker, J. (2008). Tissue factor-bearing microparticles and cancer. Semin Thromb Hemost., 
34(2):195-8. doi:10.1055/s-2008-1079260. 
 
 
